

Bevacizumab plus Radiotherapyâ€™ Temozolomide for M

New England Journal of Medicine

370, 709-722

DOI: 10.1056/nejmoa1308345

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effects of Anti-Angiogenesis on Glioblastoma Growth and Migration: Model to Clinical Predictions. PLoS ONE, 2014, 9, e115018.	1.1	28
2	Orphan drugs in glioblastoma multiforme: a review. Orphan Drugs: Research and Reviews, 0, , 83.	0.6	6
4	Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial. OncoTargets and Therapy, 2014, 7, 1551.	1.0	14
5	The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Management and Research, 2014, 6, 373.	0.9	32
6	Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. OncoTargets and Therapy, 2014, 7, 751.	1.0	12
7	High Grade Glioma "Standard Approach, Obstacles and Future Directions. , 0, ,		0
8	For the Next Trick: New Discoveries in Radiobiology Applied to Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e95-e99.	1.8	22
9	Antiangiogenic therapies for glioblastoma. CNS Oncology, 2014, 3, 349-358.	1.2	9
10	Antiangiogenesis in Cancer Therapy. , 2014, , .		0
11	Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. CNS Oncology, 2014, 3, 389-400.	1.2	38
12	Monitoring therapeutic monoclonal antibodies in brain tumor. MAb, 2014, 6, 1385-1393.	2.6	18
13	Bevacizumab for glioblastoma: current indications, surgical implications, and future directions. Neurosurgical Focus, 2014, 37, E9.	1.0	43
14	Trial Watch: Radioimmunotherapy for oncological indications. OncoImmunology, 2014, 3, e954929.	2.1	40
15	Antiangiogenic therapy for high-grade glioma. The Cochrane Library, 2014, , CD008218.	1.5	84
17	Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. Journal of Neuro-Oncology, 2014, 120, 431-440.	1.4	17
20	Therapeutic targeting of tumor angiogenesis: how far have we come?. Clinical Investigation, 2014, 4, 1113-1122.	0.0	0
21	Clinical Significance of Tryptophan Metabolism in the Nontumoral Hemisphere in Patients with Malignant Glioma. Journal of Nuclear Medicine, 2014, 55, 1605-1610.	2.8	11
23	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-Oncology, 2014, 16, vii36-vii47.	0.6	41

#	ARTICLE	IF	CITATIONS
24	Current Role of Anti-Angiogenic Strategies for Glioblastoma. Current Treatment Options in Oncology, 2014, 15, 551-566.	1.3	24
25	Hippocampal EUD in primarily irradiated glioblastoma patients. Radiation Oncology, 2014, 9, 276.	1.2	9
26	Potential novel role of bevacizumab in glioblastoma and cervical cancer. Cancer Biology and Therapy, 2014, 15, 1296-1298.	1.5	4
27	Treating glioblastoma patients with poor performance status: where do we go from here?. CNS Oncology, 2014, 3, 231-241.	1.2	3
28	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. Future Oncology, 2014, 10, 1137-1145.	1.1	16
29	Recent Updates in the Treatment of Glioblastoma: Introduction. Seminars in Oncology, 2014, 41, S1-S3.	0.8	6
30	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-Oncology, 2014, 16, viii7-viii13.	0.6	85
31	Bevacizumab for glioblastoma. Neurology, 2014, 82, 1670-1671.	1.5	7
32	<scp>FCR</scp> and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer, 2014, 120, 3494-3501.	2.0	6
33	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncology, 2014, 16, 1427-1428.	0.6	6
34	Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Frontiers in Microbiology, 2014, 5, 303.	1.5	44
35	Emerging Insights into Barriers to Effective Brain Tumor Therapeutics. Frontiers in Oncology, 2014, 4, 126.	1.3	127
36	Galectins and neovascularization in central nervous system tumors. Glycobiology, 2014, 24, 892-898.	1.3	10
38	Cytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme. Frontiers in Oncology, 2014, 4, 275.	1.3	21
39	BMPs as Therapeutic Targets and Biomarkers in Astrocytic Glioma. BioMed Research International, 2014, 2014, 1-8.	0.9	24
40	Avastin, Once Considered Promising for Glioblastoma, Disappoints in Large Trial. Neurology Today: an Official Publication of the American Academy of Neurology, 2014, 14, 20-21.	0.0	0
41	Progression-free survival: too much risk, not enough reward?. Neuro-Oncology, 2014, 16, 615-616.	0.6	16
43	Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma. Nature Reviews Neurology, 2014, 10, 179-179.	4.9	6

#	ARTICLE	IF	CITATIONS
44	Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 2048-2049.	13.9	98
45	Further delineating bevacizumab's response spectrum. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 243-244.	12.5	0
46	Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. <i>Annals of Oncology</i> , 2014, 25, 1442-1447.	0.6	90
47	High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii93-iii101.	0.6	532
48	Management of high-grade gliomas in the pediatric patient: Past, present, and future. <i>Neuro-Oncology Practice</i> , 2014, 1, 145-157.	1.0	31
49	Bevacizumab Increases the Risk of Severe Congestive Heart Failure in Cancer Patients: An Up-to-Date Meta-Analysis with a Focus on Different Subgroups. <i>Clinical Drug Investigation</i> , 2014, 34, 681-690.	1.1	35
50	Focal or combined modality for the management of brain metastasis: did high tech radiotherapy superseded drug-radiotherapy combination?. <i>Annals of Oncology</i> , 2014, 25, 2293-2294.	0.6	2
51	Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects. <i>Clinical Cancer Research</i> , 2014, 20, 5612-5619.	3.2	129
52	"We will know it when we see it;" bevacizumab and glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 469-470.	0.6	4
53	Beating the odds: extreme long-term survival with glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1159-1160.	0.6	63
54	Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 192.	1.0	13
55	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolmmunology</i> , 2014, 3, e963424.	2.1	62
56	Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. <i>Neuro-Oncology</i> , 2014, 16, 765-767.	0.6	13
57	A Randomized Clinical Trial of Vascular Endothelial Growth Factor Inhibition in the Treatment of Glioblastoma Multiforme. <i>Neurosurgery</i> , 2014, 74, N14-N17.	0.6	0
58	Glioblastoma survival. <i>Current Opinion in Neurology</i> , 2014, 27, 666-674.	1.8	82
59	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2014, 17, 430-9.	0.6	108
60	Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?. <i>Neuro-Oncology</i> , 2014, 16, 1427-1427.	0.6	4
61	Emerging Therapies for Glioblastoma. <i>JAMA Neurology</i> , 2014, 71, 1437.	4.5	148

#	ARTICLE	IF	CITATIONS
62	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014, 32, 2273-2274.	0.8	0
63	The Regulatory Network of Proneural Glioma in Tumor Progression. <i>Neurosurgery</i> , 2014, 75, N15-N16.	0.6	0
64	Ephs and Ephrins in malignant gliomas. <i>Growth Factors</i> , 2014, 32, 190-201.	0.5	26
65	The future of antiangiogenic treatment in glioblastoma. <i>Current Opinion in Neurology</i> , 2014, 27, 675-682.	1.8	16
66	Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 642-648.	0.7	8
67	Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: The potential of combination strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 38-48.	2.0	10
69	Bevacizumab in Glioblastoma " Still Much to Learn. <i>New England Journal of Medicine</i> , 2014, 370, 764-765.	13.9	46
70	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 699-708.	13.9	2,279
71	Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 85-92.	1.4	11
72	Improving outcome in newly diagnosed malignant glioma. <i>Nature Reviews Neurology</i> , 2014, 10, 68-70.	4.9	20
73	Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 66-74.	3.3	39
74	Current and Investigational Drug Strategies for Glioblastoma. <i>Clinical Oncology</i> , 2014, 26, 419-430.	0.6	31
75	REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2014, 25, 2351-2356.	0.6	51
76	Brain Metastases in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1133-1140.	0.6	26
77	Epigenetic Changes in Gliomas. , 2014, , 23-45.		0
78	NF- κ B and STAT3 in glioblastoma: therapeutic targets coming of age. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 1293-1306.	1.4	89
79	Glioma Cell Biology. , 2014, , .		3
80	Signaling Cascades Driving the Malignant Phenotype of Glioma Cells. , 2014, , 47-75.		2

#	ARTICLE	IF	CITATIONS
81	Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians. <i>CNS Drugs</i> , 2014, 28, 1127-1137.	2.7	10
83	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	3.2	89
84	Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 560-575.	3.3	36
85	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1100-1108.	5.1	800
86	Clinical trials in neurosurgical oncology. <i>Journal of Neuro-Oncology</i> , 2014, 119, 569-576.	1.4	4
87	Facing the Future of Brain Tumor Clinical Research. <i>Clinical Cancer Research</i> , 2014, 20, 5591-5600.	3.2	4
88	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1441-1458.	0.6	164
89	Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies. <i>Seminars in Oncology</i> , 2014, 41, 511-522.	0.8	21
90	The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review. <i>European Journal of Cancer</i> , 2014, 50, 2432-2448.	1.3	47
92	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology, The</i> , 2014, 15, e395-e403.	5.1	647
93	Renewing interest in targeting angiogenesis in glioblastoma. <i>Lancet Oncology, The</i> , 2014, 15, 907-908.	5.1	4
94	Vessel calibre—a potential MRI biomarker of tumour response in clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 566-584.	12.5	55
95	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncology, The</i> , 2014, 15, 943-953.	5.1	639
96	Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy. <i>Neoplasia</i> , 2014, 16, 543-561.	2.3	131
97	Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. <i>Advanced Drug Delivery Reviews</i> , 2014, 76, 98-115.	6.6	48
98	A Multilayer Grow-or-Go Model for GBM: Effects of Invasive Cells and Anti-Angiogenesis on Growth. <i>Bulletin of Mathematical Biology</i> , 2014, 76, 2306-2333.	0.9	50
100	Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 883-893.	1.5	16
101	Molecular Neuro-oncology and the Challenge of the Blood-Brain Barrier. <i>Seminars in Oncology</i> , 2014, 41, 438-445.	0.8	12

#	ARTICLE	IF	CITATIONS
103	Medical therapy of gliomas. <i>Journal of Neuro-Oncology</i> , 2014, 119, 503-512.	1.4	15
104	Clinical End Points and Relevant Clinical Benefits in Advanced Colorectal Cancer Trials. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 254-262.	1.0	0
105	Cilengitide in glioblastoma: when did it fail?. <i>Lancet Oncology</i> , The, 2014, 15, 1044-1045.	5.1	31
106	MGMT testing—the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014, 10, 372-385.	4.9	454
107	Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. <i>European Journal of Cancer</i> , Supplement, 2014, 12, 29-40.	2.2	82
108	The Role of Bevacizumab in Glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1201-1202.	2.3	2
109	Genetics and epigenetics of gliomas. <i>Swiss Medical Weekly</i> , 2014, 144, w14018.	0.8	7
110	Interferon- β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. <i>International Journal of Oncology</i> , 2014, 45, 1837-1846.	1.4	31
111	Selective depletion of tumor neovasculature by microbubble destruction with appropriate ultrasound pressure. <i>International Journal of Cancer</i> , 2015, 137, 2478-2491.	2.3	48
112	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. <i>Journal of Internal Medicine</i> , 2015, 278, 545-570.	2.7	46
113	Glioma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15017.	18.1	718
114	Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2015, 5, 14698.	1.6	20
116	Double-edged Sword in the Placement of Carmustine (BCNU) Wafers along the Eloquent Area: A Case Report. <i>NMC Case Report Journal</i> , 2015, 2, 40-45.	0.2	13
117	Dose-dense Temozolomide: Is It Still Promising?. <i>Neurologia Medico-Chirurgica</i> , 2015, 55, 38-49.	1.0	15
118	<i>In silico</i> analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20150388.	1.5	13
119	Extracranial metastasis of glioblastoma: Three illustrative cases and current review of the molecular pathology and management strategies. <i>Molecular and Clinical Oncology</i> , 2015, 3, 479-486.	0.4	55
120	Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 765-766.	0.6	3
122	The Added Value of Bevacizumab Concomitantly Administered with Carboplatin versus Carboplatin Alone in Patients with Recurrent Glioblastomas. <i>Tumori</i> , 2015, 101, 41-45.	0.6	5

#	ARTICLE	IF	CITATIONS
123	Management of diffusely infiltrating glioma in the elderly. <i>Current Opinion in Oncology</i> , 2015, 27, 502-509.	1.1	8
124	Imaging Genomics of Glioblastoma. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 155-163.	0.7	14
125	Tumor treating fields. <i>Current Opinion in Neurology</i> , 2015, 28, 659-664.	1.8	8
127	The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors. <i>Journal of Cancer</i> , 2015, 6, 812-818.	1.2	19
128	Bevacizumab for glioblastoma. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1759.	0.9	36
129	Cancer therapy and cardiovascular risk: focus on bevacizumab. <i>Cancer Management and Research</i> , 2015, 7, 133.	0.9	84
130	Bevacizumab Trough Concentration in Recurrent Glioblastoma Patients. <i>Journal of Integrative Oncology</i> , 2015, 04, .	0.3	0
131	Bevacizumab and Temozolomide plus Radiation Regimen for Glioblastoma Multiforme. <i>Hospital Pharmacy</i> , 2015, 50, 672-677.	0.4	1
132	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications. <i>Frontiers in Immunology</i> , 2015, 6, 505.	2.2	86
133	Targeting Aggressive Cancer Stem Cells in Glioblastoma. <i>Frontiers in Oncology</i> , 2015, 5, 159.	1.3	107
134	Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance. <i>PLoS ONE</i> , 2015, 10, e0126022.	1.1	59
135	International Differences in Treatment and Clinical Outcomes for High Grade Glioma. <i>PLoS ONE</i> , 2015, 10, e0129602.	1.1	11
136	The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model. <i>PLoS ONE</i> , 2015, 10, e0130357.	1.1	94
137	Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. <i>PLoS ONE</i> , 2015, 10, e0141334.	1.1	52
138	Desert Hedgehog/Patch2 Axis Contributes to Vascular Permeability and Angiogenesis in Glioblastoma. <i>Frontiers in Pharmacology</i> , 2015, 6, 281.	1.6	15
139	Nonsurgical Treatment of Recurrent Glioblastoma. <i>Current Oncology</i> , 2015, 22, 273-281.	0.9	228
140	VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment. <i>International Journal of Inflammation</i> , 2015, 2015, 1-7.	0.9	6
141	Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	8

#	ARTICLE	IF	CITATIONS
142	A Role of Boron Neutron Capture Therapy in the Multimodal Treatment for Malignant Glioma. <i>Radioisotopes</i> , 2015, 64, 79-91.	0.1	0
143	Brain Tumor Metabolism – Unraveling Its Role in Finding New Therapeutic Targets. , 0, , .		2
146	Clinical Trials in Glioblastoma – Designs and Challenges. , 2015, , .		4
148	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. <i>Journal of Neuro-Oncology</i> , 2015, 123, 307-314.	1.4	16
149	Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. <i>British Journal of Cancer</i> , 2015, 113, 226-231.	2.9	16
150	Brain Tumor Imaging. <i>Medical Radiology</i> , 2015, , 1-9.	0.0	1
151	Malignant Glioma: Viewpoint – Chemotherapy. , 2015, , 279-293.		0
152	Limited advances in therapy of glioblastoma trigger re-consideration of research policy. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 257-261.	2.0	28
154	Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1131-1137.	1.2	30
155	Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 124, 101-110.	1.4	11
157	Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). <i>International Journal of Oncology</i> , 2015, 47, 417-428.	1.4	103
158	Avancées dans les tumeurs cérébrales primitives malignes de l'adulte : quels patients transférer en réanimation médicale?. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2015, 24, 424-432.	0.1	1
159	Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor . <i>Neuro-Oncology</i> , 2015, 17, 832-842.	0.6	18
160	Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2166-2175.	0.8	112
161	Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy – Are We There Yet?. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 337-342.	1.0	8
162	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535.	3.8	982
163	Alternating Electric Fields for the Treatment of Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2511.	3.8	21
164	Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. <i>Radiation Oncology</i> , 2015, 10, 222.	1.2	62

#	ARTICLE	IF	CITATIONS
165	Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase II trial of radiotherapy/tipifarnib combination. <i>Journal of Neuro-Oncology</i> , 2015, 124, 465-473.	1.4	12
166	Advances in the treatment of newly diagnosed glioblastoma. <i>BMC Medicine</i> , 2015, 13, 293.	2.3	36
167	Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. <i>Translational Oncology</i> , 2015, 8, 446-455.	1.7	3
168	A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 743-750.	1.2	12
169	Antiangiogéniques en cancérologie thoracique : critères de prescription et gestion des effets indésirables. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 414-422.	0.0	0
170	Unravelling tumour heterogeneity—implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 69-70.	12.5	89
171	Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 122, 135-143.	1.4	29
172	Potential use of glioblastoma tumorsphere: clinical credentialing. <i>Archives of Pharmacal Research</i> , 2015, 38, 402-407.	2.7	23
173	Factorial clinical trials: a new approach to phase II neuro-oncology studies. <i>Neuro-Oncology</i> , 2015, 17, 174-176.	0.6	6
174	Assessing MGMT methylation status and its current impact on treatment in glioblastoma. <i>CNS Oncology</i> , 2015, 4, 47-52.	1.2	24
175	New Strategies in Glioblastoma: Exploiting the New Biology. <i>Clinical Cancer Research</i> , 2015, 21, 1984-1988.	3.2	31
176	Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma. <i>Brain Tumor Pathology</i> , 2015, 32, 176-183.	1.1	28
178	Differential regulation of TGF- β -induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 254-265.	0.6	65
179	Glioblastoma. , 2015, , 909-917.		6
180	Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. <i>Oncologist</i> , 2015, 20, 166-175.	1.9	66
181	Drug radiotherapy combinations: Review of previous failures and reasons for future optimism. <i>Cancer Treatment Reviews</i> , 2015, 41, 105-113.	3.4	78
182	Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. <i>Neuro-Oncology</i> , 2015, 17, 1106-1113.	0.6	21
183	Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. <i>Neuro-Oncology</i> , 2015, 17, 784-800.	0.6	49

#	ARTICLE	IF	CITATIONS
184	Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2015, 122, 317-323.	0.9	9
185	Pseudoprogession in patients with glioblastoma: clinical relevance despite low incidence. <i>Neuro-Oncology</i> , 2015, 17, 151-159.	0.6	90
186	Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 121, 91-100.	1.4	30
187	SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma. <i>Scientific Reports</i> , 2015, 5, 8588.	1.6	49
188	Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2015, 122, 567-573.	1.4	39
189	Molecular Biology of Pediatric Brain Tumors and Impact on Novel Therapies. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 10.	2.0	6
190	Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 122, 585-593.	1.4	12
191	Liquid biopsies in patients with diffuse glioma. <i>Acta Neuropathologica</i> , 2015, 129, 849-865.	3.9	81
192	Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. <i>Journal of Neurology</i> , 2015, 262, 742-751.	1.8	10
193	Lessons From Anti-VEGF Vascular Endothelial Growth Factor and Anti-VEGFR Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1197-1213.	0.8	145
194	Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015, 122, 273-281.	1.4	12
195	The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. <i>Journal of Neuro-Oncology</i> , 2015, 122, 263-271.	1.4	44
196	VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGF β 2R signaling-dependent manner. <i>Cancer Letters</i> , 2015, 360, 60-67.	3.2	39
197	Current evidence of temozolomide and bevacizumab in treatment of gliomas. <i>Neurological Research</i> , 2015, 37, 167-183.	0.6	45
198	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
199	Porphyrin Derivatives-Mediated Sonodynamic Therapy for Malignant Gliomas In Vitro. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2458-2465.	0.7	32
200	Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. <i>British Journal of Radiology</i> , 2015, 88, 20150354.	1.0	53
201	RNA-Binding Protein Musashi1 Is a Central Regulator of Adhesion Pathways in Glioblastoma. <i>Molecular and Cellular Biology</i> , 2015, 35, 2965-2978.	1.1	51

#	ARTICLE	IF	CITATIONS
202	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. <i>European Journal of Cancer</i> , 2015, 51, 1321-1330.	1.3	45
203	Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. <i>Neuro-Oncology</i> , 2015, 17, 1609-1619.	0.6	60
204	Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon- γ , and/or bevacizumab for glioblastoma. <i>Nuclear Medicine and Biology</i> , 2015, 42, 598-607.	0.3	14
205	Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 323-336.	2.0	24
206	Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000-2010. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1575-1581.	0.8	63
207	What is the optimal use of bevacizumab in glioblastoma?. <i>Nature Reviews Neurology</i> , 2015, 11, 429-430.	4.9	9
208	Data-driven modeling and characterization of anti-angiogenic molecule effects on tumoral vascular density. <i>Biomedical Signal Processing and Control</i> , 2015, 20, 52-60.	3.5	9
209	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2735-2744.	0.8	244
210	Recent advances in targeted therapy for glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 935-946.	1.4	42
211	Clinical Significance of Epigenetic Alterations in Glioblastoma. , 2015, , 339-350.		0
212	From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?. <i>Neuro-Oncology</i> , 2015, 17, 1434-1444.	0.6	144
213	Heat shock protein vaccines against glioblastoma: from bench to bedside. <i>Journal of Neuro-Oncology</i> , 2015, 123, 441-448.	1.4	63
214	Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors. <i>Nanomedicine</i> , 2015, 10, 993-1018.	1.7	98
215	Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1000-1007.	0.4	80
216	Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?. <i>Immunotherapy</i> , 2015, 7, 603-606.	1.0	13
217	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	3.2	79
218	Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2015, 33, 2296-2302.	0.8	43
219	Movement of magnetic nanoparticles in brain tissue: mechanisms and impact on normal neuronal function. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1821-1829.	1.7	48

#	ARTICLE	IF	CITATIONS
220	Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells. <i>Cancer Letters</i> , 2015, 365, 79-88.	3.2	18
221	Molecular profiling of gliomas: potential therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 955-962.	1.1	22
222	Treatment of Elderly Patients With Glioblastoma. <i>JAMA Neurology</i> , 2015, 72, 589.	4.5	78
223	Toward precision medicine in glioblastoma: the promise and the challenges. <i>Neuro-Oncology</i> , 2015, 17, 1051-1063.	0.6	178
224	Polymeric drug delivery for the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, ii9-ii23.	0.6	65
226	A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. <i>Gynecologic Oncology</i> , 2015, 137, 490-496.	0.6	52
227	VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. <i>Neurology</i> , 2015, 84, 1906-1908.	1.5	22
229	Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 121, 331-339.	1.4	39
230	Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. <i>Journal of Neuro-Oncology</i> , 2015, 122, 595-605.	1.4	11
231	Bevacizumab in high-grade gliomas: past, present, and future. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 387-397.	1.1	18
232	Î³-Glutamyl transferase 7 is a novel regulator of glioblastoma growth. <i>BMC Cancer</i> , 2015, 15, 225.	1.1	16
233	Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. <i>Journal of Neuro-Oncology</i> , 2015, 123, 251-257.	1.4	22
235	Production of Antibodies in Hybridoma and Non-hybridoma Cell Lines. <i>Cell Engineering</i> , 2015, , 65-88.	0.4	1
236	Overview of Epidemiology, Pathology, and Treatment of Primary Brain Tumors. , 2015, , 11-28.		2
238	Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 236-252.	4.0	44
239	Bevacizumab in Recurrent Glioblastoma: Five Informative Patient Scenarios. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 149-156.	0.3	3
240	Chemotherapy in glioma. <i>CNS Oncology</i> , 2015, 4, 179-192.	1.2	58
241	<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064.	3.2	264

#	ARTICLE	IF	CITATIONS
242	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , 2015, 17, 992-998.	0.6	116
243	The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas. <i>Neoplasia</i> , 2015, 17, 239-255.	2.3	114
244	The roles of CD147 in the progression of gliomas. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1351-1359.	1.1	10
245	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. <i>Journal of Neuro-Oncology</i> , 2015, 125, 401-410.	1.4	59
246	Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. <i>Science Translational Medicine</i> , 2015, 7, 303ra138.	5.8	227
247	Self-assembled 20-nm 64Cu-micelles enhance accumulation in rat glioblastoma. <i>Journal of Controlled Release</i> , 2015, 220, 51-60.	4.8	57
249	Combining radiotherapy with sunitinib: lessons (to be) learned. <i>Angiogenesis</i> , 2015, 18, 385-395.	3.7	32
250	Case-Based Review: newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 106-121.	1.0	13
251	Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations. <i>Expert Review of Medical Devices</i> , 2015, 12, 717-726.	1.4	18
252	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
253	Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. <i>Neuro-Oncology</i> , 2015, 17, 1322-1332.	0.6	217
254	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	0.6	346
255	Withholding temozolomide in glioblastoma patients with unmethylated <i>MGMT</i> promoterâ€”still a dilemma?: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, 1425-1427.	0.6	78
256	MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 1174-1176.	0.6	48
257	<i>CCR</i> 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastomaâ€”The Progress and the Limitations. <i>Clinical Cancer Research</i> , 2015, 21, 4248-4250.	3.2	5
258	Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 885-891.	1.1	12
259	PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance. <i>Tumor Biology</i> , 2015, 36, 8617-8624.	0.8	10
260	Wound healing complications in brain tumor patients on Bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 124, 501-506.	1.4	18

#	ARTICLE	IF	CITATIONS
261	The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors. <i>Current Treatment Options in Oncology</i> , 2015, 16, 36.	1.3	10
262	Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma. <i>Cell Death and Disease</i> , 2015, 6, e1732-e1732.	2.7	22
263	Novel chemotherapeutics and other therapies for treating high-grade glioma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1361-1379.	1.9	23
264	The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner. <i>Journal of Clinical Pathology</i> , 2015, 68, 830-834.	1.0	14
265	Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging. <i>Acta Oncologica</i> , 2015, 54, 1521-1528.	0.8	8
266	Can We Predict Bevacizumab Responders in Patients With Glioblastoma?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2721-2722.	0.8	13
267	Circulating biomarkers for gliomas. <i>Nature Reviews Neurology</i> , 2015, 11, 556-566.	4.9	154
268	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2015, 33, 2986-2998.	0.8	175
269	Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis. <i>Journal of Biological Chemistry</i> , 2015, 290, 23401-23415.	1.6	67
270	To what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?. <i>CNS Oncology</i> , 2015, 4, 265-272.	1.2	10
271	What next for newly diagnosed glioblastoma?. <i>Future Oncology</i> , 2015, 11, 3273-3283.	1.1	22
272	Corticosteroid use in neuro-oncology: an update. <i>Neuro-Oncology Practice</i> , 2015, 2, 6-12.	1.0	51
273	Microenvironmental regulation of therapeutic response in cancer. <i>Trends in Cell Biology</i> , 2015, 25, 198-213.	3.6	604
274	Improvement in treatment results of glioblastoma over the last three decades and beneficial factors. <i>British Journal of Neurosurgery</i> , 2015, 29, 206-212.	0.4	20
276	Current Medical Treatment of Glioblastoma. <i>Cancer Treatment and Research</i> , 2015, 163, 103-115.	0.2	66
277	Medical management of brain tumors and the sequelae of treatment. <i>Neuro-Oncology</i> , 2015, 17, 488-504.	0.6	114
278	Current Understanding and Treatment of Gliomas. <i>Cancer Treatment and Research</i> , 2015, , .	0.2	11
279	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075.	0.6	485

#	ARTICLE	IF	CITATIONS
280	Assessment of benefits and risks in development of targeted therapies for cancer – The view of regulatory authorities. <i>Molecular Oncology</i> , 2015, 9, 1034-1041.	2.1	21
281	Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. <i>Acta Neuropathologica</i> , 2015, 129, 115-131.	3.9	122
282	Novel Points of Attack for Targeted Cancer Therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 9-18.	1.2	61
283	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	0.6	28
284	Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. <i>Cancer</i> , 2015, 121, 502-516.	2.0	120
285	Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies. <i>Cancer</i> , 2015, 121, 997-1007.	2.0	62
286	The Roles of MicroRNAs in Glioblastoma Biology and Biomarker. , 2016, , .		4
287	Current Trends in High-Grade Gliomas. , 2016, , .		0
289	Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma. <i>Current Oncology</i> , 2016, 23, 468-471.	0.9	8
290	Brain Tumors: Epidemiology and Current Trends in Treatment. <i>Journal of Brain Tumors & Neurooncology</i> , 2016, 01, .	0.1	6
291	Clinical significance of angiotensin-like protein 3 expression in patients with glioblastoma. <i>Neoplasma</i> , 2016, 63, 93-98.	0.7	8
292	Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. <i>OncoTargets and Therapy</i> , 2016, 9, 1753.	1.0	4
293	Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. <i>OncoTargets and Therapy</i> , 2016, 9, 1115.	1.0	14
294	Vascular complications in glioma patients. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016, 134, 251-266.	1.0	8
295	Current Standards of Care in Glioblastoma Therapy. , 2016, , 73-80.		7
296	Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma. <i>OncoTargets and Therapy</i> , 2016, 9, 1205.	1.0	18
297	Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6669-6677.	1.0	8
298	Sirolimus and Hydroxychloroquine as an Add-On to Standard Therapy for Glioblastoma Multiforme: Case Report. <i>Journal of Biomolecular Research & Therapeutics</i> , 2016, 5, .	0.2	0

#	ARTICLE	IF	CITATIONS
299	National and Global Economic Impact of Glioblastoma. , 2016, , 271-278.		1
300	Multimodality Targeting of Glioma Cells. , 2016, , 55-72.		0
301	Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer. Journal of Thoracic Disease, 2016, 8, 2646-2650.	0.6	6
302	Hallmarks of glioblastoma: a systematic review. ESMO Open, 2016, 1, e000144.	2.0	122
303	Therapeutic Potential of Curcumin for the Treatment of Brain Tumors. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-14.	1.9	61
304	High-Grade Glioma Management and Response Assessmentâ€”Recent Advances and Current Challenges. Current Oncology, 2016, 23, 383-391.	0.9	33
305	Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. Frontiers in Oncology, 2016, 6, 165.	1.3	9
306	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. Frontiers in Oncology, 2016, 6, 256.	1.3	39
307	Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer, 2016, 16, 842.	1.1	11
308	Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme. PLoS ONE, 2016, 11, e0146617.	1.1	20
309	A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015. PLoS ONE, 2016, 11, e0148312.	1.1	20
310	Evolving Molecular Genetics of Glioblastoma. Chinese Medical Journal, 2016, 129, 464-471.	0.9	41
311	Immune Evasion Strategies of Glioblastoma. Frontiers in Surgery, 2016, 3, 11.	0.6	189
312	Health-related Quality of Life and Neurocognitive Functioning After Glioblastoma Treatment. , 2016, , 253-263.		0
313	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Oncotarget, 2016, 7, 65643-65659.	0.8	35
314	Health-related quality of life in glioma patients. , 0, , 190-204.		0
315	Chemotherapy for gliomas. , 0, , 76-90.		0
316	Comprehensive Genomic Analysis of Infiltrative Gliomas Based on Molecular Profile. Neurosurgery, 2016, 78, N15-N16.	0.6	0

#	ARTICLE	IF	CITATIONS
317	Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 249-260.	0.3	26
318	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. <i>Cancer</i> , 2016, 122, 582-587.	2.0	33
319	Time lapse <i>in vivo</i> microscopy reveals distinct dynamics of microglia-tumor environment interactions—a new role for the tumor perivascular space as highway for trafficking microglia. <i>Glia</i> , 2016, 64, 1210-1226.	2.5	54
320	Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas. <i>International Journal of Cancer</i> , 2016, 138, 1269-1280.	2.3	12
321	A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. <i>International Journal of Cancer</i> , 2016, 138, 1538-1544.	2.3	5
322	Role of microRNA's Located on Chromosome Arm 10q in Malignant Gliomas. <i>Brain Pathology</i> , 2016, 26, 344-358.	2.1	26
323	Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?. <i>Pediatric Blood and Cancer</i> , 2016, 63, 746-747.	0.8	6
324	Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric Survey (SV1 Study). <i>Chemotherapy</i> , 2016, 61, 269-274.	0.8	1
325	Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2016, 20, 282-291.	0.6	11
326	Depletion of thymopoietin inhibits proliferation and induces cell cycle arrest/apoptosis in glioblastoma cells. <i>World Journal of Surgical Oncology</i> , 2016, 14, 267.	0.8	21
327	Phenotypic Transition as a Survival Strategy of Glioma. <i>Neurologia Medico-Chirurgica</i> , 2016, 56, 387-395.	1.0	22
328	Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review. <i>Oncology Research</i> , 2016, 24, 117-128.	0.6	18
329	EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance. <i>Nature Communications</i> , 2016, 7, 12329.	5.8	57
330	Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. <i>Neuro-Oncology</i> , 2017, 19, now270.	0.6	32
331	Reply to T.J. Kruser et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1282-1283.	0.8	1
332	Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. <i>American Journal of Neuroradiology</i> , 2016, 37, 2201-2208.	1.2	59
333	Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naïve and bevacizumab-resistant glioblastoma. <i>EMBO Molecular Medicine</i> , 2016, 8, 39-57.	3.3	140
334	Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2016, 6, 217-225.	1.1	162

#	ARTICLE	IF	CITATIONS
335	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4470-4475.	3.3	251
336	Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4476-4481.	3.3	287
337	Ipilimumab and Bevacizumab in Glioblastoma. <i>Clinical Oncology</i> , 2016, 28, 622-626.	0.6	64
338	Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial. <i>Medical Decision Making</i> , 2016, 36, 615-628.	1.2	7
339	Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 1953-1956.	0.8	59
340	Investigational new drugs for brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 937-956.	1.9	16
341	Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2016, 129, 93-100.	1.4	22
342	Rehabilitation of patients with glioma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 287-304.	1.0	19
343	The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1129-1136.	0.6	85
344	Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment. <i>Radiology</i> , 2016, 281, 99-108.	3.6	114
345	Predictors of Venous Thromboembolism in Patients with Glioblastoma. <i>Pathology and Oncology Research</i> , 2016, 22, 311-316.	0.9	10
346	Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2016, 18, 1313-1318.	0.6	39
347	Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results. <i>Journal of Clinical Oncology</i> , 2016, 34, 1567-1569.	0.8	21
348	Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1259-1270.	0.9	24
349	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1304-1312.	0.6	71
350	HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. <i>Angiogenesis</i> , 2016, 19, 257-273.	3.7	22
351	Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2016, 37, 1581-1587.	1.2	31
352	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796.	3.2	95

#	ARTICLE	IF	CITATIONS
353	Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials. <i>Molecular and Clinical Oncology</i> , 2016, 4, 833-838.	0.4	35
354	Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1576-1582.	2.8	30
355	The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. <i>Developmental Cell</i> , 2016, 37, 114-125.	3.1	96
356	A critical balance: managing coagulation in patients with glioma. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 803-814.	1.4	3
357	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1199-1208.	0.6	566
358	CCGC clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273.	3.2	448
359	Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1581-1589.	1.2	28
360	Complications from radiotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 219-234.	1.0	16
361	Complications from pharmacotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 235-250.	1.0	4
362	Translation of Targeted Radiation Sensitizers into Clinical Trials. <i>Seminars in Radiation Oncology</i> , 2016, 26, 261-270.	1.0	16
363	Subventricular zone-associated glioblastoma: A call for translational research to guide clinical decision making. <i>Neurogenesis (Austin, Tex)</i> , 2016, 3, e1225548.	1.5	6
364	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. <i>Molecular Oncology</i> , 2016, 10, 1296-1304.	2.1	19
365	Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy?. <i>Clinical Oncology</i> , 2016, 28, 664-665.	0.6	1
366	Increased signal intensity in FLAIR sequences in the resection cavity can predict progression and progression-free survival in gliomas. <i>Neurocirugia</i> , 2016, 27, 269-276.	0.2	16
367	Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. <i>Cell Death and Disease</i> , 2016, 7, e2325-e2325.	2.7	34
368	High-Grade Gliomas. , 2016, , 469-482.e4.		1
369	Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 431-437.	1.4	9
370	The Long and Winding Road. <i>Advances in Pharmacology</i> , 2016, 76, 147-173.	1.2	2

#	ARTICLE	IF	CITATIONS
371	Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges. <i>Oncology Letters</i> , 2016, 11, 1281-1286.	0.8	50
372	Significant antitumor response of disseminated glioblastoma to bevacizumab resulting in long-term clinical remission in a patient with encephalocraniocutaneous lipomatosis: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 417-421.	0.4	6
373	Re-irradiation alternatives for recurrent high-grade glioma. <i>Oncology Letters</i> , 2016, 12, 2261-2270.	0.8	15
374	Glial Cells in Health and Disease of the CNS. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	0.8	9
375	Microglia in Cancer: For Good or for Bad?. <i>Advances in Experimental Medicine and Biology</i> , 2016, 949, 245-261.	0.8	18
376	Precision medicine in glioblastoma therapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 451-468.	0.4	0
377	Combining Ipilimumab and Bevacizumab in Glioblastoma: Is it Really Safe and Effective? Author Response. <i>Clinical Oncology</i> , 2016, 28, 664.	0.6	5
378	Psycho-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 305-313.	1.0	0
379	Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study. <i>Cancer</i> , 2016, 122, 3157-3165.	2.0	52
380	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. <i>Current Treatment Options in Oncology</i> , 2016, 17, 51.	1.3	32
381	Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1434-1441.	0.6	68
382	Morphological Changes of Cortical and Hippocampal Neurons after Treatment with VEGF and Bevacizumab. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 440-450.	1.9	13
383	Fractional Anisotropy Correlates with Overall Survival in Glioblastoma. <i>World Neurosurgery</i> , 2016, 95, 525-534.e1.	0.7	6
384	Transparent multi-layer graphene/polyethylene terephthalate structures with excellent microwave absorption and electromagnetic interference shielding performance. <i>Nanoscale</i> , 2016, 8, 16684-16693.	2.8	131
386	Coffee and green tea consumption in relation to brain tumor risk in a Japanese population. <i>International Journal of Cancer</i> , 2016, 139, 2714-2721.	2.3	22
387	Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers. <i>Journal of Clinical Neuroscience</i> , 2016, 33, 148-153.	0.8	7
388	Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide. <i>Journal of Neuro-Oncology</i> , 2016, 130, 165-170.	1.4	39
389	Efficacy and safety of bevacizumab for the treatment of glioblastoma. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 371-380.	0.8	12

#	ARTICLE	IF	CITATIONS
390	Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 705-718.	0.6	25
391	Caring for Patients with Newly Diagnosed High-Grade Gliomas. Seminars in Neurology, 2016, 36, 324-329.	0.5	0
392	Overview of Pathology and Treatment of Primary Brain Tumors. , 2016, , 9-22.		2
393	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. Journal of Neuro-Oncology, 2016, 129, 533-539.	1.4	5
394	Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response. Clinical Cancer Research, 2016, 22, 5765-5771.	3.2	230
395	Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme. Scientific Reports, 2016, 6, 29052.	1.6	19
396	Selective Estrogen Receptor $\hat{1}^2$ Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Scientific Reports, 2016, 6, 24185.	1.6	56
397	A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neuro-Oncology Practice, 2016, 3, 272-280.	1.0	34
398	Emerging targeted therapies for glioma. Expert Opinion on Emerging Drugs, 2016, 21, 441-452.	1.0	45
399	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine, 2016, 8, 341ra75.	5.8	158
401	Future Directions for Tumor Treating Fields. , 2016, , 117-126.		0
402	Tumor Treating Fields in Clinical Practice with Emphasis on PRiDe Registry. , 2016, , 79-92.		1
403	Tumor Treating Fields Therapy for Newly Diagnosed Glioblastoma. , 2016, , 93-102.		0
404	Targeted Therapy for Malignant Brain Tumors. Oxidative Stress in Applied Basic Research and Clinical Practice, 2016, , 433-450.	0.4	0
406	Laser Ablation of Recurrent Malignant Gliomas. Neurosurgery, 2016, 79, S35-S39.	0.6	20
408	BrÃve de lâ€™AERIO. Oncologie, 2016, 18, 355-357.	0.2	2
412	Health-related quality of life in brain tumor patients: as an endpoint in clinical trials and its value in clinical care. Expert Review of Quality of Life in Cancer Care, 2016, 1, 37-44.	0.6	14
413	Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma. An Easy Question Turned Difficult: Treat the Scan or the Patient?. Journal of Clinical Oncology, 2016, 34, 1281-1282.	0.8	6

#	ARTICLE	IF	CITATIONS
414	Noninvasive evaluation of radiation-enhanced glioma cells invasiveness by ultra-high-field 1H-MRS in vitro. <i>Magnetic Resonance Imaging</i> , 2016, 34, 1121-1127.	1.0	3
415	Radiotherapy of spinal cord gliomas. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 139-145.	1.0	14
416	Assessment of Brain Tumor Response: RANO and Its Offspring. <i>Current Treatment Options in Oncology</i> , 2016, 17, 35.	1.3	65
417	Radiobiology of Glioblastoma. <i>Current Clinical Pathology</i> , 2016, , .	0.0	2
419	Glioblastoma in the elderly: making sense of the evidence. <i>Neuro-Oncology Practice</i> , 2016, 3, 77-86.	1.0	17
420	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. <i>Recent Results in Cancer Research</i> , 2016, 198, 107-122.	1.8	12
421	The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1825-1829.	1.2	13
422	From Molecular to Clinical Radiation Biology of Glioblastoma. <i>Current Clinical Pathology</i> , 2016, , 275-292.	0.0	0
423	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2166-2174.	1.9	51
424	Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. <i>Current Treatment Options in Oncology</i> , 2016, 17, 42.	1.3	95
426	Neuroimaging Issues in Assessing Response to Brain Tumor Therapy. , 2016, , 667-680.		0
427	Limited role for transforming growth factor α pathway activation-mediated escape from VEGF inhibition in murine glioma models. <i>Neuro-Oncology</i> , 2016, 18, 1610-1621.	0.6	27
428	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
429	Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. <i>Seminars in Radiation Oncology</i> , 2016, 26, 281-298.	1.0	23
430	Tumor vasculature and glioma stem cells: Contributions to glioma progression. <i>Cancer Letters</i> , 2016, 380, 545-551.	3.2	106
431	Predicting glioblastoma response to bevacizumab through marker profiling?. <i>Neuro-Oncology</i> , 2016, 18, 149-150.	0.6	3
432	Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab. <i>Journal of Neuro-Oncology</i> , 2016, 127, 191-200.	1.4	3
433	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	0.8	159

#	ARTICLE	IF	CITATIONS
434	Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. <i>Neuro-Oncology</i> , 2016, 18, 735-743.	0.6	28
435	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. <i>Cancer Research</i> , 2016, 76, 525-534.	0.4	93
436	Ten years of anti-vascular endothelial growth factor therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 385-403.	21.5	724
437	Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM). <i>Molecular and Cellular Proteomics</i> , 2016, 15, 481-492.	2.5	41
439	Patterns of prescribing radiotherapy and bevacizumab in nationwide practice – analysis of 101 designated cancer care hospitals in Japan. <i>Journal of Radiation Research</i> , 2016, 57, 157-163.	0.8	3
440	Similar Trials With Differing Outcomes: Reconciliation in Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 291-292.	0.8	1
441	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2016, 34, 292-293.	0.8	0
442	Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts. <i>Investigational New Drugs</i> , 2016, 34, 24-40.	1.2	49
443	A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 127, 53-61.	1.4	37
444	Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. <i>Neuro-Oncology</i> , 2016, 18, 173-183.	0.6	35
445	Guidelines, –minimal requirements– and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean) Tj ETQq0 0 0 rgB10 Overlook 10 Tf 50	0.0	0
446	Neuro-oncological patients admitted in intensive-care unit: predictive factors and functional outcome. <i>Journal of Neuro-Oncology</i> , 2016, 127, 111-117.	1.4	11
447	Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. <i>Neurotherapeutics</i> , 2016, 13, 226-236.	2.1	24
448	Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 241-250.	1.4	26
449	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O ⁶ -Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1611-1619.	0.8	151
450	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 381-397.	1.0	289
451	Tumor cell–specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. <i>Journal of Neurosurgery</i> , 2016, 125, 995-1001.	0.9	1
452	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 497-521.	9.6	37

#	ARTICLE	IF	CITATIONS
453	Creating clinical trial designs that incorporate clinical outcome assessments. <i>Neuro-Oncology</i> , 2016, 18, ii21-ii25.	0.6	6
454	Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 47-53.	0.7	15
455	Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. <i>Neuro-Oncology</i> , 2016, 18, 1242-1252.	0.6	61
456	Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab. <i>Journal of Neurosurgery</i> , 2016, 125, 1008-1015.	0.9	48
457	Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. <i>Neuro-Oncology</i> , 2016, 18, 991-1001.	0.6	38
458	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 702-710.	1.9	103
459	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. <i>Journal of Neuro-Oncology</i> , 2016, 127, 569-579.	1.4	40
460	How I treat glioblastoma in older patients. <i>Journal of Geriatric Oncology</i> , 2016, 7, 1-6.	0.5	6
461	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556.	0.6	187
462	Experimental therapies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 183-197.	1.0	22
463	TTFields: where does all the skepticism come from?. <i>Neuro-Oncology</i> , 2016, 18, 303-305.	0.6	55
464	Epithelial-mesenchymal transition in glioblastoma progression. <i>Oncology Letters</i> , 2016, 11, 1615-1620.	0.8	207
465	A case of complete clearance of chronic subdural hematoma accompanied by recurrent glioblastoma multiforme after administration of bevacizumab. <i>Neurosurgical Review</i> , 2016, 39, 525-529.	1.2	2
466	Optimize and refine therapeutic index in radiation therapy: Overview of a century. <i>Cancer Treatment Reviews</i> , 2016, 45, 58-67.	3.4	60
467	The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. <i>World Neurosurgery</i> , 2016, 88, 222-236.	0.7	14
468	The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. <i>Journal of Neuro-Oncology</i> , 2016, 127, 165-171.	1.4	14
469	Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 82-88.	0.6	15
470	Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma. <i>Cancer Investigation</i> , 2016, 34, 39-44.	0.6	34

#	ARTICLE	IF	CITATIONS
471	Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. <i>Journal of Neuro-Oncology</i> , 2016, 126, 567-575.	1.4	31
472	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. <i>Cancer Immunology Research</i> , 2016, 4, 124-135.	1.6	339
473	USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance. <i>Neuro-Oncology</i> , 2016, 18, 37-47.	0.6	77
474	New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it. <i>Journal of NeuroInterventional Surgery</i> , 2016, 8, 1078-1082.	2.0	13
475	Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. <i>Oncogene</i> , 2016, 35, 2615-2623.	2.6	100
476	The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. <i>Acta Oncologica</i> , 2016, 55, 201-207.	0.8	30
477	Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. <i>Journal of Neuro-Oncology</i> , 2016, 126, 175-183.	1.4	18
478	A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. <i>Journal of Neuro-Oncology</i> , 2016, 126, 185-192.	1.4	63
479	Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. <i>Journal of Neurosurgery</i> , 2016, 124, 998-1007.	0.9	109
480	Current status and future directions of anti-angiogenic therapy for gliomas. <i>Neuro-Oncology</i> , 2016, 18, 315-328.	0.6	61
481	Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma. <i>Tumor Biology</i> , 2016, 37, 1173-1182.	0.8	39
482	Integrating chemoradiation and molecularly targeted therapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 74-83.	6.6	22
483	Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. <i>Neuro-Oncology Practice</i> , 2017, 4, 15-23.	1.0	6
484	Reliability of Semi-Automated Segmentations in Glioblastoma. <i>Clinical Neuroradiology</i> , 2017, 27, 153-161.	1.0	37
485	Trans sodium crocetin with temozolomide and radiation therapy for glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2017, 126, 460-466.	0.9	31
486	Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab. <i>Clinical and Translational Oncology</i> , 2017, 19, 51-57.	1.2	13
487	Current and future strategies for treatment of glioma. <i>Neurosurgical Review</i> , 2017, 40, 1-14.	1.2	416
488	Integrative functional genomic analysis identifies epigenetically regulated fibromodulin as an essential gene for glioma cell migration. <i>Oncogene</i> , 2017, 36, 71-83.	2.6	48

#	ARTICLE	IF	CITATIONS
489	Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. <i>Journal of Neurosurgery</i> , 2017, 126, 191-200.	0.9	148
490	The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 53-65.	1.6	80
491	SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI. <i>Neoplasia</i> , 2017, 19, 1-7.	2.3	43
492	Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 60-65.	2.0	75
493	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. <i>Seminars in Immunopathology</i> , 2017, 39, 225-239.	2.8	42
494	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 181-188.	1.4	16
495	Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 105-110.	0.4	15
496	Glioma: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 263-282.	3.9	223
497	Antiangiogenic Therapy for Malignant Gliomas. , 2017, , 163-175.		0
498	Glioblastoma. , 2017, , 265-288.		11
499	Current Standard Treatment Options for Malignant Glioma. , 2017, , 123-131.		1
500	New Directions in Anti-Angiogenic Therapy for Glioblastoma. <i>Neurotherapeutics</i> , 2017, 14, 321-332.	2.1	91
501	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. <i>Neurotherapeutics</i> , 2017, 14, 307-320.	2.1	294
502	1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 561-570.	2.8	12
503	Role of ketogenic metabolic therapy in malignant glioma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 41-58.	2.0	67
504	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3575-3584.	3.2	78
505	On glioblastoma and the search for a cure: where do we stand?. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2451-2466.	2.4	56
506	Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model. <i>BMC Cancer</i> , 2017, 17, 126.	1.1	21

#	ARTICLE	IF	CITATIONS
507	Glioma Subclassifications and Their Clinical Significance. <i>Neurotherapeutics</i> , 2017, 14, 284-297.	2.1	471
508	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017, 75, 245-258.	1.3	82
509	miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 43-48.	1.0	41
510	Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 94-102.	2.0	73
511	Abnormalities in hippocampal volume of glioma patients prior to radiotherapy. <i>Acta Oncologica</i> , 2017, 56, 427-430.	0.8	11
512	Influence of Bevacizumab on Blood-Brain Barrier Permeability and ¹⁸ F-Fluoroethyl)-L-Tyrosine Uptake in Rat Gliomas. <i>Journal of Nuclear Medicine</i> , 2017, 58, 700-705.	2.8	27
513	Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism. <i>Radiation Research</i> , 2017, 187, 79-88.	0.7	15
514	Microtubule actin cross-linking factor 1, a novel target in glioblastoma. <i>International Journal of Oncology</i> , 2017, 50, 310-316.	1.4	31
515	The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas. <i>International Journal of Oncology</i> , 2017, 50, 515-524.	1.4	12
517	Geraniin suppresses tumor cell growth and triggers apoptosis in human glioma via inhibition of STAT3 signaling. <i>Cytotechnology</i> , 2017, 69, 765-773.	0.7	16
518	Ethical difficulties in the innovative surgical treatment of patients with recurrent glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2017, 126, 2045-2050.	0.9	17
519	How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. <i>Annals of Oncology</i> , 2017, 28, 2077-2085.	0.6	30
520	PET/MRI and brain tumors: focus on radiation oncology treatment planning. <i>Clinical and Translational Imaging</i> , 2017, 5, 159-167.	1.1	3
521	Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. <i>CNS Oncology</i> , 2017, 6, 185-193.	1.2	43
522	Neuro-Oncology: Current Concepts and Emerging Therapeutics. <i>Neurotherapeutics</i> , 2017, 14, 253-255.	2.1	1
523	Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma. <i>Neuroradiology</i> , 2017, 59, 499-505.	1.1	19
524	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	4.9	125
525	Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines. <i>Cancer Biology and Therapy</i> , 2017, 18, 400-406.	1.5	12

#	ARTICLE	IF	CITATIONS
526	Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2017, 19, 1688-1697.	0.6	84
527	Primary spinal glioblastoma multiforme. <i>Medicine (United States)</i> , 2017, 96, e6634.	0.4	42
528	A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. <i>Journal of Translational Medicine</i> , 2017, 15, 104.	1.8	100
529	miRNAs: micro-managers of anticancer combination therapies. <i>Angiogenesis</i> , 2017, 20, 269-285.	3.7	55
530	The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis. <i>Clinical Neurology and Neurosurgery</i> , 2017, 159, 6-12.	0.6	8
531	Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma. <i>British Journal of Cancer</i> , 2017, 116, 1572-1584.	2.9	35
532	Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature. <i>World Neurosurgery</i> , 2017, 105, 53-62.	0.7	16
533	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	5.1	816
535	Isocostunolide inhibited glioma stem cell by suppression proliferation and inducing caspase dependent apoptosis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2863-2867.	1.0	19
536	A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery. <i>Brain Tumor Pathology</i> , 2017, 34, 98-102.	1.1	4
537	Angiogenesis inhibitors in tackling recurrent glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 507-515.	1.1	28
538	Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. <i>Cancer Medicine</i> , 2017, 6, 1192-1200.	1.3	24
539	Immune classifications with cytotoxic CD8 ⁺ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma. <i>OncImmunology</i> , 2017, 6, e1321186.	2.1	21
540	Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 17-27.	1.0	8
541	Brain Tumors and Metastases. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2017, 28, 115-141.	0.7	35
543	The role of bevacizumab in the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 133, 455-467.	1.4	157
544	Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 469-474.	0.6	34
545	Ligand-Mediated and Enzyme-Directed Precise Targeting and Retention for the Enhanced Treatment of Glioblastoma. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 20348-20360.	4.0	85

#	ARTICLE	IF	CITATIONS
546	Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. <i>Journal of Neuro-Oncology</i> , 2017, 133, 297-307.	1.4	20
547	Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era. <i>Mayo Clinic Proceedings</i> , 2017, 92, 995-1004.	1.4	15
548	Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma. <i>Cancer Letters</i> , 2017, 402, 131-141.	3.2	33
550	Glioblastoma targeted therapy: updated approaches from recent biological insights. <i>Annals of Oncology</i> , 2017, 28, 1457-1472.	0.6	314
551	Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. <i>Oncologist</i> , 2017, 22, 570-575.	1.9	23
552	The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. <i>Angiogenesis</i> , 2017, 20, 217-232.	3.7	26
553	Primary Spinal Cord Glioblastoma Multiforme: A Retrospective Study of Patients at a Single Institution. <i>World Neurosurgery</i> , 2017, 106, 113-119.	0.7	15
554	Milestones of the last 10 years. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 18-21.	0.3	8
555	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126.	0.6	107
556	Management of Elderly Patients with Glioblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 35.	2.0	12
557	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 908-917.	0.6	23
558	Central nervous system gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 213-234.	2.0	109
559	Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. <i>Brain Tumor Pathology</i> , 2017, 34, 62-77.	1.1	82
560	Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. <i>American Journal of Pathology</i> , 2017, 187, 940-953.	1.9	80
561	The Microenvironmental Landscape of Brain Tumors. <i>Cancer Cell</i> , 2017, 31, 326-341.	7.7	1,163
562	Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. <i>Radiotherapy and Oncology</i> , 2017, 123, 106-111.	0.3	32
564	Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. <i>Journal of Neuro-Oncology</i> , 2017, 132, 433-437.	1.4	12
565	Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. <i>Scientific Reports</i> , 2017, 7, 44075.	1.6	27

#	ARTICLE	IF	CITATIONS
566	Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life. <i>World Neurosurgery</i> , 2017, 102, 383-399.	0.7	14
567	Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme. <i>Scientific Reports</i> , 2017, 7, 43523.	1.6	20
568	Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. <i>Journal of Neurology</i> , 2017, 264, 350-358.	1.8	27
569	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-369.	0.8	109
570	The network of immunosuppressive pathways in glioblastoma. <i>Biochemical Pharmacology</i> , 2017, 130, 1-9.	2.0	76
571	Advances in the molecular genetics of gliomas – implications for classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 434-452.	12.5	497
572	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 53, 120-127.	3.4	178
573	Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity. <i>Cancer Drug Discovery and Development</i> , 2017, , 35-55.	0.2	1
574	Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice. <i>Neuro-Oncology Practice</i> , 2017, 4, 209-219.	1.0	17
575	Targeting Aberrant Signaling Pathways. , 2017, , 133-150.		1
576	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanine –DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-351.	0.8	110
577	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 277-287.	1.0	19
578	Toward Personalized Targeted Therapeutics: An Overview. <i>Neurotherapeutics</i> , 2017, 14, 256-264.	2.1	22
579	Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 379-389.	2.0	20
580	Nanoparticles for radiooncology: Mission, vision, challenges. <i>Biomaterials</i> , 2017, 120, 155-184.	5.7	87
581	ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. <i>Oncology Letters</i> , 2017, 14, 5443-5451.	0.8	6
582	Treatment of Glioblastoma in Older Adults. <i>Current Oncology Reports</i> , 2017, 19, 81.	1.8	45
583	Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment. <i>Scientific Reports</i> , 2017, 7, 13894.	1.6	30

#	ARTICLE	IF	CITATIONS
584	Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy. <i>Cell Stem Cell</i> , 2017, 21, 591-603.e4.	5.2	168
585	Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. <i>Cancer Investigation</i> , 2017, 35, 519-534.	0.6	54
586	Recent Advances for Targeted Therapies in Glioblastoma. <i>Current Cancer Research</i> , 2017, , 91-115.	0.2	0
587	Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy related intracranial effects. <i>British Journal of Radiology</i> , 2018, 91, 20170553.	1.0	3
588	Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 429-439.	1.0	15
589	Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. <i>Radiation Research</i> , 2017, 188, 303.	0.7	10
590	Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1359479.	5.5	206
591	Cancer-Targeted Selenium Nanoparticles Sensitize Cancer Cells to Continuous β^3 Radiation to Achieve Synergetic Chemo-Radiotherapy. <i>Chemistry - an Asian Journal</i> , 2017, 12, 3053-3060.	1.7	34
592	The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 135, 553-560.	1.4	24
593	FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas. <i>Scientific Reports</i> , 2017, 7, 10210.	1.6	20
594	Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216.		0
595	Pseudoprogression after glioma therapy: an update. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1109-1115.	1.4	40
596	GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. <i>Scientific Reports</i> , 2017, 7, 8814.	1.6	20
598	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. <i>Oncology Letters</i> , 2017, 14, 1141-1146.	0.8	58
599	Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature. <i>Journal of Clinical Neuroscience</i> , 2017, 44, 101-106.	0.8	28
600	Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data. <i>Tumor Biology</i> , 2017, 39, 101042831771489.	0.8	4
601	The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET). <i>Cancer</i> , 2017, 123, 3576-3582.	2.0	9
602	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. <i>Journal of Neuro-Oncology</i> , 2017, 135, 183-192.	1.4	138

#	ARTICLE	IF	CITATIONS
603	The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation. <i>Tumor Biology</i> , 2017, 39, 101042831770392.	0.8	10
604	Genetically Engineered Multilineage-Differentiating Stress-Enduring Cells as Cellular Vehicles against Malignant Gliomas. <i>Molecular Therapy - Oncolytics</i> , 2017, 6, 45-56.	2.0	8
605	Current Therapies and Future Directions in Treatment of Glioblastoma. <i>Current Cancer Research</i> , 2017, , 57-89.	0.2	1
606	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 123-131.	3.4	49
607	GBM radiosensitizers: dead in the water or just the beginning?. <i>Journal of Neuro-Oncology</i> , 2017, 134, 513-521.	1.4	19
608	Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature. <i>Nanoscale</i> , 2017, 9, 12096-12109.	2.8	23
609	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	2.0	4
610	FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling. <i>Neuroscience Letters</i> , 2017, 657, 77-83.	1.0	25
611	The Prognostic Impact of Ventricular Opening in Glioblastoma Surgery: A Retrospective Single Center Analysis. <i>World Neurosurgery</i> , 2017, 106, 615-624.	0.7	19
612	Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients. <i>Medicine (United States)</i> , 2017, 96, e7422.	0.4	39
613	Cell Signaling Pathways in Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 15-26.	0.7	5
614	Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 626.	3.8	148
615	Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2017, 133, 571-579.	1.4	18
616	Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. <i>Neoplasia</i> , 2017, 19, 684-694.	2.3	13
617	PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma. <i>Scientific Reports</i> , 2017, 7, 7391.	1.6	8
618	Time-sequenced drug delivery approaches towards effective chemotherapeutic treatment of glioma. <i>Materials Horizons</i> , 2017, 4, 977-996.	6.4	14
619	Anticancer potential of aminomethylidene-diazinanes I. Synthesis of arylaminomethylidene of diazinetiones and its cytotoxic effects tested in glioblastoma cells. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5068-5076.	1.4	5
620	Germline MSH6 Mutation in a Patient With Two Independent Primary Glioblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 848-853.	0.9	4

#	ARTICLE	IF	CITATIONS
621	Tumor-Host Interactions in Malignant Gliomas. , 2017, , 465-479.		0
622	The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiotherapy and Oncology, 2017, 125, 228-233.	0.3	26
623	Impact on radiation dose and volume V57 Gy of the brain on recurrence and survival of patients with glioblastoma multiformae. Radiology and Oncology, 2017, 51, 463-468.	0.6	0
624	Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963.	13.9	670
625	Implications of Antiangiogenic Therapy on Radiographic Assessment of Brain Tumors. World Neurosurgery, 2017, 108, 380-382.	0.7	0
626	Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma. Journal of Neuro-Oncology, 2017, 135, 173-181.	1.4	43
627	Antibodyâ€“drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nature Reviews Clinical Oncology, 2017, 14, 695-707.	12.5	90
628	What are the prospects for combination therapy for glioblastoma?. Expert Review of Neurotherapeutics, 2017, 17, 947-949.	1.4	3
629	Targeting EGFRvIII for glioblastoma multiforme. Cancer Letters, 2017, 403, 224-230.	3.2	48
631	Optimizing bevacizumab dosing in glioblastoma: less is more. Journal of Neuro-Oncology, 2017, 135, 99-105.	1.4	20
632	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 797-804.	0.4	40
633	Adipocytokines, Energy Balance, and Cancer. Energy Balance and Cancer, 2017, , .	0.2	4
634	Carboxyethylpyrroles: From Hypothesis to the Discovery of Biologically Active Natural Products. Chemical Research in Toxicology, 2017, 30, 105-113.	1.7	8
636	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 193-199.	1.4	55
637	Apelin and Cancer. Energy Balance and Cancer, 2017, , 137-160.	0.2	3
638	The Added Prognostic Value of Metabolic Tumor Size on FDGâ€“PET at First Suspected Recurrence of Glioblastoma Multiforme. Journal of Neuroimaging, 2017, 27, 243-247.	1.0	15
639	Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. Molecular Neurobiology, 2017, 54, 5780-5797.	1.9	52
640	Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses. Journal of Neuro-Oncology, 2017, 131, 11-20.	1.4	14

#	ARTICLE	IF	CITATIONS
641	Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence. <i>Radiology</i> , 2017, 282, 212-221.	3.6	11
642	NOS Expression and NO Function in Glioma and Implications for Patient Therapies. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 986-999.	2.5	47
643	Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis. <i>Journal of Neuro-Oncology</i> , 2017, 131, 125-133.	1.4	84
644	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	3.8	1,619
645	Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway. <i>Oncology Letters</i> , 2017, 15, 1487-1494.	0.8	42
646	Pharmacological targeting of apelin impairs glioblastoma growth. <i>Brain</i> , 2017, 140, 2939-2954.	3.7	70
647	Acute care in glioblastoma: the burden and the consequences. <i>Neuro-Oncology Practice</i> , 2017, 4, 248-254.	1.0	4
648	Glioblastoma Treatment in the Elderly. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 667-676.	1.0	32
649	Essence of survival analysis. <i>Neuro-Oncology Practice</i> , 2017, 4, 77-81.	1.0	1
650	The Response to Chemo Radiation Therapy in Unresectable Glioblastoma Multiforme Patients in Relation to MGMT Promoter Methylation Status: A Study from a Single Saudi Center. <i>Journal of Clinical Epigenetics</i> , 2017, 03, .	0.3	0
651	Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment. <i>Journal of Cancer</i> , 2017, 8, 1417-1424.	1.2	8
652	Treatment of Edema Formation in Oncology. , 2017, , 477-495.		0
653	DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. <i>Oncotarget</i> , 2017, 8, 1416-1428.	0.8	193
654	Immune Checkpoint in Glioblastoma: Promising and Challenging. <i>Frontiers in Pharmacology</i> , 2017, 8, 242.	1.6	133
655	Bevacizumab for Patients with Recurrent Multifocal Glioblastomas. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2469.	1.8	12
656	Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2576.	1.8	31
657	Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes. <i>Cancers</i> , 2017, 9, 59.	1.7	5
658	Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern. <i>International Journal of Molecular Sciences</i> , 2017, 18, 726.	1.8	7

#	ARTICLE	IF	CITATIONS
659	CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression. <i>Frontiers in Immunology</i> , 2017, 8, 1451.	2.2	47
660	Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells. <i>Frontiers in Oncology</i> , 2017, 7, 182.	1.3	16
661	Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients. <i>Neuroscience Journal</i> , 2017, 2017, 1-8.	2.3	8
662	Recognition of Transmembrane Protein 39A as a Tumor-Specific Marker in Brain Tumor. <i>Toxicological Research</i> , 2017, 33, 63-69.	1.1	13
663	Mitochondrial transcription factor A (TFAM) is upregulated in glioma. <i>Molecular Medicine Reports</i> , 2017, 15, 3781-3786.	1.1	21
664	Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma. <i>Radiation Oncology</i> , 2017, 12, 123.	1.2	13
665	Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. <i>Oncotarget</i> , 2017, 8, 49702-49712.	0.8	84
666	Actin cytoskeleton regulator Arp2/3 complex is required for DLL1 activating Notch1 signaling to maintain the stem cell phenotype of glioma initiating cells. <i>Oncotarget</i> , 2017, 8, 33353-33364.	0.8	30
667	Advances in the Treatment of Primary Brain Tumors: The Realm of Immunotherapy. , 0, , .		0
668	NANO, a practical scale for neurologic assessments in patients with brain tumors?. <i>Neuro-Oncology</i> , 2017, 19, 603-604.	0.6	2
669	Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 429-437.	1.0	15
670	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. <i>Oncotarget</i> , 2017, 8, 91779-91794.	0.8	298
671	Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov. <i>Journal of Clinical Oncology</i> , 2017, 35, 1686-1694.	0.8	52
672	Treatment of Glioblastoma. <i>Journal of Oncology Practice</i> , 2017, 13, 629-638.	2.5	94
673	Clinical trial endpoints for patients with gliomas. <i>Neuro-Oncology Practice</i> , 2017, 4, 201-208.	1.0	7
674	Adult Glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2402-2409.	0.8	561
675	Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome. <i>ELife</i> , 2017, 6, .	2.8	50
676	Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. <i>Oncotarget</i> , 2017, 8, 44015-44031.	0.8	69

#	ARTICLE	IF	CITATIONS
677	Targeting the microenvironment in solid tumors. <i>Cancer Treatment Reviews</i> , 2018, 65, 22-32.	3.4	342
678	Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 325-340.	12.5	1,192
679	Evaluation of the quality of RNA extracted from archival FFPE glioblastoma and epilepsy surgical samples for gene expression assays. <i>Journal of Clinical Pathology</i> , 2018, 71, 695-701.	1.0	11
680	Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. <i>Journal of Neuro-Oncology</i> , 2018, 138, 359-367.	1.4	12
681	Combining Clinical and Molecular Data to Predict the Benefits of Carmustine Wafers in Newly Diagnosed High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2018, 20, 3.	0.7	14
682	Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). <i>Oncologist</i> , 2018, 23, 524.	1.9	30
683	Imaging in neuro-oncology. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875986.	1.5	41
684	Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775359.	1.5	5
685	Current Challenges and Opportunities in Treating Glioblastoma. <i>Pharmacological Reviews</i> , 2018, 70, 412-445.	7.1	571
687	ARTE and craft of bevacizumab in elderly patients with glioblastoma. <i>Annals of Oncology</i> , 2018, 29, 1346-1347.	0.6	0
688	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018, 20, 1525-1535.	0.6	15
689	Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. <i>Journal of Pathology</i> , 2018, 245, 209-221.	2.1	70
690	Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. <i>Neuro-Oncology</i> , 2018, 20, 1356-1367.	0.6	8
691	A Shock to the System: Tumor-Treating Fields Plus Temozolomide for Glioblastoma. <i>Neurosurgery</i> , 2018, 82, E115-E116.	0.6	0
692	A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. <i>Cancer Cell</i> , 2018, 33, 874-889.e7.	7.7	180
693	Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. <i>Cancer Medicine</i> , 2018, 7, 1774-1783.	1.3	5
694	Palliative Care Issues in Glioblastoma #350. <i>Journal of Palliative Medicine</i> , 2018, 21, 567-568.	0.6	0
695	Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. <i>Annals of Oncology</i> , 2018, 29, 1431-1436.	0.6	73

#	ARTICLE	IF	CITATIONS
696	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. <i>Annals of Oncology</i> , 2018, 29, 1423-1430.	0.6	65
697	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	12.5	873
698	Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 1051-1059.	1.1	9
699	Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. <i>Journal of Experimental Medicine</i> , 2018, 215, 963-983.	4.2	36
700	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	0.6	93
701	Renin angiotensin system and its role in biomarkers and treatment in gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 138, 1-15.	1.4	22
702	Orthotopic Patient-Derived Glioblastoma Xenografts in Mice. <i>Methods in Molecular Biology</i> , 2018, 1741, 183-190.	0.4	18
703	Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. <i>Molecular Cancer Research</i> , 2018, 16, 767-776.	1.5	25
704	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 975-985.	0.6	11
705	Chemotherapy of High-Grade Astrocytomas in Adults. <i>Progress in Neurological Surgery</i> , 2018, 31, 116-144.	1.3	5
706	Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. <i>CNS Oncology</i> , 2018, 7, 7-13.	1.2	3
707	Role of Radiosensitizers in Radiation Treatment of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 31, 102-115.	1.3	3
708	Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. <i>Practical Radiation Oncology</i> , 2018, 8, 230-238.	1.1	22
709	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	1.0	60
710	The roles of TRIO and F-actin-binding protein in glioblastoma cells. <i>Molecular Medicine Reports</i> , 2018, 17, 4540-4546.	1.1	2
711	Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 105-111.	1.4	35
713	Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. <i>Journal of Neuro-Oncology</i> , 2018, 138, 141-145.	1.4	6
714	From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence. <i>Clinical and Translational Oncology</i> , 2018, 20, 989-1003.	1.2	9

#	ARTICLE	IF	CITATIONS
715	Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response. <i>Molecular Neurobiology</i> , 2018, 55, 6816-6833.	1.9	17
716	Targeted and theranostic applications for nanotechnologies in medicine. , 2018, , 399-511.		7
717	H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma. <i>British Journal of Cancer</i> , 2018, 118, 522-533.	2.9	17
718	A novel prognostic six CpG signature in glioblastomas. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 167-177.	1.9	30
719	The Direction of Tumour Growth in Glioblastoma Patients. <i>Scientific Reports</i> , 2018, 8, 1199.	1.6	48
720	The siren song of bevacizumab: swan song or clarion call?. <i>Neuro-Oncology</i> , 2018, 20, 147-148.	0.6	7
721	Phase 2 and biomarker study of trebananib, an angiopoietin blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer</i> , 2018, 124, 1438-1448.	2.0	38
722	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1195-1203.	0.4	45
723	Incidence and survival rates for adult malignant neuro-epithelial brain tumors in the Somme county (France): A retrospective, population-based study from 2003 to 2013. <i>Journal of Cancer Policy</i> , 2018, 15, 5-9.	0.6	0
724	Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. <i>World Neurosurgery</i> , 2018, 110, e727-e737.	0.7	14
725	Microenvironment-Derived Regulation of HIF Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme. <i>Molecular Cancer Research</i> , 2018, 16, 655-668.	1.5	21
726	Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. <i>Journal of Neuro-Oncology</i> , 2018, 137, 533-542.	1.4	19
727	Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. <i>Cancer</i> , 2018, 124, 1455-1463.	2.0	41
728	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 1162-1172.	0.6	92
729	Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres. <i>Neuro-Oncology</i> , 2018, 20, 954-965.	0.6	57
730	Analysis of immunobiologic markers in primary and recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 137, 249-257.	1.4	40
731	Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies. <i>Oncologist</i> , 2018, 23, 1063-1075.	1.9	10
732	Temozolomide for immunomodulation in the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1566-1572.	0.6	166

#	ARTICLE	IF	CITATIONS
733	Brain tumors – other treatment modalities. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.0	2
734	Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation. Clinical and Translational Radiation Oncology, 2018, 10, 47-52.	0.9	36
735	Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis. Acta Neurochirurgica, 2018, 160, 1167-1174.	0.9	10
736	Diffusely Infiltrating Cerebellar Anaplastic Astrocytoma Effectively Controlled with Bevacizumab: Case Report and Literature Review. World Neurosurgery, 2018, 115, 181-185.	0.7	3
737	Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Neuro-Oncology, 2018, 20, 1400-1410.	0.6	27
738	Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. World Neurosurgery, 2018, 113, e508-e514.	0.7	26
739	MAP30 promotes apoptosis of U251 and U87 cells by suppressing the LGR5 and Wnt/ β -catenin signaling pathway, and enhancing Smac expression. Oncology Letters, 2018, 15, 5833-5840.	0.8	14
740	Pathologic Findings and Clinical Course of Midline Paraventricular Gliomas Diagnosed Using a Neuroendoscope. World Neurosurgery, 2018, 114, e366-e377.	0.7	9
741	JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon β plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2018, 138, 627-636.	1.4	49
742	Anti-Angiogenics: Their Role in the Treatment of Glioblastoma. Oncology Research and Treatment, 2018, 41, 181-186.	0.8	28
743	Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1626-1635.	3.3	14
744	Current Clinical State of Advanced Magnetic Resonance Imaging for Brain Tumor Diagnosis and Follow Up. Seminars in Roentgenology, 2018, 53, 45-61.	0.2	10
745	Radiomics, Metabolic, and Molecular MRI for Brain Tumors. Seminars in Neurology, 2018, 38, 032-040.	0.5	19
746	New Directions in the Treatment of Glioblastoma. Seminars in Neurology, 2018, 38, 050-061.	0.5	33
747	Imaging Criteria in Neuro-oncology. Seminars in Neurology, 2018, 38, 024-031.	0.5	17
748	Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States. Neuro-Oncology Practice, 2018, 5, 251-261.	1.0	10
749	The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. Oncoimmunology, 2018, 7, e1448329.	2.1	79
750	Clinical effectiveness of bevacizumab in patients with recurrent brain tumours: A population-based evaluation. Journal of Oncology Pharmacy Practice, 2018, 24, 33-36.	0.5	8

#	ARTICLE	IF	CITATIONS
751	Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1741-1753.	2.4	15
752	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. <i>Neuro-Oncology</i> , 2018, 20, 174-183.	0.6	33
753	Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. <i>Clinical Immunology</i> , 2018, 189, 43-51.	1.4	27
754	Risk of malignant brain tumor as a second primary is significantly reduced after treatment of breast cancer. <i>Breast Journal</i> , 2018, 24, 219-220.	0.4	0
755	Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. <i>Neuro-Oncology</i> , 2018, 20, 457-471.	0.6	44
756	Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. <i>Oncogene</i> , 2018, 37, 777-786.	2.6	37
757	Radiologic progression of glioblastoma under therapy – an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2018, 20, 557-566.	0.6	24
758	Vaccination in the immunotherapy of glioblastoma. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 255-268.	1.4	50
759	Anti-VEGF treatment improves neurological function in tumors of the nervous system. <i>Experimental Neurology</i> , 2018, 299, 326-333.	2.0	14
760	Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCR Brain Tumor CSG. <i>Neuro-Oncology Practice</i> , 2018, 5, 10-17.	1.0	7
761	MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 63-71.	1.4	22
762	Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatin-based polychemotherapy regimen. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 215-224.	1.0	11
763	Overall survival in patients with glioblastoma before and after bevacizumab approval. <i>Current Medical Research and Opinion</i> , 2018, 34, 813-820.	0.9	31
764	The Evolving Role of Tumor Treating Fields in Managing Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 191-196.	0.6	48
765	Developmentally regulated signaling pathways in glioma invasion. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 385-402.	2.4	63
766	Survival improvements with adjuvant therapy in patients with glioblastoma. <i>ANZ Journal of Surgery</i> , 2018, 88, 196-201.	0.3	18
767	Neurological Complications of Primary Brain Tumors. , 2018, , 399-416.		0
768	Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma. <i>Journal of Neurochemistry</i> , 2018, 144, 421-430.	2.1	8

#	ARTICLE	IF	CITATIONS
769	Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis. <i>Clinical and Translational Oncology</i> , 2018, 20, 939-953.	1.2	63
770	Contemporary management of high-grade gliomas. <i>CNS Oncology</i> , 2018, 7, 51-65.	1.2	32
771	SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 22-28.	1.2	56
772	HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway. <i>Cancer Letters</i> , 2018, 415, 164-176.	3.2	74
773	Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. <i>Seminars in Cancer Biology</i> , 2018, 52, 117-124.	4.3	302
774	A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 228-233.	0.8	15
775	State of the Art Treatment and Surveillance Imaging of Glioblastomas. <i>Seminars in Roentgenology</i> , 2018, 53, 23-36.	0.2	7
776	Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. , 2018, 184, 13-41.		230
777	Targeting the perivascular niche in brain tumors. <i>Current Opinion in Oncology</i> , 2018, 30, 54-60.	1.1	36
778	Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 113-122.	0.6	56
779	Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e8-e14.	0.7	9
780	Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment. <i>Anti-Cancer Drugs</i> , 2018, 29, 924-928.	0.7	2
781	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.	0.8	39
782	BRAF Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3477-3484.	0.8	247
783	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 951-958.	0.8	95
784	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 148-157.	1.8	2
785	Overt tumor regression after salvage boron neutron capture therapy (BNCT) for a recurrent glioblastoma patient. <i>Therapeutic Radiology and Oncology</i> , 0, 2, 48-48.	0.2	4
786	Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?. <i>Radiology and Oncology</i> , 2018, 52, 121-128.	0.6	42

#	ARTICLE	IF	CITATIONS
787	Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	3
788	Impact of Immunotherapy in the Treatment of Glioblastoma. , 0, , .		0
789	Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 462.	1.3	108
790	Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression. <i>Theranostics</i> , 2018, 8, 5143-5158.	4.6	64
791	Lower-grade gliomas: the wrong target for bevacizumab. <i>Neuro-Oncology</i> , 2018, 20, 1559-1560.	0.6	2
792	Current Options and Future Directions in Immune Therapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 578.	1.3	21
793	Extracellular matrix differences in glioblastoma patients with different prognoses. <i>Oncology Letters</i> , 2018, 17, 797-806.	0.8	21
794	The Emerging Role of Amino Acid PET in Neuro-Oncology. <i>Bioengineering</i> , 2018, 5, 104.	1.6	26
795	Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?. <i>Cancers</i> , 2018, 10, 492.	1.7	45
796	Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab. <i>Quantitative Imaging in Medicine and Surgery</i> , 2018, 8, 268-279.	1.1	9
797	Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas – A Pilot Study. <i>Neurologia Medico-Chirurgica</i> , 2018, 58, 487-494.	1.0	18
798	Acid-Induced Activated Cell-Penetrating Peptide-Modified Cholesterol-Conjugated Polyoxyethylene Sorbitol Oleate Mixed Micelles for pH-Triggered Drug Release and Efficient Brain Tumor Targeting Based on a Charge Reversal Mechanism. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 43411-43428.	4.0	39
799	IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma. <i>Oncotarget</i> , 2018, 9, 15721-15731.	0.8	28
800	MGMT promoter methylation in Peruvian patients with glioblastoma. <i>Ecancermedicalscience</i> , 2018, 12, 812.	0.6	1
801	Evidence-based Therapy and Problem of Glioblastoma. <i>Japanese Journal of Neurosurgery</i> , 2018, 27, 91-98.	0.0	0
802	Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. <i>Neurologia Medico-Chirurgica</i> , 2018, 58, 405-421.	1.0	222
803	Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2879.	1.8	151
804	Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk. <i>Frontiers in Oncology</i> , 2018, 8, 373.	1.3	2

#	ARTICLE	IF	CITATIONS
805	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. <i>BMJ Open</i> , 2018, 8, e017240.	0.8	20
806	High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma. , 2018, , 193-221.		0
807	Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives. <i>World Neurosurgery</i> , 2018, 120, 302-315.	0.7	29
808	Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated with Bevacizumab Concurrent with Radiotherapy Followed by Adjuvant Bevacizumab plus Irinotecan versus Temozolomide Concurrent with Radiotherapy Followed by Adjuvant Temozolomide. <i>Archives in Cancer Research</i> , 2018, 06, .	0.3	1
809	LPA4-Mediated Vascular Network Formation Increases the Efficacy of Anti-“PD-1 Therapy against Brain Tumors. <i>Cancer Research</i> , 2018, 78, 6607-6620.	0.4	28
810	Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report. <i>Acta Neurochirurgica</i> , 2018, 160, 2387-2391.	0.9	2
811	Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre. <i>Brain Sciences</i> , 2018, 8, 186.	1.1	1
812	Luteolin inhibits Musashi1 binding to RNA and disrupts cancer phenotypes in glioblastoma cells. <i>RNA Biology</i> , 2018, 15, 1420-1432.	1.5	39
813	Neuroimaging in patients with high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 221-224.	0.4	0
814	Management of diffuse glioma. <i>Presse Medicale</i> , 2018, 47, e199-e212.	0.8	11
815	Methylation dependent down-regulation of GOS2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma. <i>PLoS ONE</i> , 2018, 13, e0206552.	1.1	8
816	Harnessing the immune system in glioblastoma. <i>British Journal of Cancer</i> , 2018, 119, 1171-1181.	2.9	138
817	The Evolving Role of the Oncologic Neurosurgeon: Looking Beyond Extent of Resection in the Modern Era. <i>Frontiers in Oncology</i> , 2018, 8, 406.	1.3	1
818	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	1.7	67
819	Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis. <i>Neurological Sciences</i> , 2018, 39, 2021-2031.	0.9	15
820	WINDOW consortium: A path towards increased therapy efficacy against glioblastoma. <i>Drug Resistance Updates</i> , 2018, 40, 17-24.	6.5	15
821	Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG). <i>Bioengineering</i> , 2018, 5, 88.	1.6	15
822	VEGF-Grab Enhances the Efficacy of Radiation Therapy by Blocking VEGF-A and Treatment-Induced PlGF. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 609-618.	0.4	3

#	ARTICLE	IF	CITATIONS
823	Angiogenesis and radiological tumor growth in patients with glioblastoma. <i>BMC Cancer</i> , 2018, 18, 862.	1.1	10
824	Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. <i>British Journal of Radiology</i> , 2019, 92, 20180405.	1.0	12
825	Decane-1,2-diol derivatives as potential antitumor agents for the treatment of glioblastoma. <i>European Journal of Pharmacology</i> , 2018, 837, 105-116.	1.7	4
826	Bevacizumab and Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 180-186.	1.0	78
827	Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5059-5074.	1.0	23
828	Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2018, 170, 127-131.	0.6	8
829	Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged >75 years. <i>International Journal of Clinical Oncology</i> , 2018, 23, 820-825.	1.0	7
830	Neurologic and Medical Management of Brain Tumors. <i>Neurologic Clinics</i> , 2018, 36, 449-466.	0.8	12
831	A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy. <i>Journal of Radiation Oncology</i> , 2018, 7, 223-232.	0.7	0
832	Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma. <i>World Neurosurgery</i> , 2018, 116, 464-471.e1.	0.7	1
833	Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1263-1271.	0.6	15
834	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018, 20, 897-906.	0.6	41
835	New patterns of magnetic resonance images in high-grade glioma patients treated with bevacizumab (Avastin®). <i>Clinical and Translational Neuroscience</i> , 2018, 2, 2514183X1775290.	0.4	1
836	Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study. <i>Clinical Neurology and Neurosurgery</i> , 2018, 171, 34-41.	0.6	6
837	Bioinformatic analyses reveal the key pathways and genes in the CXCR4 mediated mesenchymal subtype of glioblastoma. <i>Molecular Medicine Reports</i> , 2018, 18, 741-748.	1.1	9
838	Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1581-1589.	1.2	11
839	Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. <i>Clinical Oncology</i> , 2018, 30, 556-562.	0.6	6
840	BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. <i>Cell Death and Differentiation</i> , 2018, 25, 1808-1822.	5.0	27

#	ARTICLE	IF	CITATIONS
841	Harnessing Tumor Microenvironment for Nanoparticle-Mediated Radiotherapy. <i>Advanced Therapeutics</i> , 2018, 1, 1800050.	1.6	33
842	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018, 379, 150-161.	13.9	570
843	Genomics and Proteomics in Neuro-Oncology. , 2018, , 75-85.		0
844	Growth Factor Signaling Pathways and Targeted Therapy. , 2018, , 305-322.		0
845	Angiogenesis and Angiogenesis Inhibitors in Brain Tumors. , 2018, , 361-371.		1
846	Bevacizumab and Brain Tumors. , 2018, , 373-381.		0
847	Chemotherapy of Pediatric High-Grade Gliomas. , 2018, , 557-568.		0
848	Issues in Response Assessment of Brain Tumor Chemotherapy. , 2018, , 715-727.		2
850	Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial). <i>Journal of Neuro-Oncology</i> , 2018, 140, 75-82.	1.4	31
851	Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". <i>Cancer Treatment Reviews</i> , 2018, 69, 121-131.	3.4	46
852	Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma. <i>Epigenetics</i> , 2018, 13, 432-448.	1.3	29
853	Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody. <i>BioMed Research International</i> , 2018, 2018, 1-12.	0.9	15
854	The Treatment of Gliomas in Adulthood. <i>Deutsches A&#x0308;rzteblatt International</i> , 2018, 115, 356-364.	0.6	20
855	Molecular Pathogenesis and Emerging Treatment for Glioblastoma. <i>World Neurosurgery</i> , 2018, 116, 495-504.	0.7	13
856	Understanding and Treating Glioblastoma. <i>Neurologic Clinics</i> , 2018, 36, 485-499.	0.8	18
857	Neurologic Complications of Systemic Anticancer Therapy. <i>Neurologic Clinics</i> , 2018, 36, 627-651.	0.8	5
858	Neurocognitive Function in Adult Cancer Patients. <i>Neurologic Clinics</i> , 2018, 36, 653-674.	0.8	15
859	The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2396-2403.	3.3	25

#	ARTICLE	IF	CITATIONS
860	EGFL7 enhances surface expression of integrin $\alpha 5 \beta 1$ to promote angiogenesis in malignant brain tumors. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	33
861	The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3513-3520.	1.0	13
862	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2018, 101, 95-104.	1.3	11
863	Immunotherapy in Glioblastoma. <i>World Neurosurgery</i> , 2018, 116, 518-528.	0.7	31
864	Treatment of Glioblastoma in the Elderly. <i>Drugs and Aging</i> , 2018, 35, 707-718.	1.3	11
865	Tumors of the Central Nervous System. <i>NeuroMethods</i> , 2018, , 339-363.	0.2	0
866	Advances in Radiotherapy for Glioblastoma. <i>Frontiers in Neurology</i> , 2017, 8, 748.	1.1	103
867	Highlighting the need for reliable clinical trials in glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1031-1040.	1.1	12
868	Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1765.	1.8	44
869	Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges. <i>Pharmaceutics</i> , 2018, 10, 45.	2.0	19
870	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	1.8	376
871	Usefulness of ^{11}C -Methionine Positron Emission Tomography for Monitoring of Treatment Response and Recurrence in a Glioblastoma Patient on Bevacizumab Therapy: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 442-449.	0.3	1
872	Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas. <i>NeuroImage: Clinical</i> , 2018, 20, 51-60.	1.4	34
873	Cancer stem cells from peritumoral tissue of glioblastoma multiforme: the possible missing link between tumor development and progression. <i>Oncotarget</i> , 2018, 9, 28116-28130.	0.8	26
874	Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma â€œ the GlioCave study (NOA 17 â€œ ARO 2016/3 â€œ DTKK ROG trial). <i>BMC Cancer</i> , 2018, 18, 15.	1.1	22
875	Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. <i>BMC Cancer</i> , 2018, 18, 105.	1.1	32
877	Vinblastine and antihelminthic mebendazole potentiate temozolomide in resistant gliomas. <i>Investigational New Drugs</i> , 2018, 36, 323-331.	1.2	34
878	VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. <i>BMC Cancer</i> , 2018, 18, 553.	1.1	11

#	ARTICLE	IF	CITATIONS
879	Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1090.	1.8	34
880	PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. <i>Nature Communications</i> , 2018, 9, 3439.	5.8	95
881	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. <i>Nature Medicine</i> , 2018, 24, 1611-1624.	15.2	229
882	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 477-483.	1.4	82
883	Successful treatment using apatinib in intractable brain edema: A case report and literatures review. <i>Cancer Biology and Therapy</i> , 2018, 19, 1093-1096.	1.5	14
884	Treatment of glioblastoma in adults. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879045.	1.5	117
885	Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma. <i>FASEB Journal</i> , 2018, 32, 5835-5850.	0.2	11
886	Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. <i>CNS Oncology</i> , 2018, 7, CNS23.	1.2	18
887	Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2462.	1.8	21
888	Neurosurgeons still wanted. <i>Neuro-Oncology</i> , 2018, 20, 1150-1151.	0.6	0
889	Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma. <i>CNS Oncology</i> , 2018, 7, CNS26.	1.2	11
890	Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β ² -catenin signaling pathway. <i>Gene</i> , 2018, 672, 172-179.	1.0	23
891	TP53 gain-of-function mutation promotes inflammation in glioblastoma. <i>Cell Death and Differentiation</i> , 2019, 26, 409-425.	5.0	123
892	Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse. <i>Journal of Neuroradiology</i> , 2019, 46, 36-43.	0.6	14
893	Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 784-795.	3.2	32
894	Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma. <i>Cancer Biology and Therapy</i> , 2019, 20, 65-72.	1.5	4
895	Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. <i>Neuro-Oncology Practice</i> , 2019, 6, 194-202.	1.0	4
896	Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. <i>Supportive Care in Cancer</i> , 2019, 27, 477-484.	1.0	3

#	ARTICLE	IF	CITATIONS
897	<i>DNMT3A</i> co-mutation in an <i>IDH1</i> -mutant glioblastoma. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004119.	0.5	6
898	Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 339.	3.5	77
899	Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). <i>Journal of Neuro-Oncology</i> , 2019, 144, 303-311.	1.4	30
900	Current promising treatment strategy for glioblastoma multiforme: A review. <i>Oncology Reviews</i> , 2019, 13, 417.	0.8	79
901	The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 345-354.	0.7	15
902	Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management. , 2019, , .		0
903	The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 787-797.	1.9	22
904	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 663-677.	1.4	3
905	Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. <i>BMC Cancer</i> , 2019, 19, 628.	1.1	55
906	Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study. <i>Journal of Neuro-Oncology</i> , 2019, 144, 419-426.	1.4	10
907	PET biomarkers and probes for treatment response assessment in glioblastoma: a work in progress. <i>Clinical and Translational Imaging</i> , 2019, 7, 285-294.	1.1	1
908	Autocrine Production of PDGF Stimulated by the Tenascin-C-Derived Peptide TNIIA2 Induces Hyper-Proliferation in Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3183.	1.8	15
909	Identification of GSK3 ^{Î²} inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. <i>Scientific Reports</i> , 2019, 9, 10049.	1.6	30
910	Assumptions, damn assumptions and statistics. <i>Annals of Oncology</i> , 2019, 30, 1415-1416.	0.6	0
911	RCC2 promotes proliferation and radio-resistance in glioblastoma via activating transcription of DNMT1. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 999-1006.	1.0	21
912	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019, 21, 1447-1457.	0.6	35
913	The Role of Checkpoint Inhibitors in Glioblastoma. <i>Targeted Oncology</i> , 2019, 14, 375-394.	1.7	30
914	Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study. <i>Pharmacotherapy</i> , 2019, 39, 921-928.	1.2	8

#	ARTICLE	IF	CITATIONS
915	Vasorin stimulates malignant progression and angiogenesis in glioma. <i>Cancer Science</i> , 2019, 110, 2558-2572.	1.7	23
916	Detection of the KIAA1549-BRAF fusion gene in cells forming microvascular proliferations in pilocytic astrocytoma. <i>PLoS ONE</i> , 2019, 14, e0220146.	1.1	6
917	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. <i>Journal of Cancer</i> , 2019, 10, 3717-3727.	1.2	46
918	Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain Barrier Disruption Results in Radiographic Response. <i>World Neurosurgery</i> , 2019, 131, 234-241.	0.7	10
919	The Roles of Hypoxia Imaging Using 18F-Fluoromisonidazole Positron Emission Tomography in Glioma Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1088.	1.0	34
920	High FREM2 Gene and Protein Expression Are Associated with Favorable Prognosis of IDH-WT Glioblastomas. <i>Cancers</i> , 2019, 11, 1060.	1.7	16
921	Defining Protein Pattern Differences Among Molecular Subtypes of Diffuse Gliomas Using Mass Spectrometry*[S]. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2029-2043.	2.5	19
922	Bevacizumab for recurrent anaplastic oligodendroglial tumors. , 2019, , 367-377.		0
923	Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. <i>Radiotherapy and Oncology</i> , 2019, 138, 99-105.	0.3	34
924	Correlation between prognosis of glioblastoma and choline/N-acetyl aspartate ratio in MR spectroscopy. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2019, 18, 100498.	0.2	0
925	Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1608.	1.0	2
926	MUW researcher of the month. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 534-535.	1.0	0
927	Complementary and alternative medicine use in glioma patients in France. <i>Journal of Neuro-Oncology</i> , 2019, 145, 487-499.	1.4	8
928	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	3.4	386
929	Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 904.	1.3	29
930	Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1017.	1.3	14
931	Ellagic Acid Enhances the Antitumor Efficacy of Bevacizumab in an In Vitro Glioblastoma Model. <i>World Neurosurgery</i> , 2019, 132, e59-e65.	0.7	9
932	Current clinical management of patients with glioblastoma. <i>Cancer Reports</i> , 2019, 2, e1216.	0.6	11

#	ARTICLE	IF	CITATIONS
933	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	0.6	84
934	Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1016-1023.	0.6	8
935	Effects of VEGF blockade on the dynamics of the inflammatory landscape in glioblastoma-bearing mice. <i>Journal of Neuroinflammation</i> , 2019, 16, 191.	3.1	22
936	Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2019, 145, 531-540.	1.4	11
937	Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology. <i>World Neurosurgery</i> , 2019, 131, 346-355.	0.7	15
938	Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged 75 years. <i>Radiation Oncology</i> , 2019, 14, 2001 ⁹	1.2	19
939	Differential regulatory network-based quantification and prioritization of key genes underlying cancer drug resistance based on time-course RNA-seq data. <i>PLoS Computational Biology</i> , 2019, 15, e1007435.	1.5	19
940	Surprising Anticancer Activities of Psychiatric Medications: Old Drugs Offer New Hope for Patients With Brain Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 1262.	1.6	27
941	Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1723.	1.7	41
942	Effect of bevacizumab against cystic components of brain tumors. <i>Cancer Medicine</i> , 2019, 8, 6519-6527.	1.3	5
943	Management of Glioblastoma, Present and Future. <i>World Neurosurgery</i> , 2019, 131, 328-338.	0.7	39
944	Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. <i>Neuro-Oncology Practice</i> , 2019, 7, 164-175.	1.0	3
945	Microenvironmental Heterogeneity in Brain Malignancies. <i>Frontiers in Immunology</i> , 2019, 10, 2294.	2.2	78
947	Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma. <i>Molecules</i> , 2019, 24, 3046.	1.7	5
948	Cerebral blood volume and apparent diffusion coefficient – Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116433.	0.3	14
949	Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance. <i>Cancers</i> , 2019, 11, 1231.	1.7	90
950	Targets for improving tumor response to radiotherapy. <i>International Immunopharmacology</i> , 2019, 76, 105847.	1.7	62
951	Health-related quality of life and neurocognitive functioning with lomustine – temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1444-1453.	5.1	29

#	ARTICLE	IF	CITATIONS
952	Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation. <i>PLoS ONE</i> , 2019, 14, e0221816.	1.1	6
953	Combination of chemotherapy and radiotherapy: A thirty years evolution. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 662-665.	0.6	20
954	Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples. <i>Scientific Reports</i> , 2019, 9, 13343.	1.6	33
955	Biomarkers and smart intracranial devices for the diagnosis, treatment, and monitoring of high-grade gliomas: a review of the literature and future prospects. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz013.	0.4	2
956	A New Therapeutic Strategy for Recurrent Ovarian Cancer—Bevacizumab beyond Progressive Disease. <i>Healthcare (Switzerland)</i> , 2019, 7, 109.	1.0	8
957	Combining Ellagic Acid with Temozolomide Mediates the Cadherin Switch and Angiogenesis in a Glioblastoma Model. <i>World Neurosurgery</i> , 2019, 132, e178-e184.	0.7	5
958	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma. <i>Neurology</i> , 2019, 93, e1799-e1806.	1.5	17
959	Immunotherapy for inoperable gliomas. , 2019, , 181-192.		0
960	Overexpression of oncostatin M receptor regulates local immune response in glioblastoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 15496-15509.	2.0	20
961	EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 337-345.	1.4	30
962	The process of life adjustment in patients at onset of glioma who are receiving continuous oral anticancer drug: A qualitative descriptive study. <i>International Journal of Nursing Sciences</i> , 2019, 6, 134-140.	0.5	4
963	Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2298-2313.	0.4	56
964	Central Nervous System Tumors. , 2019, , 1-41.		0
965	Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma—a randomised multicentre trial (ASTER trial). An ANOCEF study. <i>European Journal of Cancer</i> , 2019, 109, 129-136.	1.3	13
966	Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune [®] System. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491882544.	0.6	31
967	Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma. <i>BMC Cancer</i> , 2019, 19, 445.	1.1	5
968	Molecular biomarker-guided antiangiogenic targeted therapy for malignant glioma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 4876-4882.	1.6	11
969	Genetic and molecular epidemiology of adult diffuse glioma. <i>Nature Reviews Neurology</i> , 2019, 15, 405-417.	4.9	437

#	ARTICLE	IF	CITATIONS
970	Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. <i>British Journal of Pharmacology</i> , 2019, 176, 3681-3694.	2.7	25
971	Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. <i>World Neurosurgery</i> , 2019, 129, 90-100.	0.7	52
972	Controversial roles for dexamethasone in glioblastoma – Opportunities for novel vascular targeting therapies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1460-1468.	2.4	33
974	Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. <i>Clinical Cancer Research</i> , 2019, 25, 4993-5001.	3.2	57
975	Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. <i>Journal of Neuro-Oncology</i> , 2019, 143, 605-611.	1.4	18
976	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
977	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. , 2019, 7, 142.		31
978	Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. <i>Frontiers in Neurology</i> , 2019, 10, 460.	1.1	47
979	Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme. <i>Tomography</i> , 2019, 5, 135-144.	0.8	28
980	Glioblastoma. , 2019, , 237-247.		0
981	Tumor Biology. , 2019, , 143-152.		0
982	Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. <i>Nature Communications</i> , 2019, 10, 2541.	5.8	218
983	Extracellular Vesicles in Glioma: From Diagnosis to Therapy. <i>BioEssays</i> , 2019, 41, e1800245.	1.2	54
984	Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. <i>Clinical Cancer Research</i> , 2019, 25, 5094-5106.	3.2	32
985	Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme. <i>Neuroradiology Journal</i> , 2019, 32, 241-249.	0.6	11
986	Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. <i>Chemical Society Reviews</i> , 2019, 48, 2967-3014.	18.7	389
987	Glioblastoma vs temozolomide: can the red queen race be won?. <i>Cancer Biology and Therapy</i> , 2019, 20, 1083-1090.	1.5	63
988	Targeting Hyaluronan Interactions for Glioblastoma Stem Cell Therapy. <i>Cancer Microenvironment</i> , 2019, 12, 47-56.	3.1	23

#	ARTICLE	IF	CITATIONS
989	Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. <i>Clinical Epigenetics</i> , 2019, 11, 76.	1.8	14
990	Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifer among Patient Populations. <i>Scientific Reports</i> , 2019, 9, 7442.	1.6	43
991	Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1418-1429.	1.9	22
992	Targeted Therapies for the Treatment of Glioblastoma in Adults. <i>Current Oncology Reports</i> , 2019, 21, 61.	1.8	15
993	The efficacy and toxicity of ATM inhibition in glioblastoma initiating cells-driven tumor models. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 214-222.	2.0	13
994	Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy. <i>Cancer Research</i> , 2019, 79, 2923-2932.	0.4	47
995	Low perfusion compartments in glioblastoma quantified by advanced magnetic resonance imaging and correlated with patient survival. <i>Radiotherapy and Oncology</i> , 2019, 134, 17-24.	0.3	15
996	Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. <i>Journal of Medical Economics</i> , 2019, 22, 1006-1013.	1.0	22
997	Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 845-854.	1.4	17
998	Thrombotic Complications in Gliomas. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 326-333.	1.5	10
999	Blocking VEGF by Bevacizumab Compromises Electrophysiological and Morphological Properties of Hippocampal Neurons. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 113.	1.8	16
1000	The role of caveolin-1 in tumors of the brain - functional and clinical implications. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 423-447.	2.1	10
1001	Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. <i>Journal of Translational Medicine</i> , 2019, 17, 96.	1.8	54
1002	Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. <i>CNS Oncology</i> , 2019, 8, CNS28.	1.2	169
1003	Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2019, 40, 568-575.	1.2	4
1004	Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. <i>Clinical Cancer Research</i> , 2019, 25, 3643-3657.	3.2	128
1005	Regorafenib in patients with recurrent high-grade astrocytoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1037-1042.	1.2	22
1006	Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma. <i>Cancers</i> , 2019, 11, 314.	1.7	7

#	ARTICLE	IF	CITATIONS
1007	Therapy for glioblastoma: is it working?. <i>Drug Discovery Today</i> , 2019, 24, 1193-1201.	3.2	86
1008	Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 287-301.	2.1	13
1009	Defective vascular signaling & prospective therapeutic targets in brain arteriovenous malformations. <i>Neurochemistry International</i> , 2019, 126, 126-138.	1.9	22
1010	Neuro-oncologists have spoken â€” the role of bevacizumab in the inpatient setting. A clinical and economic conundrum. <i>Neuro-Oncology Practice</i> , 2019, 6, 30-36.	1.0	9
1011	Î-Catenin Promotes Bevacizumab-Induced Glioma Invasion. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 812-822.	1.9	14
1012	Lipolytic inhibitor GOS2 modulates glioma stem-like cell radiation response. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 147.	3.5	18
1013	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	46
1014	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019, 21, 837-853.	0.6	66
1015	Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments. <i>Acta Neurochirurgica</i> , 2019, 161, 1109-1124.	0.9	10
1016	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology, The</i> , 2019, 20, 728-740.	5.1	271
1017	The landscape of the mesenchymal signature in brain tumours. <i>Brain</i> , 2019, 142, 847-866.	3.7	228
1018	Bevacizumab as a steroidâ€sparing agent during immunotherapy for melanoma brain metastases: A case series. <i>Health Science Reports</i> , 2019, 2, e115.	0.6	29
1019	Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. <i>European Journal of Cancer</i> , 2019, 112, 83-93.	1.3	15
1020	A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma. <i>Journal of Clinical Medicine</i> , 2019, 8, 263.	1.0	16
1021	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 587-595.	1.4	28
1022	Artificial intelligence in cancer imaging: Clinical challenges and applications. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 127-157.	157.7	965
1023	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	12.5	540
1024	Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. <i>Frontiers in Neurology</i> , 2019, 10, 42.	1.1	46

#	ARTICLE	IF	CITATIONS
1025	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. <i>Nature Medicine</i> , 2019, 25, 470-476.	15.2	459
1026	Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma. <i>Human Gene Therapy Clinical Development</i> , 2019, 30, 74-87.	3.2	7
1027	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 469-493.	12.5	285
1028	Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 147-161.	2.0	38
1029	Tumors of the Central Nervous System: Therapeutic Approaches. , 2019, , 69-83.		0
1030	Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 878-886.	0.4	10
1031	The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma. <i>British Journal of Cancer</i> , 2019, 120, 481-487.	2.9	45
1032	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 678-688.	6.3	384
1033	Improving survival in molecularly selected glioblastoma. <i>Lancet, The</i> , 2019, 393, 615-617.	6.3	32
1034	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. <i>The Cochrane Library</i> , 2019, , .	1.5	4
1035	Concurrent Thermochemoradiotherapy in Glioblastoma Treatment: Preliminary Results. , 0, , .		0
1036	Identification of key candidate genes and pathways in glioblastoma by integrated bioinformatical analysis. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 3439-3449.	0.8	14
1037	Multiclass Classification of Brain Cancer with Multiple Multiclass Artificial Bee Colony Feature Selection and Support Vector Machine. <i>Journal of Physics: Conference Series</i> , 2019, 1417, 012015.	0.3	3
1039	Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 1134.	1.3	28
1040	DNX-2401: an investigational drug for the treatment of recurrent glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1041-1049.	1.9	28
1041	ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 655-661.	0.6	3
1042	Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 2031.	1.0	23
1043	Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials. <i>Molecules</i> , 2019, 24, 4312.	1.7	77

#	ARTICLE	IF	CITATIONS
1045	Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. <i>Scientific Reports</i> , 2019, 9, 17794.	1.6	9
1046	Computational modeling demonstrates that glioblastoma cells can survive spatial environmental challenges through exploratory adaptation. <i>Nature Communications</i> , 2019, 10, 5704.	5.8	21
1047	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
1048	SKA1 promotes malignant phenotype and progression of glioma via multiple signaling pathways. <i>Cancer Cell International</i> , 2019, 19, 324.	1.8	17
1049	Treatment of cognitive deficits in brain tumour patients: current status and future directions. <i>Current Opinion in Oncology</i> , 2019, 31, 540-547.	1.1	69
1050	Features and therapeutic potential of T-cell receptors in high-grade glioma. <i>Chinese Medical Journal</i> , 2019, 132, 1435-1440.	0.9	4
1051	Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy. <i>Medicine (United States)</i> , 2019, 98, e17759.	0.4	5
1052	Tumor treating fields for glioblastoma: should it or will it ever be adopted?. <i>Current Opinion in Neurology</i> , 2019, 32, 857-863.	1.8	6
1053	Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma. <i>Neurologist</i> , 2019, 24, 87-89.	0.4	5
1054	Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases. <i>Cancer Management and Research</i> , 2019, Volume 11, 10083-10092.	0.9	9
1055	Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials. <i>Neuro-Oncology Practice</i> , 2019, 6, 81-92.	1.0	7
1056	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Overviews in Oncology/Hematology, 2019, 134, 104-119.	2.0	10
1057	Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. <i>Cancer Science</i> , 2019, 110, 499-508.	1.7	58
1058	shRNA-mediated PPAR γ knockdown in human glioma stem cells reduces <i>in vitro</i> proliferation and inhibits orthotopic xenograft tumour growth. <i>Journal of Pathology</i> , 2019, 247, 422-434.	2.1	13
1059	Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells. <i>Carcinogenesis</i> , 2019, 40, 2-14.	1.3	12
1060	Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1. <i>International Journal of Cancer</i> , 2019, 144, 1331-1344.	2.3	22
1061	Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies. <i>Clinical Nutrition</i> , 2019, 38, 1986-1994.	2.3	31
1062	Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome. <i>Neurosurgery</i> , 2019, 85, 793-800.	0.6	10

#	ARTICLE	IF	CITATIONS
1063	18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 558-568.	3.3	33
1064	Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma. <i>Cancers</i> , 2019, 11, 84.	1.7	4
1065	Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. <i>PLoS ONE</i> , 2019, 14, e0210608.	1.1	14
1066	The antitumour growth and antiangiogenesis effects of xanthatin in murine glioma dynamically evaluated by dynamic contrast-enhanced magnetic resonance imaging. <i>Phytotherapy Research</i> , 2019, 33, 149-158.	2.8	11
1067	Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma. <i>Oncolmmunology</i> , 2019, 8, e1525243.	2.1	46
1068	Prior malignancy impact on survival outcomes of glioblastoma multiforme; population-based study. <i>International Journal of Neuroscience</i> , 2019, 129, 447-454.	0.8	11
1069	Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 343-354.	1.9	21
1070	FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 591-602.	3.3	74
1071	The Increased Expression of Estrogen-Related Receptor β Correlates with Wnt5a and Poor Prognosis in Patients with Glioma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 173-184.	1.9	11
1072	Association of patterns of care, prognostic factors, and use of radiotherapy—temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. <i>Journal of Neuro-Oncology</i> , 2019, 142, 91-101.	1.4	52
1073	<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1809-1816.	3.2	94
1074	Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2019, 142, 79-90.	1.4	106
1075	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 110-119.	5.1	238
1076	Combination of novel systemic agents and radiotherapy for solid tumors — part I: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Over Reviews in Oncology/Hematology, 2019, 134, 87-103.	2.0	7
1077	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528.	1.9	47
1078	Astrocytes, the rising stars of the glioblastoma microenvironment. <i>Glia</i> , 2019, 67, 779-790.	2.5	115
1079	Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial. <i>Neurosurgery</i> , 2019, 84, 41-49.	0.6	39
1080	Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature. <i>European Journal of Cancer Care</i> , 2019, 28, e12410.	0.7	44

#	ARTICLE	IF	CITATIONS
1081	Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab. <i>Clinical and Translational Oncology</i> , 2020, 22, 411-419.	1.2	0
1082	Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma. <i>Oncology</i> , 2020, 98, 16-22.	0.9	23
1083	Bevacizumab as a treatment option for radiation necrosis after cranial radiation therapy: a retrospective monocentric analysis. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 70-76.	1.0	15
1084	Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2020, 81, 064-070.	0.4	38
1085	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 206-212.	3.2	48
1086	Intraoperative radiotherapy for glioblastoma: an international pooled analysis. <i>Radiotherapy and Oncology</i> , 2020, 142, 162-167.	0.3	22
1087	Synergistic Therapies for Recurrent Malignant Gliomas. <i>World Neurosurgery</i> , 2020, 133, 237-239.	0.7	3
1088	CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. <i>Cancer Gene Therapy</i> , 2020, 27, 669-679.	2.2	15
1089	WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. <i>Neuro-Oncology</i> , 2020, 22, 116-127.	0.6	26
1090	Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy. <i>Clinical and Translational Oncology</i> , 2020, 22, 447-456.	1.2	4
1091	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.	1.0	9
1092	Current Immunotherapeutic Strategies in Cancer. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	4
1093	Current Development of Monoclonal Antibodies in Cancer Therapy. <i>Recent Results in Cancer Research</i> , 2020, 214, 1-70.	1.8	16
1094	4-Hydroxy-7-oxo-5-heptenoic acid lactone is a potent inducer of brain cancer cell invasiveness that may contribute to the failure of anti-angiogenic therapies. <i>Free Radical Biology and Medicine</i> , 2020, 146, 234-256.	1.3	2
1095	Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 316-319.	0.4	6
1096	The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. <i>Medical Oncology</i> , 2020, 37, 2.	1.2	145
1097	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. <i>Neuro-Oncology</i> , 2020, 22, 470-479.	0.6	49
1098	Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2020, 7, 52-58.	1.0	1

#	ARTICLE	IF	CITATIONS
1099	ACT001 modulates the NF- κ B/MnSOD/ROS axis by targeting IKK β to inhibit glioblastoma cell growth. <i>Journal of Molecular Medicine</i> , 2020, 98, 263-277.	1.7	26
1100	Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 146, 363-371.	1.4	16
1101	Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. <i>Cancers</i> , 2020, 12, 111.	1.7	31
1102	Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies. <i>Annual Review of Pharmacology and Toxicology</i> , 2020, 60, 291-309.	4.2	17
1103	Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. <i>Neuro-Oncology</i> , 2020, 22, 450-456.	0.6	30
1104	TNIP1-mediated TNF α /NF κ B signalling cascade sustains glioma cell proliferation. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 530-538.	1.6	20
1105	Nanocarrier-based drug combination therapy for glioblastoma. <i>Theranostics</i> , 2020, 10, 1355-1372.	4.6	203
1106	Olfactory function as an independent prognostic factor in glioblastoma. <i>Neurology</i> , 2020, 94, e529-e537.	1.5	4
1107	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. <i>Neuro-Oncology</i> , 2020, 22, 694-704.	0.6	23
1108	Palliative Radiotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 253-277.	0.9	5
1109	Paracaspase MALT1 regulates glioma cell survival by controlling endosome homeostasis. <i>EMBO Journal</i> , 2020, 39, e102030.	3.5	33
1110	Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa112.	0.4	2
1111	Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas. <i>Biomolecules</i> , 2020, 10, 1370.	1.8	12
1113	Novel Molecular Markers in Glioblastoma: Benefits of Liquid Biopsy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7522.	1.8	40
1114	Potential Therapeutic Effects of the Neural Stem Cell-Targeting Antibody Nilo1 in Patient-Derived Glioblastoma Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1665.	1.3	3
1115	Advances in drug delivery technology for the treatment of glioblastoma multiforme. <i>Journal of Controlled Release</i> , 2020, 328, 350-367.	4.8	58
1116	Differences in Gating Dynamics of BK Channels in Cellular and Mitochondrial Membranes from Human Glioblastoma Cells Unraveled by Short- and Long-Range Correlations Analysis. <i>Cells</i> , 2020, 9, 2305.	1.8	8
1117	Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. <i>Molecules</i> , 2020, 25, 4641.	1.7	7

#	ARTICLE	IF	CITATIONS
1118	Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis. <i>Neurosurgical Review</i> , 2021, 44, 1943-1955.	1.2	10
1119	MP-Pt(IV): A MAOB-Sensitive Mitochondrial-Specific Prodrug for Treating Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2445-2453.	1.9	4
1120	Evaluating Outcome in HIV positive and HIV negative patients post elective brain tumor surgery at a single South African neurosurgical center – A prospective cohort study. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2020, 22, 100792.	0.2	0
1121	Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma. <i>Microorganisms</i> , 2020, 8, 1471.	1.6	16
1122	Benefits of glioma resection in the corpus callosum. <i>Scientific Reports</i> , 2020, 10, 16630.	1.6	15
1123	FLAIRctomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series. <i>Operative Neurosurgery</i> , 2021, 20, 151-163.	0.4	48
1124	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1037-1048.	1.1	8
1125	Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide. <i>Medicine (United States)</i> , 2020, 99, e21147.	0.4	10
1126	Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme. , 0, , .		0
1127	Pattern of disease progression following stereotactic radiosurgery in malignant glioma patients. <i>Journal of Clinical Neuroscience</i> , 2020, 76, 61-66.	0.8	2
1128	Pediatric Chemotherapy. , 2020, , 173-183.		0
1129	In vitro evidence for glioblastoma cell death in temperatures found in the penumbra of laser-ablated tumors. <i>International Journal of Hyperthermia</i> , 2020, 37, 20-26.	1.1	6
1130	Boron neutron capture therapy for malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2020, 149, 1-11.	1.4	45
1131	The quality of measurement properties of neurocognitive assessment in brain tumor clinical trials over the last 30 years: a COSMIN checklist-based approach. <i>Neurological Sciences</i> , 2020, 41, 3105-3121.	0.9	5
1132	Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment. <i>Current Oncology Reports</i> , 2020, 22, 93.	1.8	6
1133	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. <i>Pharmaceuticals</i> , 2020, 13, 389.	1.7	36
1134	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults. <i>Journal of Neuro-Oncology</i> , 2020, 150, 165-213.	1.4	6
1135	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 150, 269-359.	1.4	8

#	ARTICLE	IF	CITATIONS
1136	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa157.	0.4	8
1137	<p>Secretory Pathway Kinase FAM20C, a Marker for Glioma Invasion and Malignancy, Predicts Poor Prognosis of Glioma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11755-11768.	1.0	11
1138	Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients. <i>Surgical Oncology</i> , 2020, 35, 515-519.	0.8	4
1139	New Avenues in Radiotherapy of Glioblastoma: from Bench to Bedside. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	0.7	0
1140	Angiopoietin-2 Combined with Radiochemotherapy Impedes Glioblastoma Recurrence by Acting in an Autocrine and Paracrine Manner: A Preclinical Study. <i>Cancers</i> , 2020, 12, 3585.	1.7	3
1141	Targeting the RhoGEF Î²PIX/COOL-1 in Glioblastoma: Proof of Concept Studies. <i>Cancers</i> , 2020, 12, 3531.	1.7	4
1142	Efficacy of promising flavonoids from <i>Festuca</i> , <i>Lonicera</i> , and <i>Acacia</i> genera against glioblastoma multiforme; potential for the Dandenong Ranges. , 2020, , 383-422.		1
1143	ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma. <i>Oncogene</i> , 2020, 39, 5964-5978.	2.6	16
1144	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1133-1141.	1.9	28
1145	Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. <i>Journal of Cancer</i> , 2020, 11, 5056-5068.	1.2	6
1146	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines. <i>Bioengineered</i> , 2020, 11, 791-800.	1.4	12
1147	Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 1045.	1.3	29
1148	TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. <i>Cancers</i> , 2020, 12, 1935.	1.7	8
1149	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020, 297, 164-175.	3.6	19
1150	Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade. <i>Frontiers in Oncology</i> , 2020, 10, 840.	1.3	41
1151	Nanosized zeolites as a gas delivery platform in a glioblastoma model. <i>Biomaterials</i> , 2020, 257, 120249.	5.7	14
1152	Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations. <i>Molecular Neurobiology</i> , 2020, 57, 3943-3955.	1.9	12
1153	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2163-2174.	1.9	17

#	ARTICLE	IF	CITATIONS
1154	Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma. <i>Frontiers in Immunology</i> , 2020, 11, 515556.	2.2	5
1155	Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide. <i>Frontiers in Oncology</i> , 2020, 10, 581814.	1.3	10
1156	Cannabisin D from <i>Sinomenium Acutum</i> Inhibits Proliferation and Migration of Glioblastoma Cells through MAPKs Signaling. <i>Nutrition and Cancer</i> , 2021, 73, 2491-2501.	0.9	5
1157	Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?" <i>Neuro-Oncology</i> , 2020, 22, 1889-1890.	0.6	2
1158	Metabolism-based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa087.	0.4	20
1159	MR-Spectroscopy and Survival in Mice with High Grade Glioma Undergoing Unrestricted Ketogenic Diet. <i>Nutrition and Cancer</i> , 2021, 73, 2315-2322.	0.9	9
1160	MicroRNA-93 acts as an "anti-inflammatory tumor suppressor" in glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa047.	0.4	9
1161	The anti-glioblastoma effect of cold atmospheric plasma treatment: physical pathway v.s. chemical pathway. <i>Scientific Reports</i> , 2020, 10, 11788.	1.6	30
1162	Radioresistance in Glioblastoma and the Development of Radiosensitizers. <i>Cancers</i> , 2020, 12, 2511.	1.7	77
1163	Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. <i>Nature Communications</i> , 2020, 11, 4660.	5.8	80
1164	Results from a 1-day workshop on the assessment of quality of life in cancer patients: a joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1333-1341.	0.6	1
1165	Small but Fierce: Tracking the Role of Extracellular Vesicles in Glioblastoma Progression and Therapeutic Resistance. <i>Advanced Biology</i> , 2020, 4, 2000035.	3.0	3
1166	A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma. <i>Vaccines</i> , 2020, 8, 498.	2.1	2
1167	Development of a gene expression-based prognostic signature for <i>IDH</i> wild-type glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1742-1756.	0.6	18
1168	Cs-131 brachytherapy for patients with recurrent glioblastoma combined with bevacizumab avoids radiation necrosis while maintaining local control. <i>Brachytherapy</i> , 2020, 19, 705-712.	0.2	15
1169	Vesiclemia: counting on extracellular vesicles for glioblastoma patients. <i>Oncogene</i> , 2020, 39, 6043-6052.	2.6	21
1170	New drugs on the horizon for cerebral edema: what's in the clinical development pipeline?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1099-1105.	1.9	5
1171	A Ticket to Ride: The Implications of Direct Intercellular Communication via Tunneling Nanotubes in Peritoneal and Other Invasive Malignancies. <i>Frontiers in Oncology</i> , 2020, 10, 559548.	1.3	18

#	ARTICLE	IF	CITATIONS
1172	Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma. <i>Pharmaceuticals</i> , 2020, 13, 470.	1.7	9
1173	Glioblastoma Distance From the Subventricular Neural Stem Cell Niche Does Not Correlate With Survival. <i>Frontiers in Oncology</i> , 2020, 10, 564889.	1.3	9
1174	Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa082.	0.4	29
1175	Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging. <i>Frontiers in Immunology</i> , 2020, 11, 592389.	2.2	23
1176	Glioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section. <i>Neurocirug�a (English Edition)</i> , 2020, 31, 289-297.	0.1	2
1177	Consenso sobre gu�as de tratamiento de los glioblastomas elaborado por el Grupo de Trabajo de Neurooncolog�a (GTNO) de la SENEC. <i>Neurocirug�a</i> , 2020, 31, 289-298.	0.2	4
1178	Early treatment response assessment using ¹⁸ F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.254243.	2.8	25
1179	Effects of BMPER, CXCL10, and HOXA9 on Neovascularization During Early-Growth Stage of Primary High-Grade Glioma and Their Corresponding MRI Biomarkers. <i>Frontiers in Oncology</i> , 2020, 10, 711.	1.3	6
1180	Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2020, 26, 4031-4039.	3.2	27
1181	Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (��pseudo-randomized��) treatment allocation by the health insurance provider. <i>Journal of Neuro-Oncology</i> , 2020, 148, 373-379.	1.4	7
1182	Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091530.	1.4	25
1183	Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. <i>Advanced Science</i> , 2020, 7, 1902971.	5.6	95
1184	NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas. <i>Cell Death and Disease</i> , 2020, 11, 323.	2.7	18
1185	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	0.6	19
1186	Comparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma. <i>Medicine (United Tj ETQq0 0,0 �gBT /Oerlock 10</i>	0.4	0
1187	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. <i>The Cochrane Library</i> , 2020, 2020, CD013238.	1.5	19
1188	Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model. <i>Cancer Imaging</i> , 2020, 20, 35.	1.2	11
1189	Biomarkers for immunotherapy for treatment of glioblastoma. , 2020, 8, e000348.		33

#	ARTICLE	IF	CITATIONS
1190	Management of glioblastoma: State of the art and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 299-312.	157.7	969
1191	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 659-684.	1.9	15
1192	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. <i>Clinical Cancer Research</i> , 2020, 26, 4723-4736.	3.2	23
1193	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020, 22, 1667-1676.	0.6	9
1194	ACYP2 contributes to malignant progression of glioma through promoting Ca ²⁺ efflux and subsequently activating c-Myc and STAT3 signals. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 106.	3.5	6
1195	Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2020, 7, 268-276.	1.0	12
1196	New strategies for managing adult gliomas. <i>Journal of Neurology</i> , 2021, 268, 3666-3674.	1.8	14
1197	Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. <i>BMC Medicine</i> , 2020, 18, 142.	2.3	21
1198	Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target. <i>Cancers</i> , 2020, 12, 1622.	1.7	29
1199	E2F transcription factor 8 promotes proliferation and radioresistance in glioblastoma. <i>Pathology Research and Practice</i> , 2020, 216, 153030.	1.0	14
1200	Apelin Controls Angiogenesis-Dependent Glioblastoma Growth. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4179.	1.8	19
1201	Neuronal signatures in cancer. <i>International Journal of Cancer</i> , 2020, 147, 3281-3291.	2.3	35
1202	Crosstalk between GBM cells and mesenchymal stemlike cells promotes the invasiveness of GBM through the C5a/p38/ZEB1 axis. <i>Neuro-Oncology</i> , 2020, 22, 1452-1462.	0.6	32
1203	Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 475-485.	1.9	46
1204	Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. <i>Molecular Neurobiology</i> , 2020, 57, 2461-2478.	1.9	219
1205	Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. <i>Journal of Neuro-Oncology</i> , 2020, 147, 297-307.	1.4	116
1206	Identification and Analysis of Glioblastoma Biomarkers Based on Single Cell Sequencing. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 167.	2.0	28
1207	FTY720 Exerts Anti-Glioma Effects by Regulating the Glioma Microenvironment Through Increased CXCR4 Internalization by Glioma-Associated Microglia. <i>Frontiers in Immunology</i> , 2020, 11, 178.	2.2	20

#	ARTICLE	IF	CITATIONS
1208	Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions. <i>Theranostics</i> , 2020, 10, 2949-2964.	4.6	25
1209	Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model. <i>Translational Oncology</i> , 2020, 13, 100737.	1.7	11
1210	Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models. <i>Cancer Letters</i> , 2020, 478, 71-81.	3.2	18
1211	Personalized neoantigen vaccines: a glimmer of hope for glioblastoma. <i>Expert Review of Vaccines</i> , 2020, 19, 407-417.	2.0	8
1212	Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series. <i>BMC Cancer</i> , 2020, 20, 196.	1.1	15
1213	A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. <i>BMC Cancer</i> , 2020, 20, 198.	1.1	25
1214	Multifractal Properties of BK Channel Currents in Human Glioblastoma Cells. <i>Journal of Physical Chemistry B</i> , 2020, 124, 2382-2391.	1.2	12
1215	Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 32.	2.0	0
1216	Laminin Subunit Alpha-4 and Osteopontin Are Glioblastoma-Selective Secreted Proteins That Are Increased in the Cerebrospinal Fluid of Glioblastoma Patients. <i>Journal of Proteome Research</i> , 2020, 19, 3542-3553.	1.8	8
1217	Interferon- β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa043.	0.4	3
1218	Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 342-359.	1.3	19
1219	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa038.	0.4	14
1220	Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials. <i>Radiotherapy and Oncology</i> , 2020, 150, 225-235.	0.3	12
1221	Disparities in patient enrollment on glioblastoma clinical trials. <i>CNS Oncology</i> , 2020, 9, CNS59.	1.2	3
1222	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa011.	0.4	22
1223	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18 F]-fluoroethyl)-l-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1486-1495.	3.3	16
1224	Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas. <i>Pathology Research and Practice</i> , 2020, 216, 152828.	1.0	8
1225	Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV foci. <i>Neurology</i> , 2020, 94, e830-e841.	1.5	18

#	ARTICLE	IF	CITATIONS
1226	Angiogenesis in Malignant Gliomas and Bevacizumab Resistance. , 2020, , .		0
1227	Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment <i>via</i> nanotechnology. Theranostics, 2020, 10, 3223-3239.	4.6	59
1228	Expression and prognostic role of E2F transcription factors in high-grade glioma. CNS Neuroscience and Therapeutics, 2020, 26, 741-753.	1.9	31
1229	Immunohistochemistry for O6-methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: Correlation with promoter methylation status and patients' progression-free survival with the cut-off value determined by ROC analysis. Journal of Clinical Neuroscience, 2020, 73, 231-236.	0.8	0
1230	Glioblastoma Stem Cells: Driving Resilience through Chaos. Trends in Cancer, 2020, 6, 223-235.	3.8	217
1231	DNA inhibitors for the treatment of brain tumors. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 195-207.	1.5	3
1232	Small-sized gadolinium oxide based nanoparticles for high-efficiency theranostics of orthotopic glioblastoma. Biomaterials, 2020, 235, 119783.	5.7	61
1233	Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients. Journal of Neuro-Oncology, 2020, 147, 109-116.	1.4	19
1234	Proposing a tandem AND-gate CAR T cell targeting glioblastoma multiforme. Medical Hypotheses, 2020, 137, 109559.	0.8	10
1235	Synergism of 4HPR and SAHA increases anti-tumor actions in glioblastoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 217-232.	2.2	8
1236	Glioblastoma precision therapy: From the bench to the clinic. Cancer Letters, 2020, 475, 79-91.	3.2	27
1237	Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study. BMC Cancer, 2020, 20, 79.	1.1	8
1238	An Electrochemical Biosensor Designed by Using Zr-Based Metal-Organic Frameworks for the Detection of Glioblastoma-Derived Exosomes with Practical Application. Analytical Chemistry, 2020, 92, 3819-3826.	3.2	126
1239	Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. Fundamental and Clinical Pharmacology, 2020, 34, 484-494.	1.0	1
1240	Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. International Journal of Clinical Oncology, 2020, 25, 1004-1009.	1.0	16
1241	First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. Journal of Neuro-Oncology, 2020, 146, 451-458.	1.4	16
1242	Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol. BMJ Open, 2020, 10, e034378.	0.8	26
1243	Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. The Cochrane Library, 2020, 2020, CD013261.	1.5	37

#	ARTICLE	IF	CITATIONS
1244	HOX gene cluster (de)regulation in brain: from neurodevelopment to malignant glial tumours. Cellular and Molecular Life Sciences, 2020, 77, 3797-3821.	2.4	33
1246	Peritumoral administration of IFN γ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model. , 2020, 8, e000164.		12
1247	Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Research, 2020, 80, 499-509.	0.4	68
1248	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	0.6	543
1249	Betulinic Acid-Mediated Tuning of PERK/CHOP Signaling by Sp1 Inhibition as a Novel Therapeutic Strategy for Glioblastoma. Cancers, 2020, 12, 981.	1.7	16
1250	Bevacizumab (Avastin $\text{\textcircled{R}}$) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews, 2020, 86, 102017.	3.4	573
1251	Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma. Acta Neuropathologica Communications, 2020, 8, 52.	2.4	9
1252	A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. Pediatric Blood and Cancer, 2020, 67, e28283.	0.8	40
1253	Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial. Radiation Oncology, 2020, 15, 83.	1.2	11
1254	Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clinical Cancer Research, 2020, 26, 3135-3144.	3.2	7
1255	Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. Journal of Oncology Pharmacy Practice, 2021, 27, 329-339.	0.5	1
1256	Beta-blockers and glioma: a systematic review of preclinical studies and clinical results. Neurosurgical Review, 2021, 44, 669-677.	1.2	11
1257	Sonic hedgehog is expressed in human brain arteriovenous malformations and induces arteriovenous malformations in vivo. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 324-335.	2.4	7
1258	Management of glioblastoma: a perspective from Mexico. Chinese Clinical Oncology, 2021, 10, 1-1.	0.4	2
1259	Anti-angiogenic therapies in the management of glioblastoma. Chinese Clinical Oncology, 2021, 10, 37-37.	0.4	11
1260	Attention, memory, and executive functions profile in a prospective cohort of patients with malignant glioma. Applied Neuropsychology Adult, 2021, 28, 197-209.	0.7	2
1261	Pulsed radiation therapy for the treatment of newly diagnosed glioblastoma. Neuro-Oncology, 2021, 23, 447-456.	0.6	8
1262	MRI and 18F-FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clinical Cancer Research, 2021, 27, 179-188.	3.2	16

#	ARTICLE	IF	CITATIONS
1263	Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 598-605.	1.0	6
1264	Surgery for Glioblastoma in Elderly Patients. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 137-148.	0.8	5
1265	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	3.2	194
1266	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
1267	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	0.6	42
1268	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103188.	2.0	17
1269	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	12.5	826
1270	Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. <i>Nature Cancer</i> , 2021, 2, 83-97.	5.7	56
1271	Activation of nuclear factor- κ B in the angiogenesis of glioma: Insights into the associated molecular mechanisms and targeted therapies. <i>Cell Proliferation</i> , 2021, 54, e12929.	2.4	14
1272	Transcription Factor ELF1 Activates MEIS1 Transcription and Then Regulates the GF11/FBW7 Axis to Promote the Development of Glioma. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 418-430.	2.3	13
1273	A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme. <i>European Journal of Health Economics</i> , 2021, 22, 89-100.	1.4	0
1274	Hypoxia and its therapeutic possibilities in paediatric cancers. <i>British Journal of Cancer</i> , 2021, 124, 539-551.	2.9	28
1275	<i>MGMT</i> promoter methylation analysis for allocating combined <i>CCNU</i> / <i>TMZ</i> chemotherapy: Lessons learned from the <i>CeTeG</i> / <i>NOA</i> trial. <i>International Journal of Cancer</i> , 2021, 148, 1695-1707.	2.3	11
1276	Glioma stem cells and their roles within the hypoxic tumor microenvironment. <i>Theranostics</i> , 2021, 11, 665-683.	4.6	89
1277	Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. <i>Journal of Neuro-Oncology</i> , 2021, 151, 55-62.	1.4	42
1278	Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results. <i>Quality of Life Research</i> , 2021, 30, 91-103.	1.5	7
1279	Current state and future perspective of drug repurposing in malignant glioma. <i>Seminars in Cancer Biology</i> , 2021, 68, 92-104.	4.3	35
1280	Recent progress in the research of suicide gene therapy for malignant glioma. <i>Neurosurgical Review</i> , 2021, 44, 29-49.	1.2	27

#	ARTICLE	IF	CITATIONS
1281	Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases. NMC Case Report Journal, 2021, 8, 505-511.	0.2	6
1282	Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil. Strahlentherapie Und Onkologie, 2021, 197, 644-649.	1.0	5
1283	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro-Oncology, 2021, 23, 1125-1138.	0.6	10
1285	Drug penetration through the blood-brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance. , 2021, , 689-705.		0
1287	Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2021, 27, 1912-1922.	3.2	26
1288	Evidence-based approaches to chemotherapy for gliomas. , 2021, , 38-52.		0
1289	Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model. Cancer Gene Therapy, 2021, 28, 1339-1352.	2.2	13
1290	Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis. Frontiers in Neurology, 2020, 11, 603947.	1.1	10
1291	Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis. BMC Cancer, 2021, 21, 81.	1.1	22
1292	Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. Scientific Reports, 2021, 11, 2306.	1.6	25
1293	MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression. Journal of Molecular Medicine, 2021, 99, 289-301.	1.7	15
1294	Reuse of Molecules for Glioblastoma Therapy. Pharmaceuticals, 2021, 14, 99.	1.7	3
1295	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
1296	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 1 newly diagnosed disease. Neuro-Oncology Advances, 2021, 3, vdab028.	0.4	4
1297	Window of Opportunity Clinical Trials to Evaluate Novel Therapies for Brain Tumors. Neurosurgery Clinics of North America, 2021, 32, 93-104.	0.8	10
1298	Cell and gene therapies—Emerging technologies and drug delivery systems for treating brain cancer. , 2021, , 431-446.		0
1299	Glioblastoma. , 2021, , 215-230.		0
1300	Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres. Molecules, 2021, 26, 282.	1.7	6

#	ARTICLE	IF	CITATIONS
1301	Targeting tumor microenvironment-associated cells to reverse therapy resistance. , 2021, , 115-144.		0
1302	Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab008.	0.4	20
1303	Substance P containing peptide gene delivery vectors for specifically transfecting glioma cells mediated by a neurokinin-1 receptor. <i>Journal of Materials Chemistry B</i> , 2021, 9, 6347-6356.	2.9	10
1304	A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2021, 151, 193-200.	1.4	5
1305	Potential of naso-brain drug delivery in glioblastoma therapy. , 2021, , 389-404.		0
1306	Past and present drug treatments for glioblastoma. , 2021, , 17-29.		0
1307	Central Nervous System Molecular Imaging. , 2021, , 1261-1285.		0
1308	A Review of Newly Diagnosed Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 574012.	1.3	74
1309	The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme. <i>British Journal of Neurosurgery</i> , 2021, , 1-13.	0.4	1
1310	A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution. <i>Frontiers in Oncology</i> , 2021, 11, 597587.	1.3	10
1311	A vasculature-centric approach to developing novel treatment options for glioblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 87-100.	1.5	9
1312	Pathogenetic Features and Current Management of Glioblastoma. <i>Cancers</i> , 2021, 13, 856.	1.7	29
1313	Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. <i>Seminars in Cancer Biology</i> , 2022, 82, 162-175.	4.3	58
1314	Single-shot bevacizumab for cerebral radiation injury. <i>BMC Neurology</i> , 2021, 21, 77.	0.8	8
1315	CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma. <i>Cancer Medicine</i> , 2021, 10, 2013-2025.	1.3	15
1316	Neurological Complications of Targeted Therapies and Immunotherapies for Cancer. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	3
1317	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631618.	1.3	0
1318	Mifepristone Repurposing in Treatment of High-Grade Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 606907.	1.3	7

#	ARTICLE	IF	CITATIONS
1319	Putting Proteomics Into Immunotherapy for Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 593255.	2.2	11
1320	Current state of antiangiogenic therapy in neuro-oncology and own experience of its use in the radiosurgical treatment of recurrent glioblastoma. <i>Ukrainian Neurosurgical Journal</i> , 2021, 27, 34-43.	0.1	0
1321	Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies. <i>Carcinogenesis</i> , 2021, 42, 804-813.	1.3	21
1322	The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. <i>Scientific Reports</i> , 2021, 11, 6067.	1.6	17
1323	Host response to immune checkpoint inhibitors contributes to tumor aggressiveness. , 2021, 9, e001996.		9
1324	Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin $\alpha 5 \beta 1$ in Glioblastoma Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 616580.	1.8	17
1325	Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters. <i>Cell Cycle</i> , 2021, 20, 702-715.	1.3	6
1326	Perspective of mesenchymal transformation in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2021, 9, 50.	2.4	63
1328	The Normal and Brain Tumor Vasculature: Morphological and Functional Characteristics and Therapeutic Targeting. <i>Frontiers in Physiology</i> , 2021, 12, 622615.	1.3	27
1329	Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial. <i>PLoS ONE</i> , 2021, 16, e0247293.	1.1	15
1330	Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?. <i>Journal of Neuro-Oncology</i> , 2021, 152, 483-490.	1.4	13
1331	Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma. <i>Journal of Neurosurgery</i> , 2020, 134, 1-10.	0.9	15
1332	Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1367.	1.0	18
1333	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 636672.	1.3	15
1334	The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis. <i>Cancer Radiotherapy: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 182-190.	0.6	6
1335	Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. <i>Current Neuropharmacology</i> , 2021, 19, 513-537.	1.4	40
1336	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1885-1897.	0.6	23
1337	Frontiers in the treatment of glioblastoma: Past, present and emerging. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 108-138.	6.6	125

#	ARTICLE	IF	CITATIONS
1338	A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. <i>Cancers</i> , 2021, 13, 1795.	1.7	67
1339	Clinical significance of <i>CDKN2A</i> homozygous deletion in combination with methylated <i>MGMT</i> status for <i>IDH</i> wildtype glioblastoma. <i>Cancer Medicine</i> , 2021, 10, 3177-3187.	1.3	21
1340	A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2021, 86, 110-115.	0.8	1
1341	Formalin Fixation as Tissue Preprocessing for Multimodal Optical Spectroscopy Using the Example of Human Brain Tumour Cross Sections. <i>Journal of Spectroscopy</i> , 2021, 2021, 1-14.	0.6	9
1342	Causes of drug resistance and glioblastoma relapses. <i>Opuholi Golovy I Sei</i> , 2021, 11, 101-108.	0.1	0
1343	TNF \pm secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 67.	2.4	28
1344	Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma. <i>NMR in Biomedicine</i> , 2021, 34, e4516.	1.6	7
1345	The Leloir Cycle in Glioblastoma: Galactose Scavenging and Metabolic Remodeling. <i>Cancers</i> , 2021, 13, 1815.	1.7	15
1347	Historical Perspective on Surgery and Survival with Glioblastoma: How Far Have We Come?. <i>World Neurosurgery</i> , 2021, 149, 148-168.	0.7	24
1348	Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, ¹⁸ F-FMISO PET, and ¹⁸ F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1349-1356.	2.8	14
1349	The Evolving Role of Targeted Therapies in Primary Central Nervous System Tumors. <i>Advances in Oncology</i> , 2021, 1, 203-212.	0.1	1
1350	Neuroimaging in the Era of the Evolving WHO Classification of Brain Tumors, From the AJR Special Series on Cancer Staging. <i>American Journal of Roentgenology</i> , 2021, 217, 1-13.	1.0	7
1351	High-grade gliomas: a literature review. Part 1. Epidemiology, classification and approaches to combination treatment. <i>Russian Journal of Neurosurgery</i> , 2021, 23, 124-134.	0.1	0
1352	Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma). <i>International Journal of Clinical Oncology</i> , 2021, 26, 1441-1449.	1.0	3
1353	Diagnosis of Pseudoprogression Following Lomustine/Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. <i>Clinical Cancer Research</i> , 2021, 27, 3704-3713.	3.2	19
1354	Targeting Energy Metabolism to Overcome Therapeutic Resistance of Glioblastoma and Tumor-associated Edema. , 0, , 121-138.		0
1355	Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells. <i>Biomedicines</i> , 2021, 9, 523.	1.4	6
1356	Machine Learning-Based Prediction of 6-Month Postoperative Karnofsky Performance Status in Patients with Glioblastoma: Capturing the Real-Life Interaction of Multiple Clinical and Oncologic Factors. <i>World Neurosurgery</i> , 2021, 149, e866-e876.	0.7	3

#	ARTICLE	IF	CITATIONS
1357	Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4899.	1.8	69
1358	Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. <i>Cancers</i> , 2021, 13, 2400.	1.7	28
1359	Brainstem Infiltration Predicts Survival in Patients With High-grade Gliomas Treated With Chemoradiotherapy. <i>Anticancer Research</i> , 2021, 41, 2583-2589.	0.5	4
1360	Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy. <i>Brain Tumor Pathology</i> , 2021, 38, 149-155.	1.1	7
1361	Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab050.	1.4	14
1362	Immunotherapy for Glioblastoma: Current Progress and Challenges. <i>Frontiers in Immunology</i> , 2021, 12, 676301.	2.2	83
1363	Gene Therapy for the Treatment of Malignant Glioma. <i>Advances in Oncology</i> , 2021, 1, 189-202.	0.1	3
1364	Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5544.	1.8	17
1365	Role of TRPM2 in brain tumours and potential as a drug target. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 759-770.	2.8	10
1366	A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 692403.	1.3	3
1367	An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma. <i>Cancers</i> , 2021, 13, 3241.	1.7	3
1369	Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients. <i>Radiologia Medica</i> , 2021, 126, 1249-1254.	4.7	20
1370	Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance. <i>Nature Communications</i> , 2021, 12, 3720.	5.8	67
1371	Advances in Chemokine Signaling Pathways as Therapeutic Targets in Glioblastoma. <i>Cancers</i> , 2021, 13, 2983.	1.7	35
1372	Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastoma. <i>Neuro-Oncology Practice</i> , 2021, 8, 601-608.	1.0	1
1373	The use of external control data for predictions and futility interim analyses in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 247-256.	0.6	29
1374	Advances in the management of glioblastoma. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1103-1111.	0.9	58
1375	Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas. <i>Aging</i> , 2021, 13, 15444-15458.	1.4	10

#	ARTICLE	IF	CITATIONS
1376	Tumor Vessels Fuel the Fire in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6514.	1.8	35
1377	DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies. <i>Molecular Oncology</i> , 2022, 16, 11-41.	2.1	16
1378	Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?. <i>Cureus</i> , 2021, 13, e15852.	0.2	0
1380	Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. <i>European Radiology</i> , 2022, 32, 101-111.	2.3	12
1381	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021, 13, 3750.	1.7	16
1382	Chronic stress promotes glioma cell proliferation via the PI3K/Akt signaling pathway. <i>Oncology Reports</i> , 2021, 46, .	1.2	15
1383	Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1983-1994.	0.9	2
1384	Neurocytological Advances in the Treatment of Glioblastoma Multiforme. <i>Cureus</i> , 2021, 13, e16301.	0.2	2
1385	MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 703442.	1.3	17
1387	Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2022, 34, 221-234.	0.7	3
1388	Optical tissue clearing and machine learning can precisely characterize extravasation and blood vessel architecture in brain tumors. <i>Communications Biology</i> , 2021, 4, 815.	2.0	9
1389	Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device. <i>Frontiers in Oncology</i> , 2021, 11, 708017.	1.3	13
1390	Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 228.	3.5	45
1391	Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab. <i>Diagnostics</i> , 2021, 11, 1263.	1.3	5
1392	Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 154, 187-196.	1.4	8
1393	Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103372.	2.0	19
1394	Radiotherapy of High-Grade Gliomas: First Half of 2021 Update with Special Reference to Radiosensitization Studies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8942.	1.8	11
1395	Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. <i>Cancers</i> , 2021, 13, 4123.	1.7	9

#	ARTICLE	IF	CITATIONS
1396	Phytogalactolipid dLGG Inhibits Mouse Melanoma Brain Metastasis through Regulating Oxylin Activity and Re-Programming Macrophage Polarity in the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 4120.	1.7	4
1397	Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8289.	1.8	10
1398	Expression Analysis of $\alpha 5$ Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma. <i>Pharmaceuticals</i> , 2021, 14, 882.	1.7	3
1399	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 703764.	1.3	27
1400	Genome-wide profiling of alternative splicing in glioblastoma and their clinical value. <i>BMC Cancer</i> , 2021, 21, 958.	1.1	4
1401	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1265-1272.	1.1	4
1402	Transcriptional control of brain tumor stem cells by a carbohydrate binding protein. <i>Cell Reports</i> , 2021, 36, 109647.	2.9	18
1403	Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5209-5220.	0.8	4
1404	Bioactive Heterocyclic Compounds as Potential Therapeutics in the Treatment of Gliomas: A Review. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 551-565.	0.9	5
1405	Re-irradiation for high-grade gliomas: Has anything changed?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 767-786.	0.9	8
1406	Intratumoral VEGF nanotrappor reduces glioblastoma vascularization and tumor cell mass. <i>Journal of Controlled Release</i> , 2021, 339, 381-390.	4.8	12
1407	Neurosurgical Advances for Malignant Gliomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 364-370.	1.0	2
1409	Medical and Neurological Management of Brain Tumor Complications. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 53.	2.0	5
1410	Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress. <i>Frontiers in Oncology</i> , 2021, 11, 719623.	1.3	5
1411	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	3.2	18
1412	Biomimetic and cell-based nanocarriers "New strategies for brain tumor targeting. <i>Journal of Controlled Release</i> , 2021, 337, 482-493.	4.8	27
1413	Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. <i>Pathology</i> , 2022, 54, 55-62.	0.3	6
1414	Elevated RGMA Expression Predicts Poor Prognosis in Patients with Glioblastoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4867-4878.	1.0	0

#	ARTICLE	IF	CITATIONS
1415	A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. <i>Oncologist</i> , 2021, 26, e2254-e2264.	1.9	12
1416	Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 746168.	2.2	20
1417	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. <i>Lancet Oncology, The</i> , 2021, 22, e456-e465.	5.1	53
1418	Rationally designed drug delivery systems for the local treatment of resected glioblastoma. <i>Advanced Drug Delivery Reviews</i> , 2021, 177, 113951.	6.6	41
1419	The relationship between the degree of brain edema regression and changes in cognitive function in patients with recurrent glioma treated with bevacizumab and temozolomide. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 4556-4568.	1.1	5
1420	Glioma stem cells, plasticity, and potential therapeutic vulnerabilities. , 2021, , 83-102.		0
1421	Endoglin and TGF- β 2 signaling in glioblastoma. <i>Cell and Tissue Research</i> , 2021, 384, 613-624.	1.5	7
1422	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1811-1820.	2.0	11
1423	Treatment with pembrolizumab in programmed death ligand 1-“positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , 2021, 127, 1620-1629.	2.0	56
1424	New Glioma Molecular Classification for Precise Therapeutic Decision Based on Spatially-Resolved Proteogenomics Guided by MALDI-MSI and Clinical Data Integration. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1425	In search of predictive and response markers in antiangiogenic therapy of glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 184-185.	0.6	0
1426	C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors. <i>Current Cancer Drug Targets</i> , 2021, 21, 2-20.	0.8	15
1427	Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model. <i>Scientific Reports</i> , 2021, 11, 79.	1.6	14
1428	Glioma stem cells and associated molecular mechanisms in Glioblastoma Chemoresistance. , 2021, , 135-151.		0
1429	Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma. <i>Cancers</i> , 2021, 13, 229.	1.7	13
1430	The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. <i>Journal of Neurosurgical Sciences</i> , 2021, 64, 502-508.	0.3	4
1431	Anti-angiogenic therapy for high-grade glioma. <i>The Cochrane Library</i> , 2018, 2018, CD008218.	1.5	81
1432	lncRNA CCAT1 Promotes Glioma Tumorigenesis by Sponging miR-181b. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4548-4557.	1.2	91

#	ARTICLE	IF	CITATIONS
1433	Adult High-Grade (Diffuse) Glioma. Molecular Pathology Library, 2015, , 77-93.	0.1	2
1434	Advanced Physiologic Imaging: Perfusion Theory and Applications. , 2020, , 61-91.		3
1435	Primary Central Nervous System Tumors. , 2020, , 295-325.		1
1436	Glioblastoma in the Elderly. Cancer Treatment and Research, 2015, 163, 159-170.	0.2	2
1437	Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas. Cancer Treatment and Research, 2015, 163, 117-142.	0.2	5
1438	Anti-angiogenics and Radiation Therapy. , 2017, , 1-10.		2
1439	Systemic Chemotherapy in Brain Gliomas. , 2019, , 261-267.		1
1441	Imaging Biomarkers in Preclinical Studies on Brain Tumors. Biomarkers in Disease, 2015, , 391-413.	0.0	1
1442	Novel Therapies for Glioblastoma. Current Neurology and Neuroscience Reports, 2020, 20, 19.	2.0	50
1444	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. Japanese Journal of Clinical Oncology, 2020, 50, 787-793.	0.6	6
1445	An Update on Medications for Brain Arteriovenous Malformations. Neurosurgery, 2020, 87, 871-878.	0.6	13
1446	“Zooming in” on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing. Neurosurgery, 2021, 88, 477-486.	0.6	15
1451	Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance. Cancer Research, 2020, 80, 1498-1511.	0.4	35
1452	Antiangiogenic Therapy of High-Grade Gliomas. Progress in Neurological Surgery, 2018, 31, 180-199.	1.3	13
1453	Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. Journal of Clinical Investigation, 2020, 130, 6041-6053.	3.9	37
1454	Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme. BMC Cancer, 2019, 19, 117.	1.1	37
1455	The immunohistochemical landscape of the VEGF family and its receptors in glioblastomas. Surgical and Experimental Pathology, 2020, 3, .	0.2	12
1456	18 Brain tumor imaging with ALA. Series in Cellular and Clinical Imaging, 2017, , 347-384.	0.2	2

#	ARTICLE	IF	CITATIONS
1457	High-grade Gliomas. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1548-1563.	0.4	49
1458	Adult Gliomas. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1452-1475.	0.4	8
1459	Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials. Medical Science Monitor, 2016, 22, 3486-3492.	0.5	7
1460	PVT1 Promotes Angiogenesis by Regulating miR-29c/Vascular Endothelial Growth Factor (VEGF) Signaling Pathway in Non-Small-Cell Lung Cancer (NSCLC). Medical Science Monitor, 2019, 25, 5418-5425.	0.5	37
1461	Advances in treating glioblastoma. F1000prime Reports, 2014, 6, 46.	5.9	42
1462	Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis. PLoS ONE, 2014, 9, e102484.	1.1	70
1463	Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme. PLoS ONE, 2015, 10, e0137678.	1.1	6
1464	Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS ONE, 2016, 11, e0161484.	1.1	12
1465	Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. PLoS ONE, 2016, 11, e0167917.	1.1	28
1466	The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2016, 11, e0168264.	1.1	9
1467	Passage of Humanized Monoclonal Antibodies Across the Blood- Brain Barrier: Relevance in the Treatment of Cancer Brain Metastases?. Journal of Applied Biopharmaceutics and Pharmacokinetics, 2015, 2, 50-58.	0.1	3
1468	Facilitating tailored therapeutic strategies for glioblastoma through an orthotopic patient-derived xenograft platform. Histology and Histopathology, 2016, 31, 269-83.	0.5	7
1469	Glioblastoma Genomics: A Very Complicated Story. , 0, , 3-25.		18
1470	Current Standards of Care in Glioblastoma Therapy. , 0, , 197-241.		114
1471	Glioblastoma: To Target the Tumor Cell or the Microenvironment?. , 0, , 315-340.		31
1472	Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy. , 0, , 341-358.		8
1473	PET Imaging in Glioblastoma: Use in Clinical Practice. , 0, , 155-174.		15
1474	Auraptene-induced cytotoxicity mechanisms in human malignant glioblastoma (U87) cells: role of reactive oxygen species (ROS). EXCLI Journal, 2019, 18, 576-590.	0.5	30

#	ARTICLE	IF	CITATIONS
1475	The History of Neuroscience and Neurosurgery in Japan. <i>International Neuroscience Journal</i> , 2015, 1, 31-40.	0.4	5
1476	Glioblastoma: an <i>análisis</i> molecular y sus implicancias clínicas. <i>Revista Peruana De Medicina De Experimental Y Salud Publica</i> , 2015, 32, 316.	0.1	5
1477	SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma. <i>Oncoscience</i> , 2015, 2, 102-110.	0.9	13
1478	A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). <i>Oncotarget</i> , 2016, 7, 69002-69013.	0.8	6
1479	Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. <i>Oncotarget</i> , 2016, 7, 70948-70958.	0.8	43
1480	<i>in vivo</i> phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued. <i>Oncotarget</i> , 2016, 7, 71594-71607.	0.8	11
1481	Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea. <i>Oncotarget</i> , 2017, 8, 7003-7013.	0.8	72
1482	Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. <i>Oncotarget</i> , 2016, 7, 76613-76627.	0.8	27
1483	Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma. <i>Oncotarget</i> , 2017, 8, 8294-8304.	0.8	55
1484	Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 42214-42225.	0.8	81
1485	Biological basis and clinical study of glycogen synthase kinase-3 β -targeted therapy by drug repositioning for glioblastoma. <i>Oncotarget</i> , 2017, 8, 22811-22824.	0.8	38
1486	A peptide derived from apoptin inhibits glioma growth. <i>Oncotarget</i> , 2017, 8, 31119-31132.	0.8	10
1487	In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. <i>Oncotarget</i> , 2017, 8, 49165-49177.	0.8	61
1488	Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. <i>Oncotarget</i> , 2017, 8, 64932-64953.	0.8	58
1489	Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. <i>Oncotarget</i> , 2017, 8, 51492-51506.	0.8	38
1490	Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 74170-74177.	0.8	21
1491	Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. <i>Oncotarget</i> , 2014, 5, 2208-2220.	0.8	108
1492	Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas. <i>Oncotarget</i> , 2017, 8, 89607-89619.	0.8	19

#	ARTICLE	IF	CITATIONS
1493	Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. <i>Oncotarget</i> , 2017, 8, 87124-87135.	0.8	8
1494	COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor. <i>Oncotarget</i> , 2017, 8, 87353-87363.	0.8	24
1495	“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. <i>Oncotarget</i> , 2017, 8, 103890-103899.	0.8	14
1496	Acid ceramidase and its inhibitors: a <i>de novo</i> drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. <i>Oncotarget</i> , 2017, 8, 112662-112674.	0.8	51
1497	MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. <i>Oncotarget</i> , 2014, 5, 7651-7662.	0.8	79
1498	Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial. <i>Oncotarget</i> , 2018, 9, 6752-6762.	0.8	21
1499	Combination therapy of 7-O-succinyl macrolactin A tromethamine salt and temozolomide against experimental glioblastoma. <i>Oncotarget</i> , 2018, 9, 2140-2147.	0.8	4
1500	Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility. <i>Oncotarget</i> , 2014, 5, 8690-8702.	0.8	28
1501	A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. <i>Oncotarget</i> , 2018, 9, 21569-21579.	0.8	20
1502	PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma. <i>Oncotarget</i> , 2018, 9, 23923-23943.	0.8	9
1503	The immune-related microRNA miR-146b is upregulated in glioblastoma recurrence. <i>Oncotarget</i> , 2018, 9, 29036-29046.	0.8	12
1504	Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. <i>Oncotarget</i> , 2018, 9, 28155-28164.	0.8	4
1505	Tumour treating fields in a combinational therapeutic approach. <i>Oncotarget</i> , 2018, 9, 36631-36644.	0.8	26
1506	EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis. <i>Oncotarget</i> , 2020, 11, 759-774.	0.8	11
1507	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. <i>Oncotarget</i> , 2015, 6, 31050-31068.	0.8	52
1508	Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe. <i>Oncotarget</i> , 2015, 6, 2101-2119.	0.8	30
1509	Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. <i>Oncotarget</i> , 2015, 6, 11664-11675.	0.8	45
1510	Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 14507-14521.	0.8	45

#	ARTICLE	IF	CITATIONS
1511	Modulation of cerebral endothelial cell function by TGF- β 2 in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. <i>Oncotarget</i> , 2015, 6, 22480-22495.	0.8	56
1512	Endothelial-like malignant glioma cells in dynamic three dimensional culture identifies a role for VEGF and FGFR in a tumor-derived angiogenic response. <i>Oncotarget</i> , 2015, 6, 22191-22205.	0.8	17
1513	Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. <i>Oncotarget</i> , 2015, 6, 34030-34037.	0.8	17
1514	The radiosensitivity index predicts for overall survival in glioblastoma. <i>Oncotarget</i> , 2015, 6, 34414-34422.	0.8	100
1515	Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?. <i>Oncotarget</i> , 2016, 7, 2313-2328.	0.8	29
1516	Molecular heterogeneity of glioblastomas: does location matter?. <i>Oncotarget</i> , 2016, 7, 902-913.	0.8	15
1517	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. <i>Oncotarget</i> , 2016, 7, 21247-21258.	0.8	86
1518	Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation. <i>Oncotarget</i> , 2016, 7, 83976-83986.	0.8	53
1519	Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas. <i>Oncotarget</i> , 2016, 7, 20016-20032.	0.8	32
1520	Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN ⁺ glioblastoma <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 24752-24765.	0.8	13
1521	Histopathological investigation of glioblastomas resected under bevacizumab treatment. <i>Oncotarget</i> , 2016, 7, 52423-52435.	0.8	42
1522	Dynamic Reorganization of Microtubule and Glioma Invasion. <i>Acta Medica Okayama</i> , 2019, 73, 285-297.	0.1	5
1523	ONC201: a new treatment option being tested clinically for recurrent glioblastoma. <i>Translational Cancer Research</i> , 2017, 6, S1239-S1243.	0.4	31
1524	On the subventricular zone origin of human glioblastoma. <i>Translational Cancer Research</i> , 2019, 8, 11-13.	0.4	1
1525	Bevacizumab in recurrent glioblastoma. <i>Translational Cancer Research</i> , 2019, 8, S162-S163.	0.4	1
1526	Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 147-156.	0.7	15
1527	Cold Atmospheric Plasma as a Novel Therapeutic Tool for the Treatment of Brain Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 2195-2206.	0.9	13
1528	The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review. <i>Current Drug Metabolism</i> , 2020, 21, 564-578.	0.7	23

#	ARTICLE	IF	CITATIONS
1529	Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2762-2776.	1.0	4
1530	Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. <i>Anticancer Research</i> , 2017, 37, 21-33.	0.5	105
1531	A Retrospective Evaluation of Bevacizumab Treatment in Patients with Progressive Malignant Glioma in Northern Sweden. <i>Anticancer Research</i> , 2017, 37, 1869-1874.	0.5	4
1532	Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3169-3174.	0.5	6
1533	Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma. <i>Anticancer Research</i> , 2017, 37, 3871-3876.	0.5	10
1534	Dendrosomal nanocurcumin and p53 overexpression synergistically trigger apoptosis in glioblastoma cells. <i>Iranian Journal of Basic Medical Sciences</i> , 2016, 19, 1353-1362.	1.0	13
1535	Distribution of tumor-infiltrating immune cells in glioblastoma. <i>CNS Oncology</i> , 2018, 7, CNS21.	1.2	42
1536	The algorithms of adjuvant therapy in gliomas and their effect on survival. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 179-186.	0.3	5
1537	Overview on current treatment standards in high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 225-238.	0.4	18
1538	An autopsy case of widespread brain dissemination of glioblastoma unnoticed by magnetic resonance imaging after treatment with bevacizumab. , 2019, 10, 137.		6
1539	Epithelioid glioblastoma presenting as multicentric glioma: A case report and review of the literature. , 2020, 11, 8.		4
1540	Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma. <i>Journal of Rare Diseases Research & Treatment</i> , 2016, 1, 51-55.	1.1	5
1541	Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients. <i>Neurosurgical Focus</i> , 2020, 49, E11.	1.0	4
1542	The Effect of Glucocorticoids on Angiogenesis in the Treatment of Solid Tumors. , 2020, 1, .		10
1543	Distinction of Microglia and Macrophages in Glioblastoma: Close Relatives, Different Tasks?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 194.	1.8	32
1544	Molecular Mechanisms of Treatment Resistance in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 351.	1.8	106
1545	Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. <i>Oncology Letters</i> , 2017, 13, 3767-3773.	0.8	6
1546	Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?. <i>Annals of Translational Medicine</i> , 2015, 3, 7.	0.7	31

#	ARTICLE	IF	CITATIONS
1547	Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?. <i>Annals of Translational Medicine</i> , 2016, 4, 36.	0.7	8
1548	Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. <i>Annals of Translational Medicine</i> , 2016, 4, 54.	0.7	46
1549	Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 229-237.	0.1	16
1550	VEGF in the nervous system: an important target for research in neurodevelopmental and regenerative medicine. <i>Neural Regeneration Research</i> , 2015, 10, 1725.	1.6	12
1551	Comprehensive RNAseq analysis reveals PIK3CD promotes glioblastoma tumorigenesis by mediating PI3K-Akt signaling pathway. <i>Glioma (Mumbai, India)</i> , 2020, 3, 135.	0.0	1
1552	Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro. <i>Cancer Research and Treatment</i> , 2019, 51, 696-705.	1.3	16
1553	Maximizing Function and Quality of Life of Patients with Glioblastoma after Surgical Resection: A Review of Current Literature. <i>Journal of Cancer Therapy</i> , 2016, 07, 857-888.	0.1	6
1554	Chemotherapy for adults with malignant glioma: a systematic review and network meta-analysis. <i>Turkish Neurosurgery</i> , 2015, 27, 174-181.	0.1	9
1556	Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. <i>World Journal of Experimental Medicine</i> , 2014, 4, 58.	0.9	12
1557	Receptor Tyrosine Kinase Interaction with the Tumor Microenvironment in Malignant Progression of Human Glioblastoma. , 0, , .		2
1558	Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis. <i>ELife</i> , 2016, 5, e11712.	2.8	40
1559	Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard-versus Abbreviated-Course Radiotherapy. , 2015, 19, 15-20.		21
1560	Response Assessment of Bevacizumab for Treatment of Malignant Glioma by Neuroimaging. <i>Japanese Journal of Neurosurgery</i> , 2016, 25, 912-921.	0.0	1
1561	Preoperative Apparent Diffusion Coefficient of Peritumoral Lesion Associate with Recurrence in Patients with Glioblastoma. <i>Neurologia Medico-Chirurgica</i> , 2022, 62, 28-34.	1.0	3
1562	Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 269-282.	0.9	8
1563	Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 749496.	1.3	13
1564	A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab156.	0.4	4
1565	A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 155, 297-306.	1.4	5

#	ARTICLE	IF	CITATIONS
1566	Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11180.	1.8	19
1567	New Approaches to Glioblastoma. <i>Annual Review of Medicine</i> , 2022, 73, 279-292.	5.0	14
1568	Eudragit, a Nifty Polymer for Anticancer Preparations: A Patent Review. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2022, 17, 92-101.	0.8	4
1569	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab142.	0.4	15
1570	Silk Microneedle Patch Capable of On-Demand Multidrug Delivery to the Brain for Glioblastoma Treatment. <i>Advanced Materials</i> , 2022, 34, e2106606.	11.1	73
1571	Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial. <i>Journal of Neuro-Oncology</i> , 2021, 155, 117-124.	1.4	8
1572	Hypoxia signaling: Challenges and opportunities for cancer therapy. <i>Seminars in Cancer Biology</i> , 2022, 85, 185-195.	4.3	17
1573	Application of Mesenchymal Stem Cells in Targeted Delivery to the Brain: Potential and Challenges of the Extracellular Vesicle-Based Approach for Brain Tumor Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11187.	1.8	14
1574	Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells. <i>Life Sciences</i> , 2021, 287, 120100.	2.0	5
1575	N-acetyl l-aspartate and Triacetin modulate tumor suppressor MicroRNA and class I and II HDAC gene expression induce apoptosis in Glioblastoma cancer cells in vitro. <i>Life Sciences</i> , 2021, 286, 120024.	2.0	10
1576	Recent Advance and Updates in Chemotherapy for Glioma. <i>Japanese Journal of Neurosurgery</i> , 2014, 23, 547-558.	0.0	0
1577	Imaging Biomarkers in Preclinical Studies on Brain Tumors. , 2014, , 1-19.		0
1578	Novel Strategies in Chemotherapy for Gliomas. <i>Japanese Journal of Neurosurgery</i> , 2015, 24, 386-398.	0.0	0
1579	Neurosurgery Concepts: Key perspectives on Traumatic Brain Injury, New Treatments for Glioblastoma, Hemispherectomy for Extensive Middle-Cerebral-Artery Stroke, Minimally Invasive Spine Surgery and Lumbar Epidural Injections for Radiculopathy. , 2015, 6, 98.		0
1580	Glioblastoma, bone sarcoma, and liver cancer: tough battles rage on for some tumors. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 162-166.	0.1	0
1581	Organized Pneumonia Secondary to Increasing Doses of Temozolomide. <i>Cureus</i> , 2015, 7, e318.	0.2	0
1582	Outcomes of application of modern first-line chemotherapy regimens in complex treatment of glioblastoma patients. <i>Zhurnal Voprosy Neirokhirurgii Imeni N N Burdenko</i> , 2016, 80, 5.	0.1	3
1584	Targeted Therapies in Brain Tumours: An Overview. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 1-23.	0.1	0

#	ARTICLE	IF	CITATIONS
1585	Radiobiological Hints from Clinical Studies. Current Clinical Pathology, 2016, , 29-40.	0.0	0
1586	Antiangiogenic Therapy for Glioblastoma. , 2016, , 143-149.		1
1587	Hirntumoren. Springer-Lehrbuch, 2016, , 311-365.	0.1	1
1588	Chemotherapeutics and Their Efficacy. , 2016, , 133-141.		0
1589	Updates in Genetic Molecular Targeted Therapy for Glioblastoma. Cancer and Oncology Research, 2016, 4, 1-15.	0.2	0
1590	Sense and sensibility to early combine bevacizumab to radiation treatment of brain metastasis: reply to Lou and Sperduto. Annals of Translational Medicine, 2016, 4, 148-148.	0.7	0
1591	Malignome des zentralen Nervensystems (ZNS)., 2017, , 979-1010.		0
1593	Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations. Journal of Neuro-Oncology, 2017, 134, 551-557.	1.4	1
1596	Glioblastoma fed by middle meningeal artery and displaying cyst formation soon after repeated implantation of carmustine wafers: A case report. Molecular and Clinical Oncology, 2017, 7, 953-956.	0.4	1
1597	Pediatric Chemotherapy. , 2018, , 1-15.		0
1598	The Value of Anti-angiogenics in Brain Tumor Therapy. , 2018, , 1-18.		0
1599	Medical Complications of Brain Tumors. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1635-1652.	0.4	4
1600	A case of focal segmental glomerulosclerosis inferred by bevacizumab. Japanese Journal of Pediatric Nephrology, 2018, 31, 57-62.	0.0	0
1601	Problem and Handling of Anti-angiogenic Therapy for Glioblastoma : Vessel Co-option and Vascular Mimicry. Japanese Journal of Neurosurgery, 2018, 27, 723-735.	0.0	0
1602	High-Grade Gliomas. , 2018, , 580-585.e2.		0
1603	LOCAL HYPERTHERMIA IN TREATMENT FOR MALIGNANT BRAIN TUMORS. Voprosy Onkologii, 2018, 64, 54-61.	0.1	0
1604	The Value of Anti-angiogenics in Primary Brain Tumor Therapy. , 2018, , 1-18.		0
1606	Análise do Seguimento Pós-Operatório em Pacientes com Glioma de Alto Grau no Sul Catarinense. Jbnc -Jornal Brasileiro De Neurocirurgia, 2018, 27, 208-214.	0.0	0

#	ARTICLE	IF	CITATIONS
1607	Arteriovenous malformation masking associated anaplastic ganglioglioma in an adolescent. Revista Colombiana De Cancerología, 2018, 22, 180-185.	0.0	0
1608	THE VALUE OF PROGNOSTIC FACTORS FOR GLIOBLASTOMA TREATED WITH CONCURRENT THERMOCHEMORADIOTHERAPY. Siberian Journal of Oncology, 2018, 17, 27-36.	0.1	0
1609	The 2017 Incentive Award of the Okayama Medical Association in Cancer Research (2017 Hayashibara) Tj ETQq0 0 0 rgBT /Overlock 10	0.0	0
1610	Anti-angiogenic therapy for glioma: Puzzle and hope. Glioma (Mumbai, India), 2019, 2, 182.	0.0	0
1612	Central Nervous System Cancers. , 2019, , 83-131.		1
1613	The Value of Anti-angiogenics in Primary Brain Tumor Therapy. , 2019, , 609-625.		0
1615	Glioma Treatment focusing on Brain Function. Japanese Journal of Neurosurgery, 2019, 28, 686-698.	0.0	0
1616	Anti-angiogenics and Radiation Therapy. , 2019, , 349-358.		0
1617	EFFECTIVENESS OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF GLIOBLASTOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Voprosy Onkologii, 2019, 65, 546-555.	0.1	1
1618	Physical Exercise during Radiation and Chemotherapy. The Japanese Journal of Rehabilitation Medicine, 2019, 56, 618-622.	0.0	0
1619	Survival effects of a strategy favoring second-line multimodal treatment compared to supportive care in glioblastoma patients at first progression. Journal of Neurosurgery, 2019, 131, 1136-1141.	0.9	0
1620	Safety, Tolerability, and Use of Steroids. , 2020, , 127-137.		0
1621	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
1622	Indications and Limitations of Conventional Imaging“ Current Clinical Practice in the“Context of Standard Therapy. , 2020, , 1-15.		1
1623	Chemotherapy and Future Developments. , 2020, , 29-37.		0
1624	Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. Korean Journal of Radiology, 2020, 21, 471.	1.5	5
1625	Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways. Novel Approaches in Cancer Study, 2020, 4, .	0.2	4
1626	Risk of Hypertension Associated with Antivasular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. Iranian Red Crescent Medical Journal, 2020, 22, .	0.5	2

#	ARTICLE	IF	CITATIONS
1627	Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT. <i>Cancers</i> , 2021, 13, 5420.	1.7	6
1628	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 36, 113-132.	0.9	2
1629	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 770561.	1.3	51
1630	Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 113999.	6.6	32
1631	miRNA-204-5p acts as tumor suppressor to influence the invasion and migration of astrocytoma by targeting ezrin and is downregulated by DNA methylation. <i>Bioengineered</i> , 2021, 12, 9301-9312.	1.4	6
1632	Current Status of Adjuvant Therapy for Glioblastoma and Potential Novel Therapies. <i>Japanese Journal of Neurosurgery</i> , 2020, 29, 188-197.	0.0	0
1633	<i>Neuroonkologie.</i> , 2020, , 257-271.		0
1634	<i>Chemotherapy for Brain Tumors.</i> , 2021, , 357-383.		0
1635	<i>Drug Repositioning for the Treatment of Glioma: Current State and Future Perspective.</i> , 0, , .		0
1636	Using precise boron neutron capture therapy as a salvage treatment for pediatric patients with recurrent brain tumors. <i>Therapeutic Radiology and Oncology</i> , 0, 4, 30-30.	0.2	3
1637	<i>Gliome des Erwachsenenalters.</i> Springer Reference Medizin, 2021, , 1-12.	0.0	0
1638	Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa171.	0.4	4
1639	ONCOLYTIC VIROTHERAPY IN GLIOBLASTOMA TREATMENT: PROGRESS AND CHALLENGES IN CLINICAL RESEARCH (LITERATURE REVIEW). <i>Siberian Journal of Oncology</i> , 2020, 19, 133-140.	0.1	0
1640	https://researchopenworld.com/the-addition-of-valproic-acid-to-concurrent-radiation-therapy-and-temozolomide-improves-patient-outcome/ , 2020, 5, .		7
1641	Current Applications and Future Perspectives of Brain Tumor Imaging. <i>Journal of the Korean Society of Radiology</i> , 2020, 81, 467.	0.1	1
1642	Pineal Gland Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 137-150.	0.8	1
1643	<i>Tumeurs cÃ©rÃ©brales, gliomes malins.</i> , 2020, , 227-237.e2.		0
1644	Use of the measured diffusion coefficient for predicting overall and progression-free survival rates in patients with recurrent glioblastoma treated with bevacizumab. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2020, 9, 51.	0.0	1

#	ARTICLE	IF	CITATIONS
1645	Glioblastoma. , 2020, , 173-182.		0
1646	Malignome des zentralen Nervensystems (ZNS). , 2020, , 1021-1055.		0
1647	Translating Targeted Radiosensitizers into the Clinic. Cancer Drug Discovery and Development, 2020, , 17-33.	0.2	0
1648	Angiogenesis in glioblastoma: Molecular and cellular mechanisms and clinical applications. Acta Facultatis Medicae Naissensis, 2020, 37, 211-230.	0.1	1
1649	Temozolomide-Associated Organizing Pneumonia. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	1
1650	Ventricle wall resection contributes to supramaximal resection and prognosis in SVZ-involved frontal gliomas: A single center retrospective study. Clinical Neurology and Neurosurgery, 2021, 211, 107015.	0.6	2
1651	Neues zur Diagnostik und Therapie von Gliomen. Neuroradiologie Scan, 2020, 10, 199-214.	0.0	0
1652	Intracranial Mass Lesions. , 2021, , 377-389.		0
1653	HEMATOTOXIC ADVERSE DRUG REACTIONS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS AND CYTOTOXIC DRUGS IN THE TREATMENT OF GLIOBLASTOMA: A SYSTEMATIC REVIEW. Siberian Journal of Oncology, 2020, 19, 121-130.	0.1	1
1654	Quantitative Features From CHO PET Distinguish the WHO Grades of Primary Diffuse Glioma. Clinical Nuclear Medicine, 2021, 46, 103-110.	0.7	8
1655	The role of extracellular vesicles in the diagnosis of glioblastoma progression. Uspеhi Molekularnoj Onkologii, 2020, 7, 8-18.	0.1	0
1656	An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative. International Journal of Clinical and Experimental Medicine, 2015, 8, 3946-55.	1.3	2
1658	Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma. , 2016, 1, 51-55.		2
1659	Icariside II induces cell cycle arrest and apoptosis in human glioblastoma cells through suppressing Akt activation and potentiating FOXO3a activity. American Journal of Translational Research (discontinued), 2017, 9, 2508-2519.	0.0	4
1660	Management and treatment recommendations for World Health Organization Grade III and IV gliomas. International Journal of Health Sciences, 2017, 11, 54-62.	0.4	4
1661	Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma. Current Health Sciences Journal, 2015, 41, 325-332.	0.2	1
1662	Biomarkers for glioblastoma multiforme: status quo. Journal of Clinical and Translational Research, 2016, 2, 3-10.	0.3	10
1664	Newly Diagnosed Glioblastoma: A Review on Clinical Management. Oncology, 2019, 33, 91-100.	0.4	42

#	ARTICLE	IF	CITATIONS
1665	The Effect of Glucocorticoids on Angiogenesis in the Treatment of Solid Tumors. <i>Journal of Cellular Signaling</i> , 2020, 1, 42-49.	0.5	5
1667	Identification of three glioblastoma subtypes and a six-gene prognostic risk index based on the expression of growth factors and cytokines. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 4669-4682.	0.0	3
1668	Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways. <i>Novel Approaches in Cancer Study</i> , 2020, 4, 398-401.	0.2	1
1669	Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound. <i>Advanced Drug Delivery Reviews</i> , 2022, 180, 114043.	6.6	41
1670	circRNA-0002109 promotes glioma malignant progression via modulating the miR-129-5P/EMP2 axis. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 1-15.	2.3	7
1671	Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma. <i>Scientific Reports</i> , 2021, 11, 22057.	1.6	1
1672	Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, v133-v143.	0.4	11
1673	Clinicopathologic analysis of microscopic tumor extension in glioma for external beam radiotherapy planning. <i>BMC Medicine</i> , 2021, 19, 269.	2.3	8
1674	An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach. <i>Clinical and Translational Oncology</i> , 2022, 24, 742-756.	1.2	2
1675	Surviving Over a Decade With Glioblastoma: A Clinical Course Characterized by Multiple Recurrences, Numerous Salvage Treatments, and Novel Use of Cesium-131 Tiles. <i>Cureus</i> , 2021, 13, e19573.	0.2	1
1676	Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. <i>Journal of Neuro-Oncology</i> , 2021, 155, 307-317.	1.4	9
1677	Telomerase-positive circulating tumor cells are associated with poor prognosis via a neutrophil-mediated inflammatory immune environment in glioma. <i>BMC Medicine</i> , 2021, 19, 277.	2.3	13
1678	Endothelial cell-specific reduction of heparan sulfate suppresses glioma growth in mice. <i>Discover Oncology</i> , 2021, 12, 50.	0.8	3
1679	Emerging therapeutic targets for cerebral edema. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 917-938.	1.5	15
1680	Suppression of Ribosome Biogenesis by Targeting WD Repeat Domain 12 (WDR12) Inhibits Glioma Stem-Like Cell Growth. <i>Frontiers in Oncology</i> , 2021, 11, 751792.	1.3	6
1681	Chronic pathophysiological changes in the normal brain parenchyma caused by radiotherapy accelerate glioma progression. <i>Scientific Reports</i> , 2021, 11, 22110.	1.6	4
1682	Temporal Trends in Glioblastoma Survival. <i>Neurologist</i> , 2022, 27, 119-124.	0.4	7
1683	Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e048975.	0.8	5

#	ARTICLE	IF	CITATIONS
1684	A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab164.	0.4	11
1685	Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach. <i>Journal of Neurosurgical Sciences</i> , 2023, 67, .	0.3	5
1686	Our Experience in using the Novo-TTF 100A System for the Treatment of Glioblastoma. <i>Journal of the Nihon University Medical Association</i> , 2021, 80, 253-257.	0.0	0
1687	Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 812916.	1.3	13
1688	Preoperative Stereotactic Radiosurgery for Glioblastoma. <i>Biology</i> , 2022, 11, 194.	1.3	7
1689	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial. <i>Trials</i> , 2022, 23, 57.	0.7	10
1690	Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation. <i>Journal of Cancer</i> , 2022, 13, 354-363.	1.2	13
1691	Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. <i>Biomedicines</i> , 2022, 10, 130.	1.4	8
1692	EphrinB2—EphB4 Signaling in Neurooncological Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1679.	1.8	4
1693	Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. <i>Acta Neuropathologica Communications</i> , 2022, 10, 1.	2.4	28
1694	High grade gliomas. <i>Progress in Brain Research</i> , 2022, 268, 259-270.	0.9	2
1695	Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis. <i>American Journal of Neuroradiology</i> , 2022, 43, 202-206.	1.2	11
1696	New Approaches with Precision Medicine in Adult Brain Tumors. <i>Cancers</i> , 2022, 14, 712.	1.7	2
1697	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426.	0.8	67
1698	CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression. <i>Frontiers in Surgery</i> , 2021, 8, 775194.	0.6	17
1699	Metabolic characteristics of [18F]fluoroboronotyrosine (FBY) PET in malignant brain tumors. <i>Nuclear Medicine and Biology</i> , 2022, 106-107, 80-87.	0.3	11
1700	Glioma targeted therapy: insight into future of molecular approaches. <i>Molecular Cancer</i> , 2022, 21, 39.	7.9	274
1701	Global Research Trends in Radiotherapy for Gliomas: A Systematic Bibliometric Analysis. <i>World Neurosurgery</i> , 2022, 161, e355-e362.	0.7	9

#	ARTICLE	IF	CITATIONS
1702	Newly Diagnosed Glioblastoma in Elderly Patients. <i>Current Oncology Reports</i> , 2022, 24, 325-334.	1.8	3
1704	Nuclear medicine therapy of CNS tumors. , 2022, , .		0
1705	Targeting the Replication Stress of Glioblastoma. <i>World Journal of Cancer Research</i> , 2022, 12, 42-51.	0.1	0
1706	Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3510-3519.	0.8	7
1707	Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients. <i>Current Oncology Reports</i> , 2022, 24, 493-500.	1.8	3
1708	Complete and Incomplete Resection for Progressive Glioblastoma Prolongs Post-Progression Survival. <i>Frontiers in Oncology</i> , 2022, 12, 755430.	1.3	8
1709	Norepinephrine promotes glioma cell migration through up-regulating the expression of Twist1. <i>BMC Cancer</i> , 2022, 22, 213.	1.1	8
1710	Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes. <i>Frontiers in Radiology</i> , 2022, 1, .	1.2	3
1711	Molecular Mechanisms and Clinical Challenges of Glioma Invasion. <i>Brain Sciences</i> , 2022, 12, 291.	1.1	6
1712	Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy. <i>Cancers</i> , 2022, 14, 1176.	1.7	28
1713	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545.	0.6	13
1714	Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study. <i>World Neurosurgery</i> , 2022, 159, e479-e487.	0.7	2
1715	LPPR5 Expression in Glioma Affects Growth, Vascular Architecture, and Sunitinib Resistance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3108.	1.8	3
1716	Angiogenesis-Related Gene Signature-Derived Risk Score for Glioblastoma: Prospects for Predicting Prognosis and Immune Heterogeneity in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 778286.	1.8	6
1717	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance. <i>Frontiers in Oncology</i> , 2022, 12, 852950.	1.3	9
1718	Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells. <i>Cancers</i> , 2022, 14, 1551.	1.7	4
1719	A defect of amphiregulin release predicted longer survival independently of <i>YAP</i> expression in patients with pleural mesothelioma in the <i>IFCT</i> \times <i>MAPS</i> phase 3 trial. <i>International Journal of Cancer</i> , 2022, 150, 1889-1904.	2.3	1
1720	Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 874554.	1.3	10

#	ARTICLE	IF	CITATIONS
1721	Î2-Catenin marks proliferating endothelial cells in glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2022, 98, 203-206.	0.8	3
1722	Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme. <i>Neuroscience</i> , 2022, 491, 240-270.	1.1	22
1723	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
1724	Effectiveness of different treatment strategies in elderly patients with glioblastoma: An evidence map of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103645.	2.0	4
1726	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 358-383.	0.6	1
1727	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?. <i>Frontiers in Oncology</i> , 2021, 11, 718590.	1.3	14
1728	Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101956.	3.9	7
1730	Interaction of curcumin with glioblastoma cells via high and low linear energy transfer radiation therapy inducing radiosensitization effects. <i>Journal of Radiation Research</i> , 2022, 63, 342-353.	0.8	5
1731	Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma. <i>Cancers</i> , 2022, 14, 1958.	1.7	7
1732	Tumor Microenvironment in Glioma Invasion. <i>Brain Sciences</i> , 2022, 12, 505.	1.1	28
1733	Emerging therapies for glioblastoma: current state and future directions. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 142.	3.5	103
1734	Glioblastoma scRNA-seq shows treatment-induced, immune-dependent increase in mesenchymal cancer cells and structural variants in distal neural stem cells. <i>Neuro-Oncology</i> , 2022, 24, 1494-1508.	0.6	11
1735	MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. <i>Journal of Neuro-Oncology</i> , 2022, 157, 561-571.	1.4	5
1736	Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes. <i>Journal of Controlled Release</i> , 2022, 346, 110-135.	4.8	23
1765	Molecular Analysis in a Glioblastoma Cohort – Results of a Prospective Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 685.	1.1	5
1766	Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 896246.	1.3	14
1767	Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5238.	1.8	4
1768	Endothelial EphrinB2 Regulates Sunitinib Therapy Response in Murine Glioma. <i>Life</i> , 2022, 12, 691.	1.1	4

#	ARTICLE	IF	CITATIONS
1769	The Impact of Resistance Exercise on Muscle Mass in Glioblastoma in Survivors (RESIST): Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2022, 11, e37709.	0.5	2
1770	Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI). <i>Journal of Neuro-Oncology</i> , 2022, 158, 349-357.	1.4	10
1771	Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114337.	6.6	4
1772	The use of radiosensitizing agents in the therapy of glioblastoma multiforme—a comprehensive review. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 507-526.	1.0	8
1773	Multi-omics analysis predicts fibronectin 1 as a prognostic biomarker in glioblastoma multiforme. <i>Genomics</i> , 2022, 114, 110378.	1.3	7
1774	Venous thromboembolic events in glioblastoma patients: An epidemiological study. <i>European Journal of Neurology</i> , 2022, 29, 2386-2397.	1.7	7
1775	Optimal managements of elderly patients with glioblastoma. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 833-842.	0.6	2
1776	Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103703.	2.0	2
1777	Recent Advances in Research on Spinal Cord Gliomas. <i>Spinal Surgery</i> , 2022, 36, 18-23.	0.0	0
1778	Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. <i>Therapeutic Delivery</i> , 0, , .	1.2	4
1779	Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors. <i>Cell Reports</i> , 2022, 39, 110839.	2.9	18
1780	Non-metabolic functions of phosphofructokinase-1 orchestrate tumor cellular invasion and genome maintenance under bevacizumab therapy. <i>Neuro-Oncology</i> , 2023, 25, 248-260.	0.6	4
1781	JCIâ€20679 suppresses the proliferation of glioblastoma stem cells by activating AMPK and decreasing NFATc2 expression levels. <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	3
1782	Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities. <i>Heliyon</i> , 2022, 8, e09517.	1.4	10
1783	Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. <i>CNS Oncology</i> , 2022, 11, .	1.2	5
1784	Updates in IDH-Wildtype Glioblastoma. <i>Neurotherapeutics</i> , 2022, 19, 1705-1723.	2.1	26
1785	A novel <sc>DNA</sc> damage and repairâ€related gene signature to improve predictive capacity of overall survival for patients with gliomas. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 3736-3750.	1.6	7
1786	Role of magnetic resonance imaging following postoperative radiotherapy in clinical decision-making of patients with high-grade glioma. <i>Radiologia Medica</i> , 0, , .	4.7	5

#	ARTICLE	IF	CITATIONS
1787	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. <i>British Journal of Cancer</i> , 2022, 127, 976-987.	2.9	26
1788	The brilliance of nanoscience over cancer therapy: Novel promising nanotechnology-based methods for eradicating glioblastoma. <i>Journal of the Neurological Sciences</i> , 2022, 440, 120316.	0.3	10
1789	Glioblastoma. , 2023, , 388-392.		0
1792	The Cost-Effectiveness Evaluation of the Intraoperative Additional Photodynamic Therapy for the Treatment of Newly Diagnosed Glioblastoma. <i>Nippon Laser Igakkaishi</i> , 2022, , .	0.0	0
1793	Silicon-based nanoprobe cross the blood-brain barrier for photothermal therapy of glioblastoma. <i>Nano Research</i> , 2022, 15, 7392-7401.	5.8	8
1794	STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response. <i>Pharmacological Research</i> , 2022, 182, 106311.	3.1	51
1795	Diagnosis and Drug Prediction of Parkinson's Disease Based on Immune-Related Genes. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 1809-1819.	1.1	3
1796	Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. <i>Pharmacological Research</i> , 2022, 182, 106316.	3.1	3
1799	A Comprehensive Clinical Review of Adult-Type Diffuse Glioma Incorporating the 2021 World Health Organization Classification. <i>Neurographics</i> , 2022, 12, 43-70.	0.0	3
1800	Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice. <i>Neurotherapeutics</i> , 2022, 19, 1818-1831.	2.1	11
1801	Survival Outcomes and Prognostic Factors in Glioblastoma. <i>Cancers</i> , 2022, 14, 3161.	1.7	33
1802	Glioblastoma Treatment: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7207.	1.8	38
1803	Magnetic Resonance Spectroscopic Imaging for Detecting Metabolic Changes in Glioblastoma After Anti-angiogenic Therapy-A Systematic Literature Review. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	0
1804	The role of liquid biopsy in the diagnosis of glioblastoma progression. <i>Siberian Journal of Oncology</i> , 2022, 21, 104-116.	0.1	1
1805	Ubiquitin-Specific Protease 6 n-Terminal-like Protein (USP6NL) and the Epidermal Growth Factor Receptor (EGFR) Signaling Axis Regulates Ubiquitin-Mediated DNA Repair and Temozolomide-Resistance in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1531.	1.4	3
1806	Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification. <i>Cancers</i> , 2022, 14, 3149.	1.7	2
1807	Plant-based synthesis of cerium oxide nanoparticles as a drug delivery system in improving the anticancer effects of free temozolomide in glioblastoma (U87) cells. <i>Ceramics International</i> , 2022, 48, 30441-30450.	2.3	27
1808	Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	23

#	ARTICLE	IF	CITATIONS
1809	Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1810	Vascular complications in patients with brain tumors. <i>Current Opinion in Oncology</i> , 2022, 34, 698-704.	1.1	0
1811	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	1
1812	Glioblastoma " treatment and obstacles. <i>Reports of Practical Oncology and Radiotherapy</i> , 0, , .	0.3	6
1813	Molecular and Circulating Biomarkers in Patients with Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7474.	1.8	19
1814	Targeting of p21-Activated Kinase 4 Radiosensitizes Glioblastoma Cells via Impaired DNA Repair. <i>Cells</i> , 2022, 11, 2133.	1.8	2
1815	Neutrophils: New Critical Regulators of Glioma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1816	Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. <i>Journal of Neuro-Oncology</i> , 2022, 159, 509-518.	1.4	8
1817	Real-time longitudinal analysis of human gliomas reveals in vivo genome evolution and therapeutic impact under standardized treatment. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	1
1818	Diagnostic and therapeutic approach of artificial intelligence in neuro-oncological diseases. <i>Biosensors and Bioelectronics: X</i> , 2022, 11, 100188.	0.9	2
1820	Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1763.	1.4	4
1822	Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
1823	Postoperative radiotherapy with concomitant temozolomide plus anlotinib for newly diagnosed glioblastoma: Study protocol for a multicenter, double-blind, randomized phase II trial. <i>Glioma (Mumbai, India)</i> , 2022, 5, 69.	0.0	0
1824	Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma. <i>Cancers</i> , 2022, 14, 3705.	1.7	6
1825	Molecular matched targeted therapies for primary brain tumors"a single center retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2022, 159, 243-259.	1.4	7
1826	Combined anti-angiogenic and cytotoxic treatment of a solid tumour: in silico investigation of a xenograft animal model's digital twin. <i>Journal of Theoretical Biology</i> , 2022, 553, 111246.	0.8	4
1827	Multimodal targeting of glioma with functionalized nanoparticles. <i>Cancer Cell International</i> , 2022, 22, .	1.8	13
1828	Radiation therapy and antiangiogenic therapy: Opportunities and challenges. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 962-967.	0.6	4

#	ARTICLE	IF	CITATIONS
1829	Anti-Fn14-Conjugated Prussian Blue Nanoparticles as a Targeted Photothermal Therapy Agent for Glioblastoma. <i>Nanomaterials</i> , 2022, 12, 2645.	1.9	8
1830	In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
1831	Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. <i>International Reviews of Immunology</i> , 2022, 41, 582-605.	1.5	12
1832	Downregulated ferroptosis-related gene <i>SQLC</i> facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2104-2115.	1.9	8
1833	Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8835.	1.8	20
1834	Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	18
1835	Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis. <i>PLoS ONE</i> , 2022, 17, e0273242.	1.1	4
1836	Exosome-based strategies for diagnosis and therapy of glioma cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	16
1837	Use of heparin to rescue immunosuppressive monocyte reprogramming by glioblastoma-derived extracellular vesicles. <i>Journal of Neurosurgery</i> , 2022, , 1-11.	0.9	1
1838	Overview of pathology and treatment of primary brain tumours. , 2022, , 9-24.		0
1839	Neuroimaging of cerebrovascular complications in cancer patients. , 2022, , 935-954.		0
1840	A "Glocal" Approach to Developing Treatments for Malignant Brain Tumors. <i>Japanese Journal of Neurosurgery</i> , 2022, 31, 564-572.	0.0	0
1841	Neuroimaging issues in assessing glioma response to brain tumour therapy. , 2022, , 809-819.		0
1842	Advances in research on glioma microenvironment and immunotherapeutic targets. , 0, , 14-29.		0
1843	An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid. <i>Cancers</i> , 2022, 14, 4244.	1.7	4
1844	Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. <i>Cancer Cell</i> , 2022, 40, 1111-1127.e9.	7.7	30
1845	Current and promising treatment strategies in glioma. <i>Reviews in the Neurosciences</i> , 2022, .	1.4	3
1846	Effect of anesthesia on the outcome of high-grade glioma patients undergoing supratentorial resection: study protocol for a pragmatic randomized controlled trial. <i>Trials</i> , 2022, 23, .	0.7	0

#	ARTICLE	IF	CITATIONS
1847	Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth. <i>Cancer Gene Therapy</i> , 0, .	2.2	0
1848	Potassium Ion Channels in Malignant Central Nervous System Cancers. <i>Cancers</i> , 2022, 14, 4767.	1.7	5
1849	Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	3
1850	Clinical, Therapeutic, and Prognostic Experience in Patients With Glioblastoma. <i>Cureus</i> , 2022, , .	0.2	0
1851	The design and evaluation of hybrid controlled trials that leverage external data and randomization. <i>Nature Communications</i> , 2022, 13, .	5.8	7
1852	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1853	Cell cultures in assessing radioresistance of glioblastomas. <i>Zhurnal Voprosy Neirokhirurgii Imeni N N Burdenko</i> , 2022, 86, 126.	0.1	0
1854	Glioblastoma multiforme: Diagnosis, treatment, and invasion. <i>Journal of Biomedical Research</i> , 2023, 37, 47.	0.7	1
1855	Tumor Treating Fields (TTFields) therapy vs physiciansâ€™ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19). <i>Discover Oncology</i> , 2022, 13, .	0.8	3
1856	Next-Generation Sequencing Comparative Analysis of DNA Mutations between Blood-Derived Extracellular Vesicles and Matched Cancer Tissue in Patients with Grade 4 Glioblastoma. <i>Biomedicines</i> , 2022, 10, 2590.	1.4	0
1857	Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. <i>Brain Sciences</i> , 2022, 12, 1426.	1.1	1
1858	Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1859	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
1860	Currently available molecular analyses for personalized tumor therapy (Review). <i>Biomedical Reports</i> , 2022, 17, .	0.9	3
1861	Music improves the therapeutic effects of bevacizumab in rats with glioblastoma: Modulation of drug distribution to the brain. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1862	Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	1
1864	Reirradiation for Recurrent Glioblastoma: What We Know and What We Do Not. <i>Journal of Clinical Oncology</i> , 2023, 41, 1183-1188.	0.8	7
1866	Glioma stem cells and neural stem cells respond differently to BMP4 signaling. <i>Cell Regeneration</i> , 2022, 11, .	1.1	0

#	ARTICLE	IF	CITATIONS
1867	Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. <i>European Journal of Cancer</i> , 2023, 178, 162-170.	1.3	1
1868	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1869	Prodigiosin inhibits the proliferation of glioblastoma by regulating the KIAA1524/PP2A signaling pathway. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
1870	Ablation efficacy of 5-aminolevulinic acid-mediated photodynamic therapy on human glioma stem cells. <i>Photodiagnosis and Photodynamic Therapy</i> , 2023, 41, 103119.	1.3	4
1871	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. <i>Current Opinion in Neurology</i> , 2022, 35, 803-813.	1.8	7
1872	Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. <i>Cancers</i> , 2022, 14, 5522.	1.7	3
1873	Surgical cytoreduction of deep-seated high-grade glioma through tubular retractor. <i>Journal of Neurosurgery</i> , 2022, , 1-12.	0.9	0
1874	Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. <i>Journal of Neuro-Oncology</i> , 2022, 160, 361-374.	1.4	2
1875	7Î²-22 Dihydroxyhopane, Isolated from the Sub-Antarctic Lichen, Inhibits the Viability and Stemness in Glioma Stem Like Cells. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1375-1383.	1.0	0
1876	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1877	Initiatives Toward Clinical Boron Neutron Capture Therapy in Japan. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2023, 38, 201-207.	0.7	3
1878	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1879	Advances in mRNA nanomedicines for malignant brain tumor therapy. <i>Smart Materials in Medicine</i> , 2022, , .	3.7	3
1880	Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2022, 160, 433-443.	1.4	6
1881	Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival. <i>Nature Communications</i> , 2022, 13, .	5.8	14
1882	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1883	Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells. <i>Molecules</i> , 2022, 27, 7968.	1.7	2
1884	Treatment of Adult Gliomas: A Current Update. <i>Brain & Neurorehabilitation</i> , 2022, 15, .	0.4	7

#	ARTICLE	IF	CITATIONS
1885	Virtual Trials: Causally-validated treatment effects efficiently learned from an observational cancer registry. <i>Artificial Intelligence in Medicine</i> , 2023, 135, 102450.	3.8	0
1886	SYNAPSE: An international roadmap to large brain imaging. <i>Physics Reports</i> , 2023, 999, 1-60.	10.3	7
1887	Glioblastoma Antigen Expression for Tumor Targeting. , 2022, , .		0
1888	Mutual regulation between phosphofructokinase 1 platelet isoform and VEGF promotes glioblastoma tumor growth. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
1889	The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1890	Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	17
1891	Actin-Binding LIM 1 (ABLIM1) Inhibits Glioblastoma Progression and Serves as a Novel Prognostic Biomarker. <i>Disease Markers</i> , 2022, 2022, 1-9.	0.6	1
1892	Digging deeper for new targets in bevacizumab resistance. <i>Neuro-Oncology</i> , 0, , .	0.6	0
1893	Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma. , 0, 13, 583.		1
1894	Downregulation of <scp>ADAMTS3</scp> Suppresses Stemness and Tumorigenicity in Glioma Stem Cell. <i>CNS Neuroscience and Therapeutics</i> , 0, , .	1.9	1
1895	Lipid droplets and ferroptosis as new players in brain cancer glioblastoma progression and therapeutic resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
1896	Characterization of Glioblastoma Cells Response to Regorafenib. <i>Cancers</i> , 2022, 14, 6193.	1.7	2
1897	Stelletin B Sensitizes Glioblastoma to DNAâ€Damaging Treatments by Suppressing PI3Kâ€Mediated Homologous Recombination Repair. <i>Advanced Science</i> , 2023, 10, .	5.6	6
1898	Signaling pathways in brain tumors and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	13
1899	Single-cell RNA sequencing reveals changes in glioma-associated macrophage polarization and cellular states of malignant gliomas with high AQP4 expression. <i>Cancer Gene Therapy</i> , 2023, 30, 716-726.	2.2	3
1900	Key Clinical Principles in the Management of Glioblastoma. <i>JCO Oncology Practice</i> , 2023, 19, 180-189.	1.4	12
1901	Targeted therapies in patients with newly diagnosed glioblastomaâ€”A systematic metaâ€analysis of randomized clinical trials. <i>International Journal of Cancer</i> , 2023, 152, 2373-2382.	2.3	7
1902	Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
1903	Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. <i>Neuro-Oncology</i> , 2023, 25, 1085-1097.	0.6	11
1904	Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
1905	Deciphering the Clinical Trials of Immunotherapy in Glioblastoma: What a Neuroradiologist Needs to Know. <i>Neurographics</i> , 2022, 12, 176-187.	0.0	1
1906	Systemic Treatment in Glioblastoma. , 0, , .		0
1907	New therapeutic strategies based on molecularly targeted therapy in glioblastoma – a case report and review of the literature. <i>Current Issues in Pharmacy and Medical Sciences</i> , 2022, .	0.1	0
1908	Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. <i>OncoTargets and Therapy</i> , 0, Volume 16, 71-86.	1.0	6
1909	Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma. <i>Cancers</i> , 2023, 15, 830.	1.7	8
1910	Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity. <i>Yonsei Medical Journal</i> , 2023, 64, 139.	0.9	2
1911	MR Imaging, MGMT Promoter Methylation Features and Prognostic Analysis of Subventricular Zone Contacting IDH Wild-type Glioblastoma. <i>Current Medical Imaging</i> , 2023, 19, .	0.4	0
1912	Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	17
1913	Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 269-286.	2.5	0
1914	Remote Adipose Tissue-Derived Stromal Cells of Patients with Lung Adenocarcinoma Generate a Similar Malignant Microenvironment of the Lung Stromal Counterpart. <i>Journal of Oncology</i> , 2023, 2023, 1-15.	0.6	1
1915	Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism. <i>Nature Communications</i> , 2023, 14, .	5.8	20
1916	Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?. <i>Journal of Neurology</i> , 2023, 270, 2702-2714.	1.8	6
1917	Differential Transcriptome Responses in Human THP-1 Macrophages Following Exposure to T98G and LN-18 Human Glioblastoma Secretions: A Simplified Bioinformatics Approach to Understanding Patient-Glioma-Specific Effects on Tumor-Associated Macrophages. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5115.	1.8	1
1918	Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells. <i>Pathology Research and Practice</i> , 2023, 245, 154427.	1.0	6
1919	Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma. <i>Radiotherapy and Oncology</i> , 2023, 183, 109633.	0.3	3
1921	Management of Patients with High-Grade Glioma. <i>European Medical Journal Oncology</i> , 0, , 91-99.	0.0	1

#	ARTICLE	IF	CITATIONS
1922	Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials. <i>Cancer Investigation</i> , 2023, 41, 305-317.	0.6	1
1923	Deep learning automates bidimensional and volumetric tumor burden measurement from MRI in pre- and post-operative glioblastoma patients. <i>Computers in Biology and Medicine</i> , 2023, 154, 106603.	3.9	10
1924	Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. <i>Neuro-Oncology</i> , 2023, 25, 1200-1224.	0.6	5
1925	Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas. <i>Acta Neurochirurgica</i> , 2023, 165, 693-699.	0.9	0
1926	Management of initial and recurrent radiation-induced contrast enhancements following radiotherapy for brain metastases: Clinical and radiological impact of bevacizumab and corticosteroids. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100600.	0.9	3
1927	The effect of Azo-dyes on glioblastoma cells in vitro. <i>Saudi Journal of Biological Sciences</i> , 2023, 30, 103599.	1.8	2
1928	Modeling glioblastoma complexity with organoids for personalized treatments. <i>Trends in Molecular Medicine</i> , 2023, 29, 282-296.	3.5	7
1929	Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	1
1930	Antitumor Potential of Antiepileptic Drugs in Human Glioblastoma: Pharmacological Targets and Clinical Benefits. <i>Biomedicines</i> , 2023, 11, 582.	1.4	3
1932	PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor TÀcell immunotherapy. <i>Cell Metabolism</i> , 2023, 35, 517-534.e8.	7.2	20
1933	Nanotechnological advancements in the brain tumor therapy: a novel approach. <i>Therapeutic Delivery</i> , 2022, 13, 531-557.	1.2	2
1934	Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review. <i>BMC Cancer</i> , 2023, 23, .	1.1	5
1935	Update for astrocytomas: medical and surgical management considerations. , 0, , 1-26.		2
1936	Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
1937	Validation of Predictive Analyses for Interim Decisions in Clinical Trials. <i>JCO Precision Oncology</i> , 2023, , .	1.5	2
1938	Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?. <i>Cancers</i> , 2023, 15, 1561.	1.7	1
1939	Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma. , 2023, 2, 114-130.		0
1940	The value of adding DWI and FLAIR signal changes in the resection cavity on the diagnostic performance of BT-RADS category 3 for tumor progression prediction in post-treated glioma patients: a prospective pilot study. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2023, 54, .	0.3	0

#	ARTICLE	IF	CITATIONS
1941	Ketogenic therapies for glioblastoma: Understanding the limitations in transitioning from mice to patients. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	0
1942	Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	3
1943	Interstitial photodynamic therapy for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2023, 162, 217-223.	1.4	6
1944	LINC01393, a Novel Long Non-Coding RNA, Promotes the Cell Proliferation, Migration and Invasion through MiR-128-3p/NUSAP1 Axis in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5878.	1.8	2
1945	IDENTIFICATION OF ANTI-CANCEROUS DRUGS FOR THE MUTATED SNAP25 PROTEIN RELATED TO BRAIN TUMOR THROUGH STRUCTURE-BASED VIRTUAL SCREENING APPROACH. <i>Innovare Journal of Medical Sciences</i> , 0, , 40-45.	0.2	0
1946	Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future. <i>Current Oncology Reports</i> , 2023, 25, 589-598.	1.8	2
1947	Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	12
1948	Predictive value of MRI features on glioblastoma. <i>European Radiology</i> , 0, , .	2.3	0
1949	High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. <i>Cancers</i> , 2023, 15, 2196.	1.7	2
1950	TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report. <i>Brain Sciences</i> , 2023, 13, 633.	1.1	0
1951	Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?. <i>Current Oncology Reports</i> , 2023, 25, 777-785.	1.8	4
1952	Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 710-726.	2.5	2
1953	Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522311711.	0.5	0
1961	Newly diagnosed glioblastoma: A review on clinical management. , 2023, , 101-123.		0
1962	An overview of current drug delivery strategies for glioblastoma treatment and barriers to progress. , 2023, , 405-434.		0
2001	Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity. <i>Journal of Neuro-Oncology</i> , 2023, 164, 505-524.	1.4	5
2012	Editorial: Epigenetic and metabolic regulation of primary and metastatic brain cancers. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2028	Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors. <i>Journal of Neuro-Oncology</i> , 2023, 165, 21-28.	1.4	0

#	ARTICLE	IF	CITATIONS
2030	Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy. Journal of Neuro-Oncology, 0, , .	1.4	0
2054	Radionuclide Therapy in Brain Tumours. , 2024, , 109-125.		0
2065	Brain Gliomas of Adulthood. , 2023, , 1-20.		0